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Introduction:	 Streptococcus	 pneumoniae	 (the	 pneumococcus)	 is	 the	 most	 common	
cause	of	childhood	pneumonia.	Nasopharyngeal	(NP)	colonization	by	the	pneumococcus	
is	a	necessary	first	step	in	the	pathogenesis	of	pneumonia	and	yet	the	dynamic	nature	of	
pneumococcal	 colonization	 remains	 incompletely	 understood.	 In	 children,	
asymptomatic	 colonization	 of	 the	 nasopharynx	 by	 the	 pneumococcus	 is	 common	 and	
also	serves	as	a	reservoir	for	person-to-person	transmission.	 	We	aimed	to	investigate	
in	detail,	the	dynamics	of	pneumococcal	nasopharyngeal	carriage	over	the	first	year	of	
life,	 in	a	cohort	of	South	African	children,	particularly	after	 implementation	of	 the	13-
valent	pneumococcal	 conjugate	vaccine	 (PCV-13).	The	 study	will	 further	elucidate	 the	
interaction	 of	 S.	 pneumoniae	 with	 other	 respiratory	 pathogens	 and	 how	 such	
interactions	may	contribute	development	of	severe	disease.	
	
Methods:	 (i)	 We	 first	 compared	 three	 NP	 swab-types;	 nylon	 flocked,	 polyethylene	
terephthalate	 (PET)	 and	 rayon	 for	 the	 optimal	 recovery	 of	 S.	 pneumoniae.	 (ii)	 In	
addition,	a	real-time	multiplex	PCR	(rmPCR)	was	compared	to	a	sequetyping	method	in	
order	 to	 assess	 their	 suitability	 for	 high	 throughput	 pneumococcal	 capsular	 typing.	
Whole	genome	re-sequencing	was	used	to	resolve	discordant	molecular	serotyping	and	
reference-standard	Quellung	results.	(iii)	Following	optimization	of	specimen	collection	




based	 detection	 methods	 or	 placed	 into	 PrimeStore™	 for	 molecular	 based	 detection	
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methods.	 Following	 automated	 total	 nucleic	 acid	 extraction,	 a	 quantitative	 real-time	
PCR	(qPCR)	assay	for	the	detection	of	the	S.	pneumoniae	autolysin-encoding	(lytA)	gene	
was	 performed	 and	 its	 specificity	 assessed	 by	 screening	 a	 pool	 of	 heterogeneous	
bacterial	species.	The	sequetyping	assay	was	used	to	type	all	the	cultured	S.	pneumoniae	
and	 Quellung	 used	 for	 confirmation.	 (iv)	 A	 real-time	 multiplex	 reverse	 transcriptase	
PCR	 (FTDresp33)	was	 employed	 to	 determine	patterns	 of	 colonization/infection	with	




Results:	 (i)	 The	 recovery	 of	 S.	 pneumoniae	 from	 nylon	 flocked	 swabs	 was	 greater	
compared	to	both	PET	and	rayon	swabs	when	testing	mock	specimens.	Similarly,	higher	
bacterial	 loads	were	detected	by	qPCR	from	flocked	swabs	compared	with	PET	swabs	
from	 healthy	 children.	 (ii)	 The	 rmPCR	 assay	 performed	 well	 for	 the	 21	 serotypes/-
groups	included	in	the	assay	and	for	serotype	mixtures.	However,	in	our	study	setting,	a	
large	 proportion	 of	 serotypes	 were	 not	 detected	 by	 rmPCR.	 The	 sequetyping	 assay	





life.	 Of	 these,	 90%	 (1637/1809)	 were	 typeable	 while	 9%(172/1809)	 were	 non-
typeable.	 The	 point	 prevalence	 of	 NP	 carriage	 at	 2	 weeks	 of	 age	 was	 2%,	 reached	 a	
maximum	prevalence	of	60%	at	24	weeks	of	age,	and	thereafter	plateaued	throughout	
the	 first	 year	 of	 life.	 At	 each	 sampling	 point,	 non-vaccine-types	 (NVT)	 accounted	 for	
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more	 than	 80%	 of	 S.	 pneumoniae	 detected.	 The	 median	 time	 to	 first	 S.	 pneumoniae	
acquisition	was	64	days	(95%	CI	56	–	91	days),	with	no	difference	observed	between	
vaccine-type	(VT)	and	NVT	(p	=	0.69).	Serotype-specific	acquisition	rates	ranged	from	
0.06	 to	 0.15	 episodes	 /	 child	 days,	whereas	 the	 carriage	 duration	 for	 all	 48	 different	
serotypes	detected	in	this	study	was	1.2	to	29	days.	Prior	VT	pneumococcal	colonization	
before	PCV-13	vaccination	had	no	clear	effect	on	the	time	to	VT	and	NVT	colonization	
post	 PCV-13	 vaccination,	 p	 =	 0.51	 and	 p	 =	 0.12	 respectively.	 In	 contrast,	 NVT	
colonization	prior	 to	 vaccination	 increased	 the	hazard	of	 acquiring	NVT	pneumococci	
after	the	first	dose	of	PCV-13	by	3.6-fold	(95%	CI	1.95	-	6.52,	p	<	0.001).	Interestingly,	
‘residual’	carriage	of	VT	serotypes	did	not	appear	to	be	affected	by	sequential	doses	of	
PCV-13.	 Children	with	 older	 siblings	were	 at	 increased	 risk	 of	 acquiring	 both	VT	 and	
NVT	pneumococci	 (HR	=	1.83	 [95%	CI	=1.66	1.00	 -	2.73,	p=0.04]	and	HR=1.27	 -	2.64,	
p=0.001]	 respectively).	 (iv)	 Overall,	 at	 least	 one	 potential	 respiratory	 pathogen	 was	
detected	 in	 97%	 of	 the	 respiratory	 specimens	 collected	 from	 the	 children	 with	
symptoms	suggestive	of	tuberculosis.	Besides	S.	pneumoniae	(42%),	the	other	common	
bacterial	 species	 detected	 were	 Moraxella	 cartarrhalis,	 Haemophilus	 influenzae	 and	
Staphylococcus	 aureus	 (64%,	 29%	 and	 22%	 respectively).	 Clinically	 relevant	 bacteria	
included	Mycoplasma	pneumoniae,	Bordetella	pertussis	and	Chlamydia	pneumoniae.	The	
most	 common	 viruses	 included	 Metapneumovirus	 (hMPV),	 Rhinovirus,	 Influenza	 C	
virus,	Adenovirus,	 Cytomegalovirus	 and	Coronavirus	OC43.	Whilst	 there	was	no	 clear	
separation	between	the	pathogens	present	in	the	airways	of	children	with	and	without	
PTB,	 C.	 pneumoniae,	 hMPV,	 coronavirus	 043,	 influenza	 C	 virus,	 rhinovirus	 and	
cytomegalovirus	were	associated	with	PTB.	On	the	other	hand,	Pneumocystis	 jirovecii,	





Conclusion:	We	 describe,	 in	 detail,	 the	 dynamic	 nature	 of	 NP	 carriage	 in	 relation	 to	
vaccination.	We	show	that	“residual”	carriage	of	VT	strains	was	driven	by	HIV-exposure	
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Streptococcus	 pneumoniae	 (the	 pneumococcus),	 is	 a	 gram-positive,	 alpha-hemolytic,	
facultative	 anaerobic	 bacterium	 that	 colonises	 the	 nasopharynx	 of	 many	 healthy	
children	and	adults,	and	causes	disease	in	some	of	those	colonised	(1,2).	George	Miller	
Sternberg	 initially	 isolated	 the	 bacterium	 from	 the	 blood	 of	 a	 rabbit	 that	 he	 had	
inoculated	with	his	own	saliva	in	1885	and	named	it	Microbe	septicemique	du	salive	(3).	
Louise	Pasteur	independently	isolated	the	bacterium	after	Sternberg	and	referred	to	the	
organism	as	Micrococcus	pasteur	 (4).	It	was	 later	 in	 the	1920s	 that	 the	organism	was	
assigned	the	name	Diplococcus	pneumoniae	due	to	its	characteristic	paired	appearance	
on	 gram-stained	 sputum.	 Its	 current	 nomenclature,	 Streptococcus	 pneumoniae,	 is	
derived	 from	the	distinct	chain-like	(Streptococcal)	morphology	when	grown	 in	 liquid	
media	(3,4).		
Since	 its	 discovery,	 research	 on	 the	 pneumococcus	 has	 led	 to	 many	 important	
contributions	to	the	field	of	science	and	medicine.	These	discoveries	 include	the	Gram	
stain	 technique	 (5)	 and	 Quellung	 reaction;	 the	 latter	 remains	 the	 gold	 standard	 for	
pneumococcal	 serotyping	 (6,7).	 Experimental	 work	 on	 the	 pneumococcal	 capsular	
polysaccharide	(CPS)	forms	the	basis	of	current	pneumococcal	vaccine	formulations	(8).	
Frederick	 Griffith’s	 experimental	 work	 on	 pneumococcal	 virulence	 determinants	 was	
key	in	demonstrating	that	pneumococci	have	the	ability	to	take-up	exogenous	DNA	from	
closely	 related	 species	 and	 undergo	 natural	 transformation	 (9).	 Oswald	 Avery	 and	
colleagues	 later	 showed	 that	 deoxyribonucleic	 acid	 (DNA)	 was	 the	 ‘transforming	
principle’	 by	 demonstrating	 that	 treatment	 with	 DNase	 attenuated	 transformation	 in	















in	 the	 first	 two	 years	 of	 life	 (15).	 According	 to	 the	 2010	 estimates,	 the	 incidence	 is	
particularly	 high	 in	 Africa	 where	 36	 million	 episodes	 result	 in	 more	 than	 600,000	
pneumonia-related	deaths	each	year	(10,16,17).		
	




our	setting	 is	more	 than	double	 the	estimated	nationwide	 incidence	 for	South	African	
children	 younger	 than	 five	 years	 (0.14	 e/cy)	 and	 higher	 than	 the	median	 estimate	 in	




(11).	 However	 these	 differences	 may	 be	 due	 to	 differences	 in	 the	 rigor	 of	 case	
ascertainment	 and	 reporting.	 The	 observed	 incidence	 of	 pneumonia	 is	 substantially	
higher	than	the	reported	incidence	(ranged	from	0.006	–	0.085	e/cy)	from	in	children	
from	high-income	 countries	 (17).	Moreover,	 the	 incidence	 of	 pneumonia	 is	 highest	 in	
children	between	1	–	6	months	(Incidence	rate	ratio,	3.00	[95%	Confidence	interval,	CI,	
1.41-7.67])	 (16),	 suggesting	 increased	 vulnerability	 of	 younger	 children	 to	
pneumococcal	disease.		
Nasopharyngeal	(NP)	colonisation	by	the	pneumococcus	is	a	necessary	first	step	in	the	
development	 of	 both	 mucosal	 and	 invasive	 disease	 and	 yet	 the	 dynamic	 nature	 of	
pneumococcal	 colonisation	 remains	 incompletely	 understood	 (1,2,12).	 The	
pneumococcus	shares	this	ecological	niche	with	more	than	700	other	microbial	species	
including	resident	flora,	transient	colonizers	and	pathogenic	species	(18).	It	is	believed	
that	 intra-	 and	 interspecies	 competition	 within	 this	 ecological	 niche	 contributes	 to	
fluctuations	 in	 pneumococcal	 carriage	 over	 time	 (19,20).	 In	 children,	 asymptomatic	
colonisation	 by	 the	 pneumococcus	 is	 common,	 serving	 as	 a	 reservoir	 for	 person-to-
person	 transmission	 in	 the	 community	 (21).	 A	 complex	 interplay	 between	
pneumococcal	 and	 host	 factors	 determine	 whether	 the	 colonising	 pneumococcus	 is	
cleared	by	the	host’s	immune	system	or	progress	to	invasive	disease	(2).		The	outcome	






CHAPTER	 2:	 NP	 colonisation	 by	 the	 pneumococcus	 is	 key	 to	 understanding	 the	
pathogenesis	 of	 pneumococcal	 disease	 and	 is	 increasingly	 used	 as	 an	 endpoint	 for	
pneumococcal	 vaccine	 studies.	 It	 is	 important	 to	 establish	 the	 optimal	 strategy	 for	
pneumococcal	 recovery	 from	 NP	 specimens.	 Sampling	 of	 the	 nasopharynx	 may	 be	
achieved	 using	 an	 NP	 swab	 or	 aspirate.	 NP	 swabs	 are	 preferred	 as	 the	 procedure	 is	
simpler,	 quicker	 and	 better	 tolerated	 by	 children.	 The	 ideal	 swab	 would	 be	 highly	
absorbent,	 maintain	 the	 viability	 of	 microorganisms	 present,	 release	 maximum	
specimen	material	into	culture	broth	or	transport	medium	and	not	inhibit	downstream	






CHAPTER	 3:	The	CPS	 is	an	 important	virulence	 factor	as	un-encapsulated	strains	are	
virtually	absent	from	invasive	pneumococcal	disease	(IPD)	(9,24,25).	The	CPS	protects	
the	pneumococcus	 from	 ingestion	by	host	phagocytic	 cells	 and	promotes	 colonisation	
by	 limiting	 mucus-mediated	 clearance	 of	 the	 pneumococci	 (3,24–26).	 CPS	 further	
facilitates	 person-to-person	 transmission	 by	 protecting	 the	 pneumococcus	 from	
desiccation	 and	 mechanical	 damage,	 enabling	 the	 bacterium	 to	 survive	 during	
transmission	in	an	aerosolised	droplet	(27).	There	are	over	98	different	pneumococcal	
serotypes	differentiated	by	the	antigenic	CPS	(28).	 Individual	serotypes	are	associated	
with	 differing	 potential	 to	 cause	 invasive	 disease,	 antimicrobial	 drug-resistance	 and	
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have	 different	 global	 distribution	 patterns	 (9,22,25,26,29).	 Genetic	 shifts	 in	 the	
population	structure	of	pneumococci	can	result	from	serotype	replacement,	expansion	
of	 pre-existing	 clones,	 acquisition	 of	 novel	 clones,	 and	 from	 capsular	 switching	 -	 a	
change	 of	 the	 pneumococcal	 capsule	 by	 a	 clone	 due	 to	 alteration	 or	 exchange	 of	 its	
capsular	biosynthetic	gene	cluster	(cps)	(30).	
More	 practical,	 higher	 throughput	 serotyping	 techniques	 are	 required	 for	 expanding	
public	health	laboratory	services	in	many	areas	of	the	world	to	support	growing	disease	
control	 programs	 and	 epidemiological	 surveillance.	 Conventional	 serotyping	methods	
are	costly,	time-consuming	and	error	prone.	Current	DNA-based	methods	require	large	
number	 of	 serotype-specific	 primer	 pairs,	 while	 microarrays	 are	 costly	 and	 only	
available	in	selected	laboratories.	Chapter	3	therefore	presents	data	from	head-to-head	
comparisons	 of	 the	 accuracy	 of	 two	 methods	 suitable	 for	 large-scale	 serotyping,	 viz.	
sequetyping	and	multiplex	real-time	PCR.	The	sequetyping	assay	utilizes	a	single-primer	
PCR	and	sequence-based	method	 targeting	 the	 capsular	 regulatory	gene	wzh,	and	can	
correctly	identify	a	high	number	of	serotypes,	including	those	included	in	the	13-valent	




on	 the	 dynamics	 of	 pneumococcal	 serotype-specific	 colonisation	 is	 needed	 for	











PCVs	 are	 effective	 in	 preventing	 serotype-specific	 invasive	 disease;	 however,	 there	 is	
growing	concern	over	replacement	of	vaccine	serotypes	with	non-vaccine	serotypes	in	
carriage	 and	 invasive	 clinical	 isolates	 (20,36–39).	Our	understanding	of	 the	 serotype-
specific	 mucosal	 immunity	 induced	 by	 PCV	 is	 incomplete.	 The	 effect	 of	 sequential	
vaccination	 on	 longitudinal	 colonisation	 with	 vaccine	 vs.	 non-vaccine	 serotypes	 in	
individual	 children	 is	 largely	 unknown.	 Furthermore,	 the	 effect	 of	 serotype-specific	
colonisation	 (i.e.,	 the	 pneumococcus	 acting	 as	 a	 natural	 immunizing	 agent)	 on	
subsequent	acquisition	of	the	same	or	different	serotypes	and	on	vaccine	effectiveness	
remains	 poorly	 understood.	 Chapter	 4	 describes	 longitudinal	 pneumococcal	
colonisation	patterns	and	serotype	distribution	during	the	first	year	of	life	among	South	
African	 infants	 participating	 in	 a	 birth	 cohort	 (Drakenstein	 Child	 Health	 Study).	 In	
addition,	 this	 chapter	 details	 serotype-specific	 acquisition	 rates	 and	 duration	 of	
pneumococcal	carriage.	Chapter	5	specifically	investigates	risk	factors	for	acquisition	of	




this	 niche	 may	 play	 a	 key	 role	 in	 determining	 the	 outcome	 of	 infection	 in	 children.	
Recent	 studies	 into	 the	 pathobiome	 have	 highlighted	 the	 impediments	 to	 the	 long-




with	 respiratory	 tract	 infections,	 this	 includes	 children	with	 suspected	pulmonary	TB	
and	those	infected	with	human	immunodeficiency	virus	(HIV)	(40–47).	The	diagnosis	of	
TB	 in	 children	 is	 largely	made	 on	 the	 basis	 of	 clinical	 and	 radiological	 presentations,	
which	may	be	non-specific	(48).	In	children,	tuberculosis	(TB)	may	present	as	either	an	





Little	 is	 known	 about	 the	 range	 of	 respiratory	 pathogens	 that	 may	 be	 detected	 in	
children	 presenting	 with	 suspected	 TB,	 either	 as	 the	 primary	 cause	 of	 respiratory	
symptoms	in	children	who	do	not	have	TB,	or	as	co-pathogens	in	children	who	do	have	
TB.	Although	interactions	between	specific	bacterial	and	viral	pathogens	occupying	the	
NP	 microbiome	 have	 been	 described,	 there	 are	 no	 published	 data	 providing	 a	
comprehensive	picture	of	the	bacterial	and	viral	composition	of	the	NP	microbiome	in	
children	 with	 TB.	 This	 chapter	 therefore	 describes	 the	 identification	 of	 potential	
respiratory	tract	pathogens	(other	than	M. tuberculosis)	from	NP	samples	collected	from	









CHAPTER	 7:	 This	 section	will	 summarize	 the	 key	 findings	 from	 these	 studies	 in	 the	
context	of	existing	knowledge	and	highlight	how	this	work	has	advanced	knowledge	in	
terms	 of	 NP	 sample	 collection,	 capsular	 serotyping,	 determinants	 of	 pneumococcal	
carriage	 and	 the	 role	of	NP	microbial	 interactions	 in	health	 and	disease.	This	 chapter	
will	 also	 highlight	 our	 approach	 to	 future	 studies,	 which	 will	 include	 increasing	 the	
sample	 size	 of	 the	 longitudinal	 cohort,	 application	 of	 whole	 genome	 sequencing	 to	
further	 study	 the	 molecular	 epidemiology	 of	 the	 pneumococcus	 in	 the	 cohort	 and	















































































































































































































































Streptococcus	 pneumoniae	 colonizes	 the	 nasopharynx	 of	 many	 healthy	 children	 and	
causes	pneumonia	in	a	small	proportion	of	those	colonized	(1-4).	Since	nasopharyngeal	
(NP)	 colonization	 by	 S.	 pneumoniae	 is	 key	 to	 understanding	 the	 pathogenesis	 of	
pneumococcal	 disease	 and	 is	 increasingly	 used	 as	 an	 endpoint	 for	 pneumococcal	
vaccine	 studies,	 it	 is	 important	 to	 establish	 the	 optimal	 strategy	 for	 recovery	 of	 S.	
pneumoniae	from	NP	specimens.	Sampling	of	the	nasopharynx	may	be	achieved	using	an	
NP	swab	or	aspirate.	NP	swabs	are	preferred	as	the	procedure	is	simpler,	quicker	and	
better	 tolerated	by	 children.	The	 ideal	 swab	would	be	highly	 absorbent,	maintain	 the	









century	 that	 further	 technological	 improvements	 in	 swab	 design	 were	 made,	
particularly	 by	 the	 move	 from	 wrapped	 cotton	 fibre,	 to	 the	 use	 of	 calcium	 alginate	
swabs	 in	 glass	or	plastic	 tubes	with	 and	without	 various	 transport	media.	The	 cotton	
material	originally	used	contained	fatty	acids	which	were	shown	to	inhibit	bacteria	such	
as	 Group	 A	 Streptococci,	 Haemophilus	 influenzae,	 Corynebacterium	 diphtheriae,	 and	
Neisseria	gonorrhoeae	 (6).	 Calcium	 alginate	 tips	 on	 the	 other	 hand	were	 a	welcomed	
option	 for	 the	 collection	of	microbial	 specimens	 for	 analysis.	 Similar	 to	 cotton	 swabs,	
45	
	
calcium	 alginate	 swabs	 are	 constructed	 by	 wrapping	 calcium	 alginate	 material	 onto	
twisted	metal	or	flexible	metal	or	plastic	wires.	However	calcium	alginate	swabs	proved	
toxic	 to	 tissue	 cultures	 and	 inhibited	 the	 Polymerase	 Chain	 Reaction	 (PCR)	 (7-9).	
Subsequently,	 non-toxic	 synthetic	 fibre-wrapped	 swabs	 such	 as	 rayon	 (viscose),	
manufactured	 from	 regenerated	 cellulose,	 and	 polyethylene	 terephthalate	 (PET),	 a	
thermoplastic	 polymer	 resin	 of	 the	 polyester	 family,	 manufactured	 under	 the	 brand	
name	Dacron	 or	 Terylene,	 have	 been	 developed	 and	 has	 become	 the	 preferred	 swab	
types	utilized	in	routine	microbiological	specimen	collection	products.		
	
Traditional	 fibre-wrapped	 swabs,	 such	 as	 PET	 and	 rayon	 swabs	 are	 constructed	 by	
winding	the	respective	polymer	onto	the	tip	of	a	swab	shaft.	When	stretched	from	end	




recovery	 of	 microorganisms.	 Another	 element	 for	 consideration	 in	 swab	 design	 is	 to	
create	a	swab	with	a	soft	and	absorbent	tip	that	will	cause	minimal	discomfort	or	injury	











flocked	 swabs	 have	 been	 shown	 to	 improve	 specimen	 collection	 through	 efficient	
specimen	material	release	from	the	swab	when	compared	to	spun	polymer	swabs	(10).	
Flocked	swabs	absorb	liquid	by	a	capillary	action	that	is	created	by	the	surface	tension	
between	 the	 fibre	 strands.	 This	 brush-like	 design	 allows	 effective	 dislodging	 and	
retrieval	of	cellular	material.	Unlike	the	traditional	fibre	wrapped	swab	design,	flocked	























The	 aim	 of	 the	 experiments	 described	 in	 this	 chapter	 is	 to	 compare	 pneumococcal	






1. To	 compare	 the	 liquid	 volume	 absorption	 by	 nylon	 flocked,	 PET	 and	 rayon	
swabs.	
2. To	 compare	 the	 quantitative	 culture	 recovery	 of	 S.	 pneumoniae	 from	 nylon	
flocked,	PET	and	rayon	swabs	employing	calibrated	cell	suspensions.	
3. To	 compare	 bacterial	 NP	 culture	 recovery	 employing	 nylon	 flocked	 and	 PET	
swabs	from	healthy	volunteers.	











Mid-log	 phase	 broth	 culture	 of	 S.	 pneumoniae	 (ATCC	 49619,	 serotype	 19F)	 was	













log	 phase	 corresponding	 to	 0.5	 OD600nm,	 10	 fold	 serial	 dilutions	 were	 made	 of	 the	
primary	 stock	 culture	 (Figure	 2)	 in	 1	 x	 PBS	 solution	 in	 1.5	 ml	 conical	 bottom	
microcentrifuge	tubes	(Corning	Inc,	New	York,	United	States	of	America).	A	20	µl	aliquot	
of	the	104	to	106	dilution	was	plated	in	triplicate	onto	blood	agar	(BA)	plates	containing	
Columbia	 blood	 agar	 base	 with	 2%	 agar,	 5%	 horse	 blood	 and	 4	 mg/ml	 gentamicin	
(Greenpoint	Media	Laboratory,	National	Health	Laboratory	Service,	Cape	Town,	South	




al.,	 and	 supplied	 by	 Wits	 Health	 Consortium,	 Johannesburg,	 South	 Africa	 (14).	 To	






Figure	 2:	 S.	 pneumoniae	 dilution	 series	 for	 the	 quantification	 of	 the	 viable	 cell	 count.	 Each	








phase	 of	 0.5	 OD600nm	 in	 Todd-Hewitt	 broth	 from	 which	 10-fold	 serial	 dilutions	 were	
prepared	 in	PBS	(see	section	2.3.2.1).	Of	 the	dilutions	made,	10	aliquots	of	20	µl	 from	
 
 























S.	 pneumoniae	 strains	 at	 10-2	 to	 10-4	 dilutions	 respectively	 for	 10	 minutes	 at	 room	
temperature	until	 the	inoculum	was	absorbed	into	the	swab.	The	inoculum	containing	






5%	 CO2	 overnight	 and	 colony-forming	 units	 (CFU)	 determined	 (Figure	 3).	 The	
percentage	of	S.	pneumoniae	recovery	was	calculated	as	the	proportion	of	the	mean	CFU	
recovered	from	each	swab	type	divided	by	the	mean	CFU	recovered	from	the	“control”	
(simulating	 100%	 CFU	 recovery).	 The	 experiment	 was	 repeated	 over	 three	 different	
days.	 In	 order	 to	 determine	 the	 intra-	 and	 inter	 assay	 variability	 of	 these	 assays,	we	
used	 the	 1/1000	 dilution	 series	 for	 each	 strain.	 It	 was	 mostly	 this	 dilution	 that	 we	












Paired	 nasopharyngeal	 swabs	 were	 obtained	 from	 42	 otherwise	 healthy	 children	
undergoing	 elective	 surgery	 at	 Red	 Cross	 War	 Memorial	 Children’s	 Hospital.	 Paired	
swabs	 comprised	 nylon	 flocked	 and	 PET	 swabs.	 Rayon	 swabs	 were	 not	 included	 as	
previous	 findings	 demonstrated	 poor	 recovery	 of	 Staphylococcus	 aureus	 ((15–19).	 In	
addition,	our	own	findings	(below)	had	demonstrated	that	nylon	flocked	and	PET	swabs	
were	 better	 than	 rayon	 swabs	 for	 S.	 pneumoniae	 release,	 and	 there	 are	 practical	




from	 one	 nostril	 and	 a	 PET	 swab	 from	 the	 other	 nostril.	 The	 order	 of	 sampling	was	
randomized.		
Following	sampling,	swabs	were	immediately	placed	into	1	ml	of	STGG,	transported	on	
ice	 to	 the	 laboratory	 and	 frozen	 at	 -80oC	 for	 later	 batch	 processing	 (Figure	 4).	 After	
thawing,	 STGG	 samples	 were	 vortexed	 for	 15	 seconds	 before	 a	 20	 µl	 aliquot	 was	
inoculated	onto	BA	plates	and	 incubated	at	37oC	 in	5%	CO2	overnight.	Presumptive	S.	
pneumoniae	 colonies	 were	 identified	 by	 colony	 morphology,	 α-hemolysis	 and	 ethy-
hydrocupreine	 (optochin)	disk	 susceptibility	 (Oxoid,	Basingstoke,	United	Kingdom).	A	














total	 nucleic	 acid	 extraction	 employing	 the	QIAsymphony®	Virus/Bacteria	mini	 kit	 on	







Quantitative	 real-time	 PCR	 (qPCR)	 assay	 for	 the	 detection	 of	 the	 S.	 pneumoniae	
autolysin-encoding	gene	(lytA)	was	performed	as	described	by	Carvalho	et	al	(20).		The	
assay	 specificity	was	 assessed	by	 screening	 a	 pool	 of	 heterogeneous	 bacterial	 species	
(Table	2).	The	reaction	mix	contained	2.5	µl	genomic	DNA	in	a	total	reaction	volume	of	
12.5	 µl	 containing;	 1X	 TaqMan®	 gene	 expression	 mastermix	 (Applied	 Biosystems,	
California,	 United	 States	 of	 America)	 and	 200	 nM	 of	 each	 primer	 and	 probe.	 PCR	
amplification	 was	 performed	 on	 the	 Bio-Rad	 CFX96	 Touch™	 Real-Time	 PCR	
amplification	 system	 (Bio-Rad	 Laboratories,	 Hercules,	 United	 States	 of	 America).	




pneumoniae	 ATCC	49619	 strain	 genomic	DNA).	 The	 quantification	 cycle	 (Cq)	 value	 at	
the	 detection	 limit	 point	 was	 36.	 A	 positive	 (S.	 pneumoniae	 ATCC	 49619)	 and	 non-
template	 control	 (sterile	 water)	 were	 included	 in	 each	 qPCR	 run.	 Results	 below	 the	
lowest	limit	of	detection	were	considered	negative.	
2.3.5	Statistical	analysis	
Statistical	 analysis	 was	 performed	 using	 GraphPad	 Prism	 version	 6.01	 (GraphPad	
Software	 Inc,	 California,	 United	 States	 of	 America)	 and	 STATA	 software	 version	 11.0	




sum	 test	was	used	 to	 assess	 the	median	between	 two	 groups	when	 the	data	was	not	
normally	 distributed.	 Analysis	 of	 variance	 was	 performed	 to	 determine	 whether	 the	
mean	CFU	of	S.	pneumoniae	recovered	was	different	within	triplicates	of	each	swab	type	
or	across	S.	pneumoniae	strains	when	the	experiments	were	repeated	on	three	different	
days.	 Analyses	 exclude	 the	 zero	 values.	 Including	 the	 zero’s	 would	 indicate	 a	 much	
lower	median.	The	 converse	 is	 true	 if	 the	 zero	values	are	excluded	and	only	 focus	on	
children	with	a	positive	swab.	To	ensure	that	we	captured	all	of	this	information	we	first	
reported	 the	 percentage	 of	 children	 with	 a	 positive	 swab	 and	 then	 calculated	 the	

















Replicate	#	 flocked	 PET		 rayon	
1	 80	µl	 30	µl	 30	µl	
2	 80	µl	 20	µl	 30	µl	
3	 90	µl	 30	µl	 40	µl	
4	 90	µl	 30	µl	 30	µl	
5	 90	µl	 30	µl	 40	µl	
6	 90	µl	 30	µl	 30	µl	
7	 70	µl	 30	µl	 30	µl	
8	 80	µl	 30	µl	 30	µl	
9	 80	µl	 30	µl	 40	µl	
10	 70	µl	 30	µl	 30	µl	




triplicates	 of	 each	 swab	 type	 performed	 on	 the	 same	 day	 (p	 =	 0.85)	 or	 when	 the	
experiments	 were	 repeated	 on	 three	 different	 days	 (p	 =	 0.89),	 suggesting	 that	 the	
experiments	 were	 reproducible.	 Therefore	 the	 S.	 pneumoniae	 CFU	 recovered	 from	
triplicates	of	each	swab	type	and	on	three	different	days	were	pooled	(Table	S2.2).		
Overall,	there	was	a	significant	difference	in	the	mean	CFU	of	S.	pneumoniae	recovered	














S.	pneumoniae	strain	(“Control”	)a	 Swab	type	 nb	 Mean	CFU	recovery/ml	(SD)c	 Percentage	recovery	d	
Serotype	19Fe	(18	x	107)	
Flocked	 9	 18		x	107		(5.7	x	106)	 100	(97.1-103.9)	
PET	 9	 7.3	x	107		(3.7	x	106)	 41	(37.7-45.1)	
rayon	 9	 1.3		x	107		(2.7	x	106)	 7	(4.2-12.5)	
Serotype	1	(19	x	107)	
Flocked	 9	 19		x	107		(5.4	x	106)	 100	(84.3-105.2)	
PET	 9	 8.5		x	107		(3.8	x	106)	 45	(39.0-47.0)	
Rayon	 9	 1.0		x	107		(2.1	x	106)	 5	(1.2-7.8)	
Serotype	5	(5.8	x	107)	
Flocked	 9	 5.8		x	107		(3.2	x	106)	 100	(91.3-104.0)	
PET	 9	 2.6		x	107		(8.2	x	106)	 45	(8.6-68.6)	
Rayon	 9	 0.7		x	107		(1.1	x	106)	 12	(9.1-12.0)	
SD,	Standard	deviation	
(a)	 Represents	 a	 simulated	 100%	 release	 of	 S.	 pneumoniae	 into	 skim	 milk-tryptone-glucose-
glycerol	 (STGG)	media	 and	 is	 used	 as	 a	 reference	 to	 calculate	 the	 percentage	 of	 recovery.	 (b)	
Pooled	replicates	of	each	swab	type	from	three	independent	experiments	performed	over	three	
different	days.	(c)Mean	of	colony	forming	units	(CFU)	obtained	from	9	different	replicates	of	each	
swab	 type	 tested.	(d)Percentage	of	 recovery	was	calculated	as	 the	proportion	of	 the	mean	CFU	
recovered	from	each	swab	type	divided	by	the	control	(100%	CFU	recovery)	for	each	respective	









replicates	 of	 each	 swab	 type	 using	 (Tables	 S1.3-1.5)	 S.pneumoniae	 serotype	 19F	 (Fig	 5A),	










age	 8	 [IQR	 5–16]	months).	 S.	 pneumoniae	 was	 cultured	 from	 18	 of	 the	 42	 (43%)	NP	








2.4.3.2	 Comparative	 nucleic	 acid	 amplification	 of	 S.	 pneumoniae	












Figure	 6:	 	 Screenshot	 of	 the	 plate	 set	 up	 and	 results	 of	 Streptococcus	 pneumoniae	 autolysin	





Organism	 Type	strain	 16S	rRNA*	 lytA	PCR	result	
Enterococcus	faecalis	 #ATCC	29212	 +	 -	





Streptococcus	pneumoniae	 ATCC	700669	 +	 +	
Streptococcus	pneumoniae		 ATCC	6303	 +	 +	
Streptococcus	pneumoniae		 ATCC	49619	 +	 +	
Streptococcus	anginosus	 CAP	QC	2008	 +	 -	
Streptococcus	bovis	 ATCC	9809	 +	 -	
Streptococcus	equi	 ATCC	43079	 +	 -	
Streptococcus	pyogenes	 ATCC	12203	 +	 -	
Streptococcus	pygenes	 ATCC	19615	 +	 -	
Streptococcus	pygenes	 ATCC	8668	 +	 -	
Streptococcus	pygenes	 NSCC	stock	 +	 -	
Streptococcus	thermophilis	 ATCC	19258	 +	 -	
Streptococcus	viridans	 NCTC	7868	 +	 -	
Staphylococcus	saprophyticus	 ATCC	15305	 +	 -	




















using	 either	 nylon	 flocked	 or	 PET	 (Dacron™)	 swabs	 from	 apparently	 healthy	 children	 as	
determined	by	both	lytA	targeted	qPCR	(A)	and	quantitative	culture	(B).	
	
The	 comparison	 of	 S.	 pneumoniae	 detection	 by	 culture	 and	 qPCR	 from	 NP	 samples	














Positive	 Negative	 Total	 	 Positive	 Negative	 Total	
	
Culture	
Pos	 16	(38%)	 0	 16	(38%)	 	 13	(31%)	 1	(2%)	 14	(33%)	
Neg	 10	(24%)	 16	(38%)	 26	(62%)	 	 11	(26%)	 17	(41%)	 28	(67%)	





data	 from	 the	US	Centres	 for	Disease	Control	and	Prevention	 (CDC)	 (24)	 suggests	 the	
use	of	either	PET		or	calcium	alginate	swabs	collected	in	STGG	transport	medium	for	S.	
pneumoniae	carriage	studies.	The	present	study	demonstrates	that	nylon	flocked	swabs	
demonstrate	 increased	absorptive	 capacity	and	 increased	yield	of	S.	pneumoniae	from	
mock	 specimens.	 In	 addition,	 PET	 swabs	 recovered	 significantly	more	 S.	 pneumoniae	
than	rayon	swabs.	The	differences	observed	in	the	liquid	absorption	support	the	notion	
that	 the	 brush-like	 design	 of	 nylon	 flocked	 swabs	 creates	 a	 highly	 absorbent	 layer	 of	
fibres	 that	absorb	 liquid	by	a	capillary	action	(10,13,18).	The	 findings	 from	this	study	
are	 in	 line	 with	 what	 has	 previously	 been	 shown	 for	 other	 bacteria	 (10,25,26).	 For	
instance,	Verhoeven	et	al.	showed	that	flocked	swabs	were	superior	to	rayon	swabs	for	
the	recovery	of	Staphylococcus	aureus	using	culture	(19).	Similarly,	nylon	flocked	swabs	








Whilst	 we	 found	 no	 significant	 statistical	 difference	 in	 bacterial	 detection	 by	 culture	
between	nylon	 flocked	 and	PET	 swabs	 from	NP	 samples	 collected	 from	 children	 (p	=	
0.17),	 we	 demonstrated	 a	 trend	 to	 increased	 CFU	 counts.	 This	 was	 supported	 by	
detection	of	significantly	more	S.	pneumoniae	DNA	by	qPCR	from	nylon-flocked	swabs	
compared	to	PET	swabs	(p	=	0.005).	The	importance	of	bacterial	load	has	been	recently	
demonstrated	 by	 Albrich	 et	 al.	 showing	 that	 the	 density	 of	 NP	 colonization	 by	 S.	
pneumoniae	was	higher	in	patients	with	pneumococcal	community-acquired	pneumonia	
compared	to	control	patients	using	PET	swabs	for	both	culture	and	lytA-targeted	qPCR	
(29).	 Further,	 using	 the	 PCR-based	methods,	 the	 severity	 of	 pneumonia	 caused	 by	 S.	




It	 has	been	 shown	 that	 the	DNA	extraction	methods	may	 influence	 the	DNA	 recovery	
from	both	 cotton	and	 flocked	 swabs	used	 for	 the	 collection	of	DNA	 from	saliva	 stains	
(32).	 Therefore,	 in	 order	 to	 assess	 whether	 the	 observed	 high	 bacterial	 load	 in	 this	
study	from	flocked	swabs	 is	not	 inherent	to	the	DNA	extraction	method,	studies	using	
different	 nucleic	 acid	 extraction	 methods	 are	 warranted.	 Whilst	 some	 concerns	 may	
arise	 due	 to	 the	 NP	 swabs	 that	 were	 collected	 from	 either	 right	 or	 left	 nostril	 in	 a	







the	 recovery	 and/or	 detection	 of	 S.	 pneumoniae	 from	NP	 swabs.	 Importantly,	 flocked	




































































































































































































Pneumococcal	 serotype	 identification	 is	 essential	 for	 disease	 surveillance	 and	
monitoring	pneumococcal	vaccine	effectiveness	and	serotype	 replacement.	 Serotyping	
of	 the	 pneumococcal	 polysaccharide	 capsule,	 the	 immunogenic	 component	 of	 current	
vaccines,	 remains	 the	 cornerstone	 of	 pneumococcal	 strain	 characterization.	 To	 date,	
more	 than	 98	 capsular	 serotypes	 have	 been	 described	 and	 new	 ones	 continue	 to	 be	
described	 (1,2).	 Colonisation	 of	 the	 nasopharynx	 with	 a	 homologous	 strain	 of	
pneumococci	precedes	the	development	of	invasive	and	respiratory	tract	disease	(3-5).	
Multiple	pneumococcal	serotypes	can	colonize	the	nasopharynx	successively	over	long	
period	 of	 time,	 or	 at	 any	 one	 time	 (7-8).	 Invasive	 disease	 is	 commonly	 regarded	 as	
resulting	 from	 a	 single	 serotype.	 Public	 health	 programs	 employ	 serotype	 prevalence	
data	from	invasive	disease	to	assist	vaccine	selection.	
	
One	 of	 the	 challenges	 for	 pneumococcal	 surveillance	 programs	 is	 the	 lack	 of	 an	
inexpensive	 and	 robust	 pneumococcal	 serotyping	 method.	 Assessment	 of	 serotyping	
methods	 needs	 to	 take	 into	 account	 the	 number	 of	 pneumococci	 to	 be	 serotyped,	




ability	 to	 switch	 its	 capsular	 PS	 (9-11).	 Accurate	 identification	 of	 the	 pneumococcal	
capsular	 PS,	 the	 immunogenic	 component	 of	 the	 current	 vaccines,	 remains	 the	





















































































































































































































































































































































3.2.1	 Phenotypic	methods	 1 
Phenotypic	capsular	typing	tools	utilize	antiserum	to	determine	serotype/-group specific	 2 
pneumococcal	capsular	PS.		 3 
3.2.1.1	 Quellung	reaction	 4 
Pneumococcal	 serotype	 identification	 has	 mostly	 relied	 on	 phenotypic	 serotyping	 5 
methods,	most	 notably	 the	 Quellung	method	 developed	 in	 1902	 (12).	 The	 antiserum	 6 
utilized	 in	 this	 assay	 is	 costly;	 methods	 employed	 are	 labour	 intensive,	 and	 require	 7 
significant	technical	expertise	and	experience.		Quellung,	or	the	capsular	reaction	test,	is	 8 
still	the	classic	reference	standard	for	pneumococcal	serotyping.	Although	there	maybe	 9 
variations	 in	how	 the	 test	 is	performed,	 the	underlying	principle	 involves	an	antigen- 10 
antibody	reaction	between	a	specific	pneumococcal	capsular	polysaccharide	(CPS)	and	 11 
serotype-specific	 antisera	 (13-valent	 pneumococcal	 conjugate	 vaccine	 [PCV-13]	 12 
serotypes:	4,	6B,	9V,	14,	18C,	19F,	23F,	1,	3,	5,	6A,	19A	and	7F)	(12,13).		 13 
This	 antigen-antibody	 reaction	 results	 in	 a	 change	 in	 the	 refractive	 index	 of	 14 
pneumococcal	 capsule	 such	 that	 it	 appears	 “swollen”.	 The	 test	 is	 normally	performed	 15 
using	sequential	pooled	antisera	until	a	positive	reaction	is	observed.	Subsequently,	the	 16 
individual	 group	 or	 capsular	 serotype-specific	 antisera	 included	 in	 the	 antisera	 pool	 17 
that	 gave	 a	 positive	 reaction	 is	 then	 used	 to	 determine	 the	 serogroup	 or	 serotype	 18 
respectively.	When	 viewed	 under	 a	microscope	 (after	 adding	 a	 counter	 stain	 such	 as	 19 




The	 performance	 characteristics	 of	 other	 capsular	 PS	 typing	 tools	 are	 normally	 23 
compared	 to	 those	 of	 Quellung	 reaction	 due	 to	 its	 unsurpassed	 sensitivity	 and	 24 
specificity,	 summarized	 in	 table	 5	 above	 (15).	 The	 Quellung	 reaction	 is	 however	 less	 25 
practical	 for	 high	 throughput	 capsular	PS	 typing	 strategy	 and	 can	not	 detect	multiple	 26 
serotypes	within	the	same	sample.	Since	one	requires	a	viable	bacterium	to	perform	this	 27 
test,	autolysis	of	 the	bacteria	 in	culture	and	prior	antibiotic	 therapy	or	a	 low	bacterial	 28 
load	 might	 result	 in	 culture	 negative	 clinical	 specimens	 and	 subsequently	 a	 failed	 29 





timeous,	 cheaper,	 easier	 alternative	 serological-based	 serotyping	 methods	 were	 35 
developed.	These	methods	are	summarized	below	with	performance	characteristics	of	 36 
some	 of	 these	methods	 summarized	 in	 table	 5	 and	 some	 of	 them	 discussed	 in	 detail	 37 
below.	Although	some	of	these	methods	initially	showed	a	lot	of	potential,	very	few	of	 38 
them	were	actually	adopted	into	routine	use	due	to	some	inherent	limitation.	 39 
3.2.1.2	 Co-aggulation	and	latex	agglutination	 40 
A	 positive	 result	 is	 reported	 when	 visible	 swelling	 (agglutination)	 occurs	 between	 41 
pneumococcal	capsular	PS	and	serotype-specific	antisera.	The	use	of	a	microscope	is	not	 42 
required.	Due	 to	 the	 initial	cross-reactivity	 that	was	reported,	chessboard	system	was	 43 
introduced	and	served	as	a	basis	for	the	latex-coated	serotyping	kit	(Pneumotest-Latex).	 44 





sourced	 latex	 reagents	 are	 expensive	 and	producing	 these	 reagents	 in-house	 requires	 49 
extensive	QC	protocols	to	minimize	misinterpretation	of	results.	 50 
3.2.1.3	 Immunoblot	assays	 51 
Fenoll	et	al	and	Bogaert	et	al	have	suggested	alternative	pneumococcal	capsular	typing	 52 
tools,	 dot	 blot	 (19)	 and	 colony	blot	 (20)	methods	 respectively.	 Both	methods	 require	 53 
heavy	 pneumococcal	 suspension	 that	 is	 spotted	 (blotted)	 onto	 nitrocellulose	 54 
membranes,	incubation	with	serotype-specific	antisera	and	addition	of	goat	anti-rabbit	 55 
immunoglobulin	G	(IgG)	that	 is	conjugated	to	peroxidase	enzymes.	A	positive	result	 is	 56 
seen	when	a	dark	colour	 that	 is	 surrounded	by	a	halo	 is	 seen	after	adding	a	chemical	 57 
substrate	 to	 the	membranes.	 The	 colony	 blot	method	 is	 able	 to	 identify	 other	minor	 58 
serotypes	within	 a	 sample	while	 the	 dot	 blot	method	 cannot	 and	 at	 times	 difficult	 to	 59 
distinguish	serotypes	within	a	serogroup.	These	assays	remain	time-consuming	for	high	 60 
throughput	capsular	 typing.	Bronsdon	et	al	attempted	to	modify	 the	dot	blot	assay	by	 61 
directly	placing	 the	nitrocellulose	membrane	on	 top	of	blood	agar	plates	with	 a	 fresh	 62 
growth	of	pneumococci	 (21).	However,	 limitations	seen	with	 the	original	 Immunoblot	 63 
assays	still	apply.	 64 
3.2.1.4	 ELISA	and	EIA	 65 
Enzyme-linked	 immunosorbent	assay	(ELISA)	and	competitive	enzyme	 immunoassays	 66 
(EIA)	for	pneumococcal	serotyping	directly	from	serum,	NP	swabs	and	urine	have	been	 67 
developed	(22-24).	When	compared	to	the	methods	described	above,	these	techniques	 68 
require	high	antibody	titers	to	 improve	avidity	and	even	when	these	are	produced	in- 69 
 78 
house,	 they	would	still	 require	extensive	QC	protocols.	They	are	also	 time-consuming,	 70 
results	available	after	several	days.	 71 
3.2.1.5	 Flow	cytometry	 72 
Flow	cytometry	allows	the	simultaneous	detection	of	up	to	23	different	serotypes	(later	 73 
expanded	 to	 36	 serotypes),	 and	 resolution	 of	 cross-reactive	 serotypes	 (25-27).	 74 
Separation	of	 cells	 is	based	on	 the	differences	 in	 size,	 granularity	 and	 red-fluorescent	 75 
labels	 of	 the	 microsphere	 beads.	 The	 method	 uses	 capsular	 PS-specific	 latex	 or	 76 
microsphere	beads	that	are	coated	with	rabbit	antisera	which	are	capable	of	binding	to	 77 
specific	 capsular	PS.	Following	an	overnight	 incubation	with	 individual	pneumococcal	 78 
lysates,	fluorescein	(green-fluorescence)-conjugated	anti-rabbit	antibody	is	then	added	 79 









Although	 not	 discussed,	 other	 less	 common	 phenotypic	 typing	 methods	 include	 89 




3.2.2	 Genotypic	methods	 93 
Genotypic	 typing	methods	 identify	 the	 pneumococcal	 capsular	 PS	 on	 the	 basis	 of	 the	 94 
nucleotide	 sequence	 of	 capsular	 genes	 within	 the	 capsulation	 locus.	 The	 publicly	 95 
available	 of	 the	more	 than	 90	 pneumococcal	 capsular	 nucleotide	 sequences	 (1,2)	 has	 96 
facilitated	the	development	of	many	genotypic	typing	tools	(8,32–41).		 97 
3.2.2.1	 Multiplex	PCR	 98 
PCR	 assays	 targeting	 serotype-specific	 genes	 within	 the	 capsulation	 locus	 have	 been	 99 
developed.	These	have	increased	sensitivity	and	specificity	and	require	sequential	PCR	 100 
primer	 pools	 specific	 for	 commonly	 encountered	 disease-causing	 pneumococcal	 101 
serotypes	 (40,41).	 Most	 of	 these	 conventional	 multiplex	 PCR	 assays	 have	 limited	 102 
multiplexing	 options	 and	 are	 prone	 to	 carry-over	 amplicon	 contamination.	 The	 103 
detection	format	is	agarose	gel-based,	therefore	subjective	and	not	quantitative.		 104 
3.2.2.2	 PCR-RFLP	 105 
Batt	et	al	has	described	a	PCR-Restriction	Fragment	Length	Polymorphism	(PCR-RFLP)	 106 
that	is	based	on	visualization	of	digested	PCR	fragments	(42).	Serotype	determination	is	 107 
based	on	the	amplicon	band	patterns.	This	method	is	error	prone	due	because	 it	does	 108 
not	utilize	serotype	specific	gene	for	serotype	determination,	the	similarity	of	banding	 109 
patterns	is	subjective.	 110 





by	 capillary	 electrophoresis.	 The	 unique	 fluorescent	 data	 is	 then	 analyzed	 on	 and	 115 
automated	fluorescence	fragment	size	analyzer.	Initial	equipment	costs	are	expensive.	 116 
3.2.2.4	 PCR/ESI-MS	 117 
PCR	amplicon	generated	using	serotype-specific	primers	are	subjected	to	electrospray	 118 
ionisation	 mass	 spectrometry	 (PCR/ESI-MS)	 (44).	 The	 unique	 molecular	 patterns	 119 
determined	from	differences	in	the	PCR	amplicons	base	composition	are	compared	to	a	 120 
database	 of	 known	 signatures	 obtained	 from	 known	 capsulation	 loci.	 Performance	 121 




3.2.2.5	 mPCR/RLB	 126 
An	 alternative	 capsular	 typing	 method	 that	 combines	 mPCR	 with	 reverse	 line	 blot	 127 
hybridisation	 (mPCR/RLB)	has	been	described	 (37,45,46).	Originally	designed	 to	only	 128 
detect	serotypes	 included	 in	PPV-23,	 this	assay	has	now	been	expanded	to	potentially	 129 
include	 all	 the	 90	 pneumococcal	 serotypes	 (45).	 The	 assay	 the	 can	 not	 differentiate	 130 
serotypes	with	shared	identical	or	very	similar	wzy	sequences	with	one	or	two	others	in	 131 
the	 same	or	 closely	 related	 serogroups.	These	 include:	7B/7C/40,	10F/10C,	11B/11C,	 132 
15F/15A,	 19B/19C,	 24F/24A/24B,	 25F/25A/38,	 28F/28A,	 32F/32A,	 33B/33D,	 133 
35F/47F,	 35A/35C/42,	 and	 41F/41A.	 As	 a	 result,	 further	 confirmatory	 testing	 using	 134 
serotype-specific	antisera	may	be	required.	 135 
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3.2.2.6	 Real-time	PCR	 136 
A	number	 of	 rtPCR	 assays	have	been	developed	 to	 provide	 rapid,	more	 sensitive	 and	 137 
potentially	quantitative	pneumococcal	capsular	typing	tool	(39,47,48).	These	assays	can	 138 
be	 applied	 to	 pneumococcal	 isolates	 or	 culture	 negative	 clinical	 specimens.	 As	 with	 139 
other	PCR	based	assays,	closely	related	serotypes	cannot	be	differentiated.	These	assays	 140 
require	 multiple	 serotype-specific	 primer-probe	 pairs	 to	 provide	 broader	 serotype	 141 
coverage	 and	 multiplexing	 options	 may	 be	 limited.	 PCR	 with	 subsequent	 target	 142 
detection	is	prone	to	amplicon	contamination	and	is	more	labour	intensive	than	rmPCR.	 143 
A	 sequential	 rmPCR	 described	 by	 Pimenta	 et	 al	 (39)	 allowed	 the	 identification	 of	 21	 144 
serotypes/-groups	including	the	thirteen	serotypes	covered	by	the	PCV-13	vaccine	and	 145 
8	 additional	 key	 serotypes/-groups	 likely	 to	 be	 encountered	 in	 the	 Africa.	 When	 146 
compared	to	other	rmPCR	formats	(49),	this	sequential	triplex	assay	is	able	to	resolve	 147 
serogroup	 6	 by	 differentiating	 6A/6B	 from	 the	 emergent	 6C	 serotype	 that	 is	 not	 148 
included	in	the	current	PCV-13	formulation	(50).	rmPCR	obviates	the	need	for	amplicon	 149 
manipulation,	 is	 highly	 sensitive,	 fast	 and	 less	 labour	 intensive.	 PCR	 assays	 do	 not	 150 
require	 viable	 isolates	 and	 have	 the	 potential	 to	 detect	 multiple	 serotypes	 151 
simultaneously	(39,48,49,51,52).		 152 
3.2.2.7	 Nanofluidic	RT-PCR	 153 
This	is	a	high	throughput	rtPCR	that	utilizes	nanofluidics	(Fluidigm	Biomark	HD	system)	 154 
(53).	This	technique	utilizes	previously	described	primers	and	newly	designed	primers	 155 
to	 identify	up	 to	50	different	pneumococcal	serotypes.	The	assay	uses	minute	reagent	 156 
volumes	and	provides	both	qualitative	and	quantitative	data	for	both	dominant	and	low	 157 
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abundance	 co-colonization	 serotypes	 clinical	 samples.	 Nonetheless,	 primer	 specificity	 158 
remains	a	concern,	as	closely	related	serotypes	cannot	be	distinguished.	 159 
3.2.2.8	 Microarray	 160 
Microarray	 assays	 utilize	 serotype-specific	 probes	 that	 target	 the	 highly	 variable	 161 
glycosyl-transferase	 genes	 (wzx	 and	wzy	 for	 most	 serotypes	 and	wze	 in	 the	 case	 of	 162 
serotype	3)	 to	 identify	43	serotypes	 including	all	PPV-23	serotypes	(8,54,55).	Labeled	 163 
pneumococcal	 DNA	 is	 added	 to	 a	 microarray	 chip	 and	 binds	 to	 the	 corresponding	 164 
nucleotide	sequence	on	the	array	chip.	After	a	run,	signal	and	background	intensities	of	 165 
each	 spot	 are	 analyzed	 using	 a	 microarray	 scanner.	 The	 microarray	 capsular	 typing	 166 
approach	 is	 rapid	 and	 has	 the	 capability	 to	 detect	 all	 pneumococcal	 serotypes	 and	 167 
simultaneously	 detect	 other	 virulence	 factors	 and	 antimicrobial	 resistance	 markers	 168 
from	pneumococcal	 isolates	or	 culture	negative	clinical	 samples.	Microarrays	can	also	 169 
detect	serotypes	with	low	abundance	in	co-colonization	clinical	samples	(8).	However,	 170 
the	 cost	 of	 setting	 up	 a	microarray	 and	 the	 required	 high	 level	 of	 technical	 expertise	 171 
limits	 its	 widespread	 use,	 especially	 in	 developing	 countries	 where	 pneumococcal	 172 
disease	burdens	are	high.	 173 
3.2.2.9	 Capsular	Sequence	Typing	 174 
Elberse	 et	 al.	 has	 described	 a	 singleplex	 PCR	 reaction	 using	 multiple	 primer	 sets	 175 
combined	 with	 sequencing	 of	 resulting	 amplicons	 that	 is	 similar	 to	 the	 sequetyping	 176 





by	 interrogating	 a	 public	 database	 (http://www.rivm.nl/mpf/spn/cst/).	 As	 with	 the	 181 
sequetyping	 assay,	 the	 assay	 utilizes	 non	 serotype-specific	 genes.	 Changes	 in	 the	 182 
nucleotide	 sequence	within	 this	 regulatory	 gene	may	 affect	 the	 regulation	 of	 capsule	 183 
production	but	this	change	may	not	have	any	biological	relevance	in	the	composition	of	 184 
the	pneumococcal	capsular	PS.	 185 
3.2.3.0	 Sequetyping	 186 
More	recently	sequetyping,	a	sequence-based	typing	method,	has	been	described	(38).	 187 
This	method	employs	partial	amplification	and	sequencing	of	the	capsule	biosynthesis	 188 
protein-tyrosine	 phosphatase	 gene,	 wzh,	 generating	 a	 1,061	 bp	 amplicon	 which	 is	 189 
subjected	 to	 sequencing	 and	 comparison	 to	 published	 wzh	 sequences	 available	 via	 190 
GenBank	(http://www.ncbi.nlm.nih.gov/blast/)	(38).	The	sequetyping	assay	was	shown	 191 
to	correctly	identify	all	but	two	of	the	PCV-13	vaccine	serotypes	to	serotype	level	whilst	 192 
serotypes	 7F	 and	 18C	 were	 “serogroup-specific”.	 In	 addition,	 the	 sequetyping	 assay	 193 
could	 identify	 up-to	 88%	 (122/138)	 of	 a	 pool	 of	 tested	 pneumococcal	 strains	 194 
representing	46	different	serotypes	to	at-least	the	correct	serotype/-group.	 195 
	 196 
Prior	 to	 the	 work	 described	 in	 this	 chapter,	 there	 were	 no	 published	 head-to-head	 197 
comparisons	of	the	accuracy	of	the	sequetyping	vs.	multiplex	PCR	approaches.		 198 
3.2.3.1	 Sequence	inference	from	WGS	 199 
The	high	sequence	homology	in	the	capsulation	locus	of	pneumococcal	serotypes	within	 200 
a	 serogroups	 and	 cross-reactivity	 with	 closely	 related	 non-pneumococcal	 201 
polysaccharide	genes	that	are	observed	especially	in	respiratory	samples	posses	major	 202 
limitations	 to	 target-based	genotypic	 typing	approaches.	The	 increasing	availability	of	 203 
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new	 sequence	 data	 and	 reduced	 cost	 of	 next	 generation	 sequencing	 technologies	 has	 204 
taken	the	quest	high	throughput	capsular	typing	tools	to	are	era	of	possibilities	(56,57).	 205 
At	present,	a	number	of	bioinformatics	tools	can	be	applied	to	whole	genome	sequence	 206 
(WGS)	data	 to	deduce	 the	pneumococcal	capsule	 type.	 In	addition	 to	making	serotype	 207 
inference,	 WGS	 data	 can	 be	 used	 to	 analyze	 the	 sequence	 diversity	 in	 the	 entire	 208 
capsulation	 loci	 in	 a	 greater	 detail	 and	 the	 associated	 evolutionary	 changes	 in	 the	 209 
pneumococcal	 population	 structure	 (9–11,57,58).	 Although	 WGS	 is	 becoming	 210 
affordable,	 the	 set	 up	 cost	 in	 developing	 countries	 is	 still	 high	 and	 high	 technical	 211 
expertise	 in	 sample	preparation	 together	with	 the	bioinformatics	 capability	 to	extract	 212 
and	analyze	high	throughput	data	from	this	platform	makes	it	less	attractive	especially	 213 
in	developing	countries.	 214 
3.2.3.2	 Target	enrichment	based	NGS	 215 
Liyanapathirana	et	al	has	describe	an	alternative	method	to	WGS	that	employs	a	target	 216 
enrichment	 based	 next	 generation	 sequencing	 approach	 to	 identify	 33	 pneumococcal	 217 
serotypes	 (59).	Two	primer	pairs	are	used;	 the	 first	pair	distinguishes	pneumococcus	 218 
from	 other	 streptococcal	 species	 using	 primer	 that	 target	 pneumococcal	 specific	 219 
autolysin	(lytA)-encoding	gene	while	the	second	pair	targets	a	500	bp	serotype	specific	 220 
gene	within	 the	capsulation	 loci.	The	PCR	amplicons	are	enriched	prior	 to	sequencing	 221 
on	a	bench-top	sequencer.	Performance	characteristics	are	shown	in	table	5	above.	As	 222 
with	WGS,	 this	method	also	 requires	huge	 set	up	 cost	 in	highly	 trained	expertise	 and	 223 





health	 laboratory	 services	 in	 many	 areas	 of	 the	 world	 to	 support	 growing	 disease	 228 
control	 programs	 and	 epidemiological	 surveillance.	 While	 the	 newer	 phenotypic	 229 
methods	all	have	their	distinct	benefits	and	often	surpass	Quellung	in	terms	of	rapidity	 230 
and	cost,	some	of	the	methods	require	sophisticated	and	expensive	instruments.	Given	 231 
the	 heterogeneity	 and	 recombinogenic	 nature	 of	 pneumococci,	 capsular	 typing	 tools	 232 




3.3	 Aims	and	Objectives	 237 
The	overall	aim	of	the	experiments	described	in	this	chapter	is	to	compare	rmPCR	and	 238 
sequetyping	 assays	 for	 suitability	 for	 high	 throughput	 pneumococcal	 capsular	 typing.	 239 
Specific	objectives	are:	 240 
1. To	 compare	 rmPCR	 and	 sequetyping	 methods	 employing	 40	 pneumococcal	 241 
strains	Quellung	serotyped	control	strains.	 242 
2. To	 examine	 the	 ability	 of	 rmPCR	 and	 sequetyping	 assays	 to	 detect	 mixed	 243 
serotypes.	 244 
3. Applying	 rmPCR	 and	 sequetyping	 to	 pneumococcal	 strains	 isolated	 from	 the	 245 
nasopharynx	 of	 83	 healthy	 infants	 from	 the	 Drakenstein	 Community,	Western	 246 
Cape.	 247 
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3.4	 	 MATERIALS	AND	METHODS	 248 
3.4.1	 Assay	validation	 249 
3.4.1.1	 Control	strain	preparation	 250 
Isolates	comprised	40	Quellung-typed	control	 strains,	 figure	8,	 (kindly	donated	by	Dr.	 251 
Anne	 von	Gottberg,	 Centre	 for	Respiratory	Diseases	 and	Meningitis	 (CRDM),	National	 252 
Institute	 for	Communicable	Diseases	(NICD),	South	Africa	[61]).	These	were	randomly	 253 
selected	 isolates	 obtained	 from	 our	 collaborators	 (NICD)	 that	 included	 vaccine	 254 
serotypes	 and	 other	 serotypes	 that	 are	 commonly	 circulating	 in	 our	 setting.	 These	 255 
isolates	were	transported	on	Dorset	egg	medium	(62),	subcultured	onto	Columbia	blood	 256 











*Of	 the	 40	 isolates	 that	were	 tested	 by	 rmPCR,	 only	 25	were	 included	 as	 part	 of	 the	 263 
rmPCR	targets.	 264 
	 265 
3.4.1.2	 Carriage	isolates	 266 
Subsequently,	 135	 pneumococcal	 isolates	 (Figure	 8)	 were	 cultured	 from	 267 
nasopharyngeal	(NP)	swabs	that	were	collected	from	83	healthy	 infants	by	employing	 268 




































horse	 blood	 (BA)	 plates	 and	 incubated	 at	 37
o
C	 in	 5%	 CO2	 overnight.	 Presumptive	 276 
pneumococcal	 isolates	 were	 identified	 by	 colony	 morphology,	 α-hemolysis	 and	 277 
ethylhydrocupreine	 (optochin)	 disk	 susceptibility	 (Oxoid,	 Basingstoke,	 UK)	 as	 278 
previously	described	(64,65).	 279 
3.4.1.3	 Nucleic	acid	extraction	 280 
Prior	 to	rmPCR	and	sequetyping,	all	 isolates	were	subjected	 to	nucleic	acid	extraction	 281 
employing	 a	 heat	 lysis	 method	 as	 previously	 described	 (66).	 Briefly,	 a	 sweep	 of	 282 
pneumococcal	colonies	was	obtained	from	primary	BA	plates	that	were	inoculated	with	 283 
thawed	 STGG	 aliquots	 containing	 either	 pneumococcal	 control	 strains	 or	 carriage	 284 
isolates.	The	colony	sweeps	were	resuspended	 in	100	μl	of	phosphate-buffered	saline,	 285 
pH	 7.4	 (PBS;	 Sigma-Aldrich,	 St.	 Louis,	 MI)	 thereafter	 heated	 at	 95
o
C	 for	 5	 min.	 The	 286 
supernatant	containing	genomic	DNA	(gDNA)	was	ten-fold	serially	diluted	in	PBS	before	 287 
nucleic	acid	amplification.	 288 
3.4.1.4	 Real-time	multiplex	PCR	assay	 289 
The	 rmPCR,	 designed	 as	 a	 7x3-plex	 that	 targets	 21	 serotypes.	We	 used	 the	multiplex	 290 
scheme	for	an	African	region,	based	on	a	relatively	limited	sample	observed,	table	S3.1	 291 
(39).	This	assay	targets	all	the	pneumococcal	serotypes	included	in	PCV-13	and	8	other	 292 
additional	 serotypes/-groups	 (PCV-13	 serotypes:	 1,	 3,	 4,	 5,	 6A/6B,	 7F/7A,	 9V/9A,	 14,	 293 





master	mix	 (Bioline,	 Taunton,	MA),	 primers	 and	 probes	 for	 serotype	 as	 described	 by	 298 
Pimenta	 et	 al,	 5	 µl	 gDNA	 (diluted	 1:1000)	 and	 nuclease/RNase-free	 water	 (Applied	 299 





3.4.1.5	 Sequetyping	assay	 305 
The	 assay	was	 performed	 as	 previously	 described	 (38)	with	minor	modification:	 the	 306 
PCR	reaction	comprised	12.5	µl	of	2X	KAPA	Taq	Ready	Mix®	(KAPA	Biosystems,	Boston,	 307 
MA),	 1	 µl	 of	 primer	 mix,	 2	 µl	 gDNA	 (diluted	 1:10),	 8.5	 µl	 nuclease/RNase-free	 H2O	 308 
(Applied	Biosystems)	in	a	final	volume	of	25	µl	(Table	S3.9).	Thermal	cycling	consisted	 309 
of	 an	 initial	 denaturation	 at	 95°C	 for	 5	min,	 followed	 by	 30	 cycles	 of	 denaturation	 at	 310 
95°C	for	30	s,	annealing	at	65°C	for	30	s,	and	extension	at	72°C	for	90	s	employing	an	 311 
Applied	 Biosystems®	 2720	 Thermal	 Cycler	 (Applied	 Biosystems).	 The	 PCR	 products	 312 






PCR	 products	 were	 prepared	 for	 sequencing	 employing	 Exo-SAP	 IT
®
	 (Affymetrix,	 317 
Maumee,	OH)	 according	 to	 the	manufacturer’s	 instructions.	 Prepared	 amplicons	were	 318 
submitted	 for	 cycle	 sequencing	 employing	 the	BigDye
®
	 Sequence	Terminator	kit	V3.1	 319 
(Applied	 Biosystems)	 and	 analysed	 on	 an	 ABI	 3500	 XL	 Genetic	 Analyzer	 (Appplied	 320 
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Biosystems)	 by	 Inqaba	 Biotech	 (Inqaba	 Biotechnical	 Industries	 [Pty]	 Ltd,	 Pretoria,	 321 
South	Africa).	 Sequencing	was	 performed	 in	 both	 directions	 using	 forward	 (cps1),	 5’- 322 
GCA	ATG	CCA	GAC	AGT	AAC	CTC	TAT-3’,	and	reverse	(cps2),	5’-CCT	GCC	TGC	AAG	TCT	 323 
TGA	TT-3’	primers.		 324 
DNA	 sequences	 obtained	 were	 assembled	 and	 edited	 using	 DNA	 Baser	 Sequence	 325 
Assembler	v4	(www.DnaBaser.com).	The	consensus	sequences	were	used	to	interrogate	 326 
the	 GenBank	 database	 (http://www.ncbi.nlm.nih.gov/blast/)	 and	 assign	 a	 serotype	 327 
using	 the	 criteria	 as	 per	 protocol	 (38).	 Briefly,	 the	 serotype	 of	 the	 wzh	 nucleotide	 328 
sequence	from	GenBank	with	the	highest	BLAST	bit	score	was	assigned,	provided	that	 329 
sequence	identity	was	>98%	with	the	query	amplicon	nucleotide	sequence.		 330 
3.4.1.6	 Sequetyper	program	 331 
To	 automate	 the	 above	 process,	 a	 Java-based	 program,	 Sequetyper	 (available	 at	 332 
http://www.gematics.com/sequetyper.html)	 was	 developed	 and	 validated	 to	 333 
automatically	 analyse	 and	 determine	 the	 pneumococcal	 serotype	 based	 on	 334 
interrogation	 of	 GenBank	 with	 the	 input	 forward	 and	 reverse	 sequences	 of	 the	 335 
generated	wzh	 amplicon.	 This	 application	 is	 suitable	 for	 high-throughput	 analysis	 of	 336 
sequetyping	 data.	 Briefly,	 the	 Sequetyper	 program	 will	 search	 within	 a	 given	 input	 337 
directory	 for	 the	 forward	 and	 reverse	 compliment	AB1	 sequencing	 trace	 files	 using	 a	 338 
file-naming	convention	(detailed	in	the	help	menu	of	the	program),	perform	base	calling	 339 
using	 a	 Phred-scaled	 quality	 cut-off	 value	 of	 0.05.	 Phred-scaled	 quality	 scores	 are	 340 




figure	 9	 where	 a	 thymine	 nucleotide	 base	 has	 been	 assigned	 a	 Phred-scaled	 quality	 344 
score	of	50.		 345 
Table	6:	Phred	quality	scores	 346 
Phred Quality Score Error (Probability of incorrect  
base call) 
Base call accuracy (1-Error) 
10 1 in 10 = 10% 90% 
20 1 in 100 = 1% 99% 
30 1 in 1000 = 0.1% 99.9% 
40 1 in 10000 = 0.01% 99.99% 
50 1 in 100000 = 0.001% 99.999% 
60 1 in 100000 = 0.0001% 99.9999% 
 347 
 348 
Figure	9:	Phred	quality	scores.	The	quality	of	 the	electropherograph	are	assesed	based	on	the	 349 




This	 implies	 that	 there	 is	 a	 1	 in	 100,000	 chance	 (99.999%	 base	 call	 accuracy)	 of	 354 
incorrectly	calling	the	thymine	nucleotide	base.	The	sequence	and	quality	files	are	read	 355 
in	 and	 the	 consensus	 sequences	 are	 used	 to	 perform	 a	 blastn	 alignment	 using	 four	 356 
stringent	 criteria.	These	output	 files	 are	 also	 generated	with	 the	 results	 for	 review.	A	 357 
typical	Phred-quality	output	 for	serotype	19F	(ATTCC	49619)	 is	 shown	 in	 figure	S3.1.	 358 
The	sequetyper	has	a	local	database	of	nucleotide	sequences	that	are	derived	from	four	 359 




nucleotide	 sequences;	 while	 the	 third	 criterion	 return	 any	 pneumococcal	 	 nucleotide	 362 
sequence	(This	reduces	the	risk	of	not	picking	up	any	nucleotide	sequences	that	do	not	 363 
indicate	 the	 serotype	 name	 in	 its	 filename)	 excluding	 shortgun	 sequences;	 and	 the	 364 
fourth	 criterion	 involves	 a	 search	 for	 pneumococcal	 	 nucleotide	 sequences	 from	 the	 365 
Capsular	 Sequence	 typing	 database	 (34).	 Sequetyper	 then	 performs	 a	 comprehensive	 366 
search	 across	 all	 the	 four	 criteria,	 returns	 a	 pool	 of	 all	 nucleotide	 sequences	with	 an	 367 
identity	of	>95%.	The	algorithm	then	searches	within	this	pool	only	and	best	alignment	 368 
with	a	nucleotide	sequence	identity	of	>98%	from	the	four	criteria	to	assign	a	serotype.	 369 
The	 output	 files	 are	 generated	 in	 either	 “.html”,	 “.xls”	 or	 “.txt”	 format.	 Because	 the	 370 
algorithm	uses	a	local	BLAST	search,	the	program	can	run	offline	and	does	not	require	 371 
Internet	 connectivity.	 This	 application	 is	 suitable	 for	 high-throughput	 analysis	 of	 372 
sequetyping	 data.	 Sequetyper	 was	 validated	 employing	 175-paired	 forward-	 and	 373 
reverse	 sequences	 generated	 during	 the	 study.	 Briefly,	 manually	 identified	 sequence	 374 
identities	 were	 re-evaluated	 blindly	 through	 sequetyper	 and	 results	 compared.	 Two	 375 
manual	vs.	sequetyper	discordant	 identities	were	obtained,	and	subsequent	to	manual	 376 
re-evaluation	assigned	according	to	original	sequetyper	results.	The	discordant	results	 377 
were	due	to	as	a	result	of	mislabeling	of	AB1	files	such	that	the	algorithm	returned	with	 378 
an	error	while	 the	 second	was	due	 to	 a	DNABaser	miscalling	 a	nucleotide	base	when	 379 
generating	a	contig.	 380 
3.4.2	 Discordant	Analysis		 381 
3.4.2.1	 Quellung	testing	 382 
Pneumococcal	 control	 and	 nasopharyngeal	 isolates	 were	 submitted	 to	 CRDM	 for	 383 




3.4.1.2	 Next-generation	sequencing	 387 
Three	 pneumococcal	 carriage	 isolates	 serotyped	 as	 16F	 by	 Quellung	 and	 rmPCR	 but	 388 
identified	 as	 9V	 by	 sequetyping	were	 subjected	 to	WGS.	 The	 3	 discordant	 isolates	 as	 389 
well	as	a	control	strain	identified	as	9V	by	Quellung,	sequetyping	and	rmPCR	were	also	 390 




determine	 absolute	 concentration,	 polyphenolic/polysaccharide/chaotropic	 salt	 395 
contamination	and	gDNA	integrity	respectively.	Quantified	gDNA	was	submitted	to	the	 396 
Centre	 for	 Proteomics	 and	 Genomic	 Research	 (CPGR)	 for	 WGS.	 Briefly,	 sequencing	 397 
libraries	 were	 generated	 using	 the	 Nextera	 XT	 DNA	 Sample	 Prep	 Kit	 (Illumina,	 San	 398 




3.4.1.3	 De	novo	sequence	assembly		 403 
The	quality	of	the	output	sequence	data	was	assessed	using	FastQC	(69)	and	sequencing	 404 
adapters	were	 trimmed	using	Trimmomatic	 (70).	The	3'-end	nucleotides	with	PHRED	 405 




individually	 using	 RAST	 (Rapid	 Annotation	 using	 Subsystem	 Technology)	 (73).	 The	 409 
contigs	containing	putative	cps	regions	were	identified	through	the	standalone	blastall	 410 
homology	 searches	 against	 the	 16F	 (Accession:	 CR931668)	 and	 9V	 (Accession:	 411 
CR931648)	annotated	reference	genomes	and	then	extracted	to	a	separate	file	using	a	 412 
shell	 command	based	 on	 SAM	 tools	 (74).	 These	 contigs	were	 then	 aligned	 and	 visual	 413 
representation	 of	 the	 alignments	was	 performed	 using	 the	 Artemis	 Comparison	 Tool	 414 
(ACT)	v6	and	WebACT	(75).		 415 
3.4.3	 Data	analysis	 416 




than	 one	 isolate	was	 tested	 from	 the	 same	 child,	 isolates	 of	 the	 same	 serotype	were	 421 
included	only	once	in	the	analysis.		 422 
3.4.4	 Ethical	consideration	 423 
Ethical	 approval	 was	 obtained	 from	 the	 Human	 Research	 Ethics	 Committee	 of	 the	 424 
Faculty	 of	 Health	 Sciences,	 University	 of	 Cape	 Town	 (HREC	 ref:	 062/2011)	 and	 the	 425 
Western	Cape	Provincial	 Child	Health	Research	 committee.	Mothers	provided	written	 426 
informed	consent	at	enrolment.	 427 
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3.5	 RESULTS		 428 
3.5.1	 Method	Comparison	 429 
3.5.1.1	 Assessment	of	nucleic	acid	quality	 430 
Table	7	shows	a	summary	of	the	nucleic	acid	extraction	and	quality	assessment	of	the	 431 














1	 11A	 51.1	 1.66	 +	 +	
2	 6A	 326.3	 1.89	 +	 +	
3	 7F	 67.4	 1.80	 +	 +	
4	 23A	 87.3	 1.82	 +	 +	
5	 9V	 73.6	 1.77	 +	 +	
6	 15B	 125.7	 1.97	 +	 +	
7	 2	 157.1	 1.97	 +	 +	
8	 15F	 157.5	 1.68	 +	 +	
9	 19F	 120.7	 1.83	 +	 +	
10	 3	 112.1	 1.77	 +	 +	
11	 27	 93.7	 1.77	 +	 +	
12	 9N	 445.7	 1.95	 +	 +	
13	 16F	 245.4	 1.99	 +	 +	
14	 33F	 181.8	 1.84	 +	 +	
15	 4	 209.6	 1.89	 +	 +	
16	 12F	 22.8	 1.89	 +	 +	
17	 19A	 229.6	 1.78	 +	 +	
18	 23B	 173.9	 1.89	 +	 +	
19	 15A	 242.8	 1.88	 +	 +	
20	 31	 120.5	 1.89	 +	 +	
21	 28A	 38.2	 1.93	 +	 +	
22	 35B	 122.2	 1.84	 +	 +	
23	 14	 201	 1.91	 +	 +	
24	 12B	 77.5	 1.83	 +	 +	
25	 8	 71.7	 1.91	 +	 +	
26	 33A	 147	 1.85	 +	 +	
27	 46	 259.4	 2.04	 +	 +	
28	 10A	 28.4	 1.77	 +	 +	
29	 35C	 48	 1.65	 +	 +	
30	 18C	 83.4	 1.76	 +	 +	
31	 10F	 101.9	 1.65	 +	 +	
32	 21	 11.1	 1.72	 +	 +	
 96 
+,	detected;	 -,	not	detected.	 *16S	rRNA	PCR	was	performed	as	described	by	Woo	et	al	 436 
(77).	 437 
3.5.1.2	 Real-time	multiplex	PCR		 438 
Of	 the	 40	 pneumococcal	 control	 isolates	 subjected	 to	 rmPCR,	 25	 isolates	 yielded	 a	 439 
positive	 signal;	 15	 isolates	 failed	 to	 yield	 detectable	 amplification	 signal	 (Figure	 10).	 440 
The	serotype	identities	of	these	isolates	were	not	included	in	the	rmPCR	assay.	Of	the	25	 441 
rmPCR	 positive	 isolates,	 results	 were	 100%	 (25/25)	 concordant	 with	 Quellung	 442 
confirmed	serotypes	(Table	8).		 443 
33	 22F	 29.7	 1.99	 +	 +	
34	 23F	 105.1	 1.96	 +	 +	
35	 6C	 113.1	 1.76	 +	 +	
36	 1	 87.2	 1.82	 +	 +	
37	 5	 112.3	 1.86	 +	 +	
38	 7C	 93.2	 1.78	 +	 +	
39	 11B	 88.7	 1.89	 +	 +	
40	 24B	 107.3	 1.74	 +	 +	
 97 
 444 
Figure	 10:	 Screenshot	 of	 the	 plate	 set	 up	 and	 results	 of	 the	 sequential	 triplex	 real-time	 PCR	 445 























































3.5.1.3	 Sequetyping		 453 
Of	 the	40	pneumococcal	 control	 isolates	 subjected	 to	 sequetyping,	33	 isolates	yielded	 454 
single	amplicons	of	~	1,061	bp;	7	 isolates	 failed	 to	yield	detectable	amplicons	(Figure	 455 
11).	 Sequence	 analysis	 yielded	 29/33	 (88%)	 sequetype-Quellung	 concordant	 results	 456 








Figure	11:	Agarose	gel	electrophoresis	of	amplicons	generated	by	 the	sequetyping	assay.	 	The	 464 
figure	 shows	 ethidium	 bromide-stained	 amplicons	 of	 pneumococcal	 control	 strains	 including	 465 
controls	 generated	by	 the	 sequetyping	 assay.	 Lanes	1,	 20,	 21	 and	40:	 1-Kb	molecular	marker	 466 
(Bioline);	Lane	2:	Non	template	control;	Lane	3:	pneumococcal	ATCC46919;	Lanes	4-19	and	22- 467 
39:	pneumococcal	control	strains. 468 
3.5.1.4	 Carriage	isolates	 469 







Serotype	(n)a	 rmPCR	(n)	b	 Sequetyping	(n)	 Remarks	
1	(1)	 100%	(1)	 100%	(1)	 	
3	(1)	 100%	(1)	 100%	(1)	 	
4	(1)	 100%	(1)	 100%	(1)	 	
 100 
6A	(2)	 100%	(2)	 50%	(1)	 2	rmPCR	as	6A/6B;	1	sequetyped	as	9V	
6B	(11)	 100%	(11)	 100%	(11)	 11	rmPCR	as	6A/6B	
6C	(1)	 100%	(1)	 100%	(1)	 1	rmPCR	as	6C/6D;	1	sequetyped	as	6C/6D	
10A/11A	(1)	 100%	(1)	 100%	(1)	 1	rmPCR	as	11A/11D;	1	sequetyped	as	10A	
11A	(8)	 100%	(8)	 75%	(6)	 8	rmPCR	as	11A/11D;	6	sequetyped	as	
11A/11D/18F;	2	no	amplicon	in	sequetyping	
14	(5)	 100%	(5)	 100%	(5)	 	
15A	(10)	 100%	(10)	 100%	(10)	 10	rmPCR	as	15A/15F	
16F	(8)	 100%	(8)	 63%	(5)	 3	sequetyped	as	9V	
17F/1¥	(2)	 100%	(2)	 100%	(2)	 2	rmPCR	as	1;	2	sequetyped	as	1	
18C	(3)	 100%	(3)	 33%	(1)	 3	rmPCR	as	18A/18B/18C/18F;	1	sequetyped	
as	18B,	2	sequetyped	with	low	identity	score	
19A	(8)	 100%	(8)	 75%	(6)	 2	no	amplicon	in	sequetyping	
19F	(5)	 100%	(5)	 100%	(5)	 	
22F	(2)	 100%	(2)	 100%	(2)	 2	rmPCR	as	22A/22F;	2	sequetyped	as	
22A/22F	
7C	(1)*	 N/A	 100%	(1)	 	
9N	(4)*	 N/A	 100%	(4)	 	
10A	(8)*	 N/A	 100%	(8)	 	
13	(14)*	 N/A	 93%	(13)	 1	sequetyped	as	15B;	13	sequetyped	as	13/20	
15B	(7)*	 N/A	 100%	(7)	 7	sequetyped	as	15B/15C	
15C	(7)*	 N/A	 100%	(7)	 7	sequetyped	as	15B/15C	
17F	(3)*	 N/A	 33%	(1)	 2	sequetyped	as	33C	
19B	(2)*	 N/A	 100%	(2)	 1	sequetyped	as	19C,	1	sequetyped	as	19F	
21	(5)*	 N/A	 100%	(5)	 	
25A/38	(3)*c	 N/A	 Negd	 3	no	amplicon	in	sequetyping	
35A	(9)*	 N/A	 89%	(8)	 8	sequetyped	as	33A/33F/35A,	1	sequetyped	
as	13/20	
OMNI	NEG	(3)	 Neg	 Neg	 	
	 	 	 	
Total	(132)	 69	 112	 	
The	 numbers	 in	 closed	 brackets	 indicate	 the	 correct	 identification	 of	 a	 Quellung-confirmed	 477 
serotype	by	the	rmPCR	and	sequetyping	assays;	brmPCR:	real-time	multiplex	PCR;	*	=	serotypes	 478 


















Yes	 No	 Negative	 Yes	 No	 Negative	 	
Quellung	
	
Typable	 69	 0	 63¥	 112	 13	 7	 132	
nontypable	 0	 0	 3	 0	 0	 3	 3	
Total	 	 69	 0	 66	 112	 13	 10	 135	
 101 
Of	 the	135	pneumococcal	nasopharyngeal	 isolates	 that	were	 sequetyped,	125	 isolates	 489 
yielded	 single	 amplicons	 of	~	 1,061bp.	 A	 correct	 serotype/-group	was	 determined	 in	 490 
112	 (85%)	 of	 the	 132	 nasopharyngeal	 isolates.	 The	 partial	 wzh	 sequence	 of	 2/3	 491 
Quellung	 18C	 isolates	 did	 not	 match	 any	 of	 the	 pneumococcal	 wzh	 sequences	 in	 492 
GenBank	with	>98%	identity	while	the	third	was	determined	as	18B.	The	wzh	PCR	was	 493 
negative	 for	 seven	 isolates	 of	which	 three	were	 serotype	25A/38;	 two	were	 serotype	 494 
11A	 and	 two	 were	 serotype	 19A,	 as	 confirmed	 by	 Quellung	 testing.	 Consistent	 495 
misidentifications	 by	 sequetyping,	 occurring	 in	more	 than	 one	 isolate,	were	 observed	 496 
for	 serotype	 16F	 (two	 isolates	 sequetyped	 as	 9V)	 and	 for	 serotype	 17F	 (two	 isolates	 497 
sequetyped	as	33C).		 498 
Figure	 12	 shows	 the	 serotype	 distribution	 of	 the	 pneumococcal	 isolates,	 excluding	 499 
duplicate	 isolates	 of	 the	 same	 serotype	 from	 the	 same	 infant.	 The	 most	 frequently	 500 
identified	serotypes	were	11A	(9	infants),	13	(8	infants),	15B,	15C	(both	7	infants),	16F	 501 
and	 10A	 (both	 6	 infants).	 Of	 the	 91	 isolates	 (the	 total	 number	 of	 isolates	 when	 502 









3.5.2	 Discordant	Analysis	 511 
3.5.2.1	 Next-generation	sequencing		 512 
A	total	of	14.3	million	paired-end	sequence	reads	(2	x	250)	were	obtained	for	the	four	 513 
samples	as	 shown	 in	 table	11.	The	quality	 control	 steps	used	preserved	 the	 sequence	 514 









































































































































One	of	pneumococcal	control	strains	and	 two	DCHS	strains	were	serotyped	as	16F	by	 521 
Quellung	and	rmPCR,	but	mistyped	as	9V	by	sequetyping.	A	comparison	of	the	cps	gene	 522 
loci	showed	that	the	wzh	sequence	of	all	the	three	queried	16F	strains	was	entirely	9V- 523 
like	 (Figure	 13).	 This	 is	 in	 contrast	 to	 the	 rest	 of	 their	 cps	 loci:	 which	 in	 terms	 of	 524 
structural	gene	organization	as	well	as	 specific	 sequence	of	 these	genes	were	entirely	 525 
16F-like.	 Comparative	 genome	 analyses	 of	 the	 annotated	 gene	 structure	 showed	 a	 526 
marked	 clustering	 for	 the	 other	 three	 queried	 16F	 serotypes	 all	 were	 significantly	 527 
different	 from	 the	9V	 reference	 (Figure	14).	MLST	 loci	 of	 these	16F	 strains	 showed	a	 528 
shared	 a	 16F-like-MLST-type,	 except	 the	 third	 strain	 (103385)	 which	 had	 a	 unique	 529 















9V	 1	688	340	 52	 57.1	 2.1	 144x	
16F	 4	621	214	 47	 68.1	 2.1	 368x	
103347	 2	226	252	 62	 77.3	 2.1	 184x	
103385	 5	773	884	 56	 82.3	 2.1	 437x	
Sample	 ST	 aroE*	 ddl	 gdh	 gki	 recP	 spi	 xpt	
9V_NICD	 6530	 1	 6	 11	 10	 5	 6	 1	
16F_NICD	 5326	 50	 31	 9	 15	 1	 36	 3	
103347	 4088	 50	 14	 8	 1	 16	 6	 88	
103385	 ??	 50	 31	 ??	 15	 1	 36	 3	
 104 
 537 




serotype	9V	reference,	 the	middle	 lines	represent	the	queried	16F	strain	and	the	bottom	lines	 542 
shows	the	16F	reference.	The	portion	of	the	wzh	gene	that	is	amplified	by	the	sequetyping	assay	 543 
















Figure	 14	 Comparative	 genome	 analysis	 of	 pneumococcal	 serotypes	 16F	 and	 9V.	 When	 the	 550 


















3.6	 DISCUSION	 564 
To	identify	the	accuracy	of	a	rapid	high	throughput	molecular	serotyping	assay,	rmPCR	 565 




serotypes/-groups	in	PCV-13,	all	of	which	were	included	in	our	analysis.	 	Concordance	 570 
with	 Quellung	 was	 100%	 (25/25)	 for	 those	 control	 isolates	 included	 in	 the	 rmPCR	 571 
panel.		 572 
Amongst	the	pneumococcal	carriage	isolates	tested,	the	correct	serotype/-group	could	 573 
be	assigned	 to	52%	of	 typable	 isolates	 (69/132)	by	rmPCR.	47%	(63/132)	of	 isolates	 574 
were	not	included	in	the	rmPCR	panel,	and	therefore	the	rmPCR	was	100%	accurate	for	 575 
those	 isolates	 included	 in	 the	panel.	The	high	number	of	negative	results	 from	rmPCR	 576 
amongst	nasopharyngeal	isolates	was	not	surprising	since	this	assay	is	likely	to	be	less	 577 
useful	 in	 areas	 where	 pneumococcal	 conjugate	 vaccines	 have	 been	 implemented	 578 
resulting	 in	 serotype	 replacement	 which	 may	 arise	 as	 a	 result	 of	 either	 serotype	 579 
unmasking	 or	 capsular	 switching.	 Data	 from	 the	 United	 States	 on	 invasive	 580 
pneumococcal	isolates	showed	a	decline	in		serotypes	included	in	the	rmPCR	assay	from	 581 
92%	(3812/4106)	prior	to	PCV-7	implementation	to	79%	(2939/3708)	after	PCV-7	roll	 582 
out	 	 and	 a	 further	 decrease	 to	 74%	 (2581/3480)	 post	 PCV-13	 implementation	 583 
(Unpublished	 US	 Active	 Bacterial	 Core	 surveillance	 data).	 Amongst	 our	 small	 cohort,	 584 
non-vaccine	 serotypes	 11A,	 13,	 15B,	 15C,	 16F	 and	 10A	 were	 the	 most	 prevalent	 585 
serotypes	 identified.	 Similarly,	 data	 from	a	number	 of	 other	post	PCV-13	 surveillance	 586 
studies	have	reported	serotypes	11A,	15A/B/C,	16,	but	also	22F,	21	and	34	as	prevalent	 587 
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PCR	 for	 7	 strains	 and	 misidentification	 of	 4	 serotypes.	 	 Amongst	 nasopharyngeal	 600 
isolates,	 85%	 of	 typable	 isolates	 (112/132)	were	 correctly	 identified	 by	 sequetyping.	 601 
For	7	isolates	no	PCR	product	was	obtained	and	sequetyping	misidentified	13	isolates.	 602 
Based	on	published	sequence	data	one	would	have	expected	 the	sequetyping	assay	 to	 603 




advantage	 of	 this	 technique.	 It	 is	 not	 clear	why,	 in	 this	 study,	 amplification	 failed	 for	 608 
7/40	 (18%)	 control	 strains.	 Interrogation	 of	 published	 gene	 sequences	 for	 these	 609 
serotypes	 indicated	 that	 these	 serotypes	 should	 generate	 PCR	 products	 with	 the	 610 
protocol	used	here	(38).	PCR	inhibition	was	excluded	based	on	successful	lytA	PCR	in	all	 611 
7	 strains.	 Interestingly,	 four	 of	 the	 nasopharyngeal	 carriage	 isolates	 that	 failed	 to	 612 
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amplify	 during	 sequetyping	 were	 serotypes	 for	 which	 a	 similar	 problem	 was	 613 
encountered	 when	 sequetyping	 the	 control	 isolates	 (serotypes	 11A	 and	 19A).	 The	 614 
remaining	 three	 sequetype-negative	 isolates	 were	 of	 serotype	 25A/38	 which	 were	 615 
expected	to	be	non-amplifiable	because	of	absence	of	the	reverse	primer	binding	site	in	 616 
the	 wzd	 gene	 (1,38,87).	 Sequetyping	 misidentified	 three	 control	 strains	 (for	 which	 617 
Quellung	and	rmPCR	were	concordant).	The	sequence	obtained	 from	wzh	amplicon	of	 618 
serotype	2	did	not	match	any	of	the	wzh	nucleotide	sequences	in	GenBank	with	>98%	 619 
sequence	identity.	The	original	study	describing	sequetyping	did	not	test	this	serotype	 620 
although	 their	 insilico	 analysis	 had	 predicted	 that	 the	 primer	 sets	 should	 be	 able	 to	 621 
amplify	 serotype	 2	 (38).	 Further	 tests	 are	 needed	 to	 resolve	 this,	 particularly	 re- 622 




results	 by	 Quellung.	 Misidentification	 of	 17F	 isolates	 as	 33C	 was	 predicted	 by	 the	 627 




16F	was	 entirely	 9V-like,	 the	 serotype	 specific	wzy/wzx	 genes	were	 entirely	 16F-like.	 632 
Based	on	analysis	of	the	core	genome,	the	16F	control	strain	was	identified	as	sequence	 633 
type	(ST)	5326,	one	of	the	nasopharyngeal	isolates	was	identified	as	ST4088,	while	the	 634 
other	 nasopharyngeal	 isolates	 was	 a	 new	 ST,	 which	 was	 a	 single-locus	 variant	 of	 635 
ST5326.	 These	 sequence	 types	 are	 all	 commonly	 associated	 with	 serotype	 16F	 (75).	 636 
Therefore,	our	strains	seem	to	be	16F	strains	 in	almost	every	sense;	 they	only	have	a	 637 
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9V-wzh	gene.	This	structural	difference	is	not	expected	to	have	occurred	as	in	response	 638 
to	 vaccine	 pressure,	 because	none	 of	 the	 currently	 used	 vaccine	 formulations	 include	 639 
serotype	16F	and	 the	exchanged	9V	gene	does	not	 result	 in	 a	modified	phenotype.	 In	 640 
practice,	 in	our	setting,	each	isolate	with	a	9V	sequetype	result	should	be	investigated	 641 
further.	 642 
Both	 molecular	 assays	 are	 able	 to	 type	 many	 pneumococcal	 strains	 only	 to	 the	 643 
serogroup	 level.	 Discrimination	 of	 individual	 serotypes	 within	 a	 serogroup	 may	 be	 644 
important	 for	 more	 detailed	 assessment	 of	 carriage	 and	 vaccine	 effectiveness.	 When	 645 
selecting	 a	 serotyping	 method,	 test	 characteristics	 other	 than	 accuracy	 may	 also	 be	 646 
relevant.	 The	 sequetyping	 assay,	 which	 involves	 a	 single	 amplification	 step,	 is	 647 
inexpensive	compared	with	the	rmPCR	assay,	which	is	labour	intensive,	includes	many	 648 
costly	PCR	probes	 and	 is	 constrained	by	 the	 limited	multiplexing	options	of	 real-time	 649 
PCR.	 Interpretation	 of	 the	 sequetyping	 results	 is	 based	 on	 the	 publically	 available	 650 
GenBank	database.	An	advantage	of	this	is	its	free	accessibility,	but	the	uncontrolled	and	 651 
changing	nature	of	 this	database	 could	be	a	 risk	 for	 the	assignment	of	 serotypes.	Our	 652 
automated	 ‘sequetyper’	 application	makes	 analysis	 of	 the	 relevant	 sequence	 data	 for	 653 
sequetyping	 rapid	 and	 simple.	 A	 significant	 disadvantage	 of	 sequetyping	 is	 that	 the	 654 
targeted	wzh	gene	is	not	serotype-specific	and	does	itself	not	determine	serotype	–	the	 655 
results	are	 inferred	based	on	association.	 It	 is	entirely	 feasible	therefore	(as	we	found	 656 
here)	that	for	specific	serotypes	and	in	particular	populations	of	pneumococci	that	this	 657 
association	may	not	 correctly	 predict	 serotype.	 The	 technique	 is	 therefore	 likely	 only	 658 
useful	for	typing	pneumococci	from	populations	of	pneumococci	where	such	association	 659 
has	 been	 confirmed	 using	 another	 typing	 technique.	 In	 our	 case	 this	 would	 mean	 660 
confirming	serotype	for	a	smaller	subset	such	as	serotype	9V,	13,	20	and	serogroup	33.	 661 
The	 CDC	 Streptococcal	 laboratory	 has	 recently	 provided	 an	 extended	 version	 of	 the	 662 
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conventional	multiplex	PCR	assay	(not	available	at	 the	time	of	 this	study)	that	utilises	 663 
41	 serotype-specific	 primer	 sets	 to	 detect	 up	 to	 70	different	 pneumococcal	 serotypes	 664 
(http://www.cdc.gov/streplab/downloads/pcr-oligonucleotide-primers.pdf).	 The	basis	 665 
for	this	assay	is	similar	to	the	rmPCR	employed	here	although	less	costly.	The	benefits	 666 
of	deducing	more	than	70	serotypes	by	this	assay	needs	to	be	weighed	against	the	fairly	 667 
labour	 intensive	 protocol	 and	 risk	 of	 amplicon	 contamination.	 A	 comprehensive	 668 
multicenter	study	has	recently	compared	the	20	pneumococcal	serotyping	methods	and	 669 
shown	that	micro-arrays	(with	a	culture	amplification	step)	had	the	highest	sensitivity	 670 
and	 positive	 predictive	 value	 (95.8%	 and	 93.7%	 respectively)	 compared	 to	 other	 671 
methods	 (6).	 	 In	 addition,	 microarray	 performed	 better	 at	 detecting	 multiple	 672 




non-vaccine	 serotypes	 that	 can	 be	 detected,	 low	 cost	 and	 ease	 of	 use.	 Our	 results	 677 
suggest	 the	 need	 for	 an	 extended	 and	 carefully	 curated	 database	 of	 serotype-specific	 678 
sequence	data,	which	will	 increase	 the	accuracy	and	expand	 the	 serotype	 coverage	of	 679 
the	 sequetyping	 method.	 However,	 given	 the	 potential	 for	 gene	 exchange	 that	 could	 680 
result	 in	 false	 assignment	 of	 serotype	 by	 sequetyping,	 it	 is	 necessary	 to	 confirm	 681 
serotype	assignment	using	a	different	method.	This	may	still	be	cost-saving	as	it	would	 682 
involve	 testing	 only	 the	 specific	 serotype	 assigned	 by	 serotyping,	 using	 the	 Quellung	 683 
method,	 for	example.	The	rmPCR	assay,	 ideally	extended	to	 include	more	serotypes	 is	 684 
reliable	 but	 cost,	 time	 required	 to	 perform	 testing,	 and	 currently	 restricted	 serotype	 685 
coverage	may	limit	its	widespread	application	for	large	epidemiological	studies.	In	the	 686 
future	 it	 is	 likely	 that	WGS	will	 be	 increasingly	 used	 as	 a	 tool	 for	 serotype	 inference.	 687 
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WGS	has	many	advantages,	in	that	additional	information	(such	as	multi-locus	sequence	 688 
type	 and	 antimicrobial	 resistance)	 can	 be	 inferred	 from	 the	 same	 dataset	 without	 689 
additional	 testing,	 and	 that	 serotype	 can	 be	 definitively	 assigned.	 As	 sequence	 costs	 690 
decline	further,	bioinformatics	pipelines	are	increasingly	automated	and	the	technology	 691 
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4.1	 INTRODUCTION	 1070 
The	 pneumococcus,	 along	 with	 a	 myriad	 other	 bacterial	 species,	 forms	 part	 of	 the	 1071 
human	 commensal	 flora	 that	 colonises	 the	 nasopharyngeal	 (NP)	 mucosal	 epithelium	 1072 
asymptomatically	 (1).	 Children	 under	 the	 age	 of	 two	 years	 are	 more	 frequently	 1073 
colonised	 by	 pneumococci	 than	 older	 children	 and	 adults	 (2,3).The	 nasopharynx	 1074 
therefore	 serves	 as	 a	 reservoir	 and	 source	 for	 person-to-person	 transmission	 of	 1075 
pneumococci	 (2-4).	 Invasive	pneumococcal	 disease	 (IPD)	 is	 an	 evolutionary	dead-end	 1076 
because	none	of	the	common	forms	of	pneumococcal	disease,	promote	the	transmission	 1077 
of	 pneumococcus	 (5).	 This	 suggests	 that	 pneumococcal	 virulence	 determinants	 are	 1078 




developed	 countries	 (3,8,9),	 whereas	 25%	 -	 60%	 of	 older	 children	 from	 developing	 1083 
countries	 remain	 colonised	 (10-12).	 Pneumococcal	 carriage	 studies	 are	 important	 in	 1084 
understanding	 the	 dynamics	 of	 pneumococcal	 serotype-specific	 colonisation	 and	 the	 1085 
effects	of	vaccination	on	serotype	distribution.	 1086 
4.1.1	 Pneumococcal	carriage:	A	fundamental	step	in	 1087 
pneumococcal	disease	 1088 
The	 outcome	 of	 NP	 carriage	 involves	 a	 complex	 interplay	 between	 host-dependent	 1089 
factors	 such	 as,	 age,	 immune	 status,	 underlying	 medical	 conditions,	 pathogen- 1090 
dependent	 factors	 such	 as	 virulence	 characteristics	 of	 the	 colonising	 strain	 and	 co- 1091 
colonisation	 and	 interactions	 with	 other	 microbes.	 The	 mechanisms	 through	 which	 1092 
 121 
asymptomatic	carriage	evolves	into	invasive	disease	are	poorly	understood.	However,	it	 1093 
is	 believed	 that	 the	 adherence	 of	 the	 pneumococcus	 to	 the	 NP	 epithelial	 mucosa	 via	 1094 
multiple	receptor-ligand	interactions	is	the	initial	step	(13,14).	Host	mucosal	immunity	 1095 
including	mucus-mediated	 clearance,	 serotype-specific	 antibodies	 (immunoglobulin	 G	 1096 
[IgG],	 secretory	 IgA,	 IgM),	 complement,	 and	 opsonophagocytic	 cells	 are	 key	 to	 1097 
preventing	 acquisition	 of	 pneumococcal	 carriage	 (2,3).	 Escape	 from	 immunological	 1098 
control	 may	 result	 in	 establishment	 of	 colonisation,	 bacterial	 proliferation	 and	 1099 
increased	 colonisation	 density,	 which	may	 in	 turn	 lead	 to	 spread	 to	 the	 surrounding	 1100 
tissue	 compartments	 to	 cause	 non-invasive	 mucosal	 disease	 (otitis	 media	 [OM],	 1101 
sinusitis,	 pharyngitis),	 Figure	 15.	 Pneumococci	 may	 also	 be	 aspirated	 or	 spread	 by	 1102 





Figure	 15:	 Pneumococcal	 diseases	 and	 pathogenic	 route.	 An	 inoculum	 of	 pneumococci	 via	 1107 
airborne	droplets	may	 colonise	 the	nasopharynx	 and	 spread	 local	 from	 the	nasopharynx	 into	 1108 
the	middle	ear,	 sinus,	and	 larynx	 leading	 to	otitis	media,	 sinusitis,	and	 laryngitis,	 respectively.	 1109 
Pneumococci	 can	 also	 be	 aspirated	 into	 alveoli	 leading	 to	 pneumonia	 or	 translocate	 into	 the	 1110 
bloodstream	 or	 meninges	 and	 cause	 septicemia	 and	 meningitis	 respectively.	 Figure	 1111 
modified	from	Bogaert	et	al	(3)	 1112 
	 1113 




that	 exchange	 of	 genetic	 determinants,	 such	 as	 those	 encoding	 antibiotic	 resistance,	 1118 
virulence	and	serotype,	occurs	via	transformation,	enabling	the	bacterium	to	overcome	 1119 



















inherent	 limitation	of	underestimating	 the	 carriage	duration	 in	 instances	where	 some	 1122 
serotypes	 are	 carried	 for	 short	 durations.	 Pneumococcal	 carriage	 duration	 varies	 1123 
considerably	across	epidemiological	settings,	with	carriage	duration	estimates	ranging	 1124 
from	 10	 days	 (serotype	 3)	 to	 120	 days	 (serotype	 6B)	 (19,20).	 The	 duration	 of	 1125 




Cross-sectional	 pneumococcal	 carriage	 studies	 have	 been	 key	 in	 understanding	 1130 
pneumococcal	carriage	dynamics	pre	–	and	post	pneumococcal	conjugate	vaccine	(PCV)	 1131 
implementation	(25–28).	These	studies	however	fail	to	provide	data	on	the	acquisition	 1132 
and	 duration	 of	 carriage,	 by	 virtue	 of	 their	 cross-sectional	 design.	 Given	 the	 complex	 1133 
interplay	between	the	pneumococcus	and	other	potential	carriage	determinants	(3,29– 1134 
31),	 pneumococcal	 carriage	 dynamics	 are	 best	 understood	 from	 longitudinal	 data	 1135 
(7,9,11,15,18,19,21,32–37).	 When	 the	 sampling	 frequency,	 length	 of	 follow-up	 and	 1136 
clinical	data	collection	are	adequate,	longitudinal	study	designs	allow	the	estimation	of	 1137 
acquisition,	carriage	duration	and	relevant	risk	factors	(9,15,19,34).	 1138 
4.1.3	 Pneumococcal	serotype	distribution	 1139 
The	 pneumococcal	 sero-epidemiology	 among	 NP	 carriage	 isolates	 varies	 across	 1140 
geographical	region,	age	group,	and	ethnicity.		 1141 





(3.2%),	 3	 (2.8%),	 11	 (2.7%)	 and	 16F	 (2.3%)	 (34).	 In	 Kenya,	 prior	 to	 PCV-7	 1146 
implementation,	 children	 were	 colonised	 by	 serotypes	 6B	 (10.4%),	 14	 (10.4%),	 19F	 1147 
(5.4%),	9	(5.4%),	23F	(4.3%)	and	4	(1.1%).	Serotype	18C	was	also	not	detected	in	this	 1148 




9V	 (3%).	 Unlike	 the	 Kenyan	 study,	 serotype	 13	was	 not	 isolated	 in	 any	 of	 the	 South	 1153 
African	 children	 that	 were	 included	 in	 this	 study	 (46).	 Other	 non-PCV-7	 serotypes	 1154 
detected	among	South	African	children	were	serotypes	6A	(12%),	19A	(7%),	1	(5%),	15	 1155 
(3.8%),	11	(0.8%),	5	(2%),	3	(0.8%),	7F	(0.3%),	20	(0.4%),	16F	(0.4%)	and	20	(0.4%)	 1156 
(46,47).	 Such	 studies	 provide	 crucial	 baseline	 data	 for	 monitoring	 vaccine	 efficacy.	 1157 
Although	fluctuations	in	serotype	distributions	may	take	place	over	time	even	without	 1158 
obvious	 changes	 in	 selective	 pressures,	 significant	 changes	 in	 the	 pneumococcal	 1159 
population	 structure	 have	 been	 seen	 post	 PCV	 implementation	 and	 in	 relation	 to	 the	 1160 
volume	of	antibiotic	prescription	(48-50).	 1161 
	 1162 
Individual	 serotypes	 are	 associated	with	 differing	 potential	 to	 cause	 invasive	 disease,	 1163 
antimicrobial	 drug-resistance	 and	 have	 different	 global	 distribution	 patterns	 (30,38– 1164 
41).	 	Of	the	more	than	98	pneumococcal	serotypes	described	to	date	(42),	only	a	third	 1165 
account	for	approximately	≥70%	invasive	pneumococcal	disease	(IPD),	with	serotype/- 1166 
groups	 1,	 3,	 6,	 14,	 19	 and	 23	 being	 the	 most	 common	 causes	 of	 invasive	 disease	 1167 
worldwide	(43).	Prior	to	the	introduction	of	PCV-7,	serotype	14	was	noted	as	the	most	 1168 
common	 cause	 of	 IPD	 in	 the	 United	 States	 of	 America,	 Canada,	 Europe,	 Oceania	 and	 1169 
 125 
Latin	America,	while	serotypes	1,	5	and	serogroup	6	were	most	common	causes	of	IPD	 1170 
in	Asia	 and	Africa	 respectively(3,44).	Minor	 differences	 in	 serotype	 distribution	were	 1171 
noted	amongst	African	countries	in	the	pre-PCV-7	era.		 1172 
4.1.4	 Inter-and	intra	species	competition	within	the	NP	 1173 
microbiome:	A	fitness	test	of	a	“sugar-coated	commensal”	 1174 
Studies	of	the	NP	microbiome	have	identified	more	than	700	bacterial	species	including	 1175 
Moraxella	 spp,	 Staphylococcus	 aureus,	 Haemophilus	 spp.,	 Neisseria	 spp.,	 and	 1176 
Streptococcus	spp	(1).	It	is	believed	that	inter-	and	intra	species	competition	within	this	 1177 
ecological	niche	contributes	to	fluctuations	in	pneumococcal	carriage	over	time	(50,51).	 1178 
Interspecies	 competitive	 strategies	 includes	 production	 of	 bacteriocins	 (antimicrobial	 1179 
peptides	or	proteins)	which	attack	other	bacteria	and	are	accompanied	by	an	immunity	 1180 
protein	 to	 protect	 against	 self-destruction	 (52–55);	 production	 of	 hydrogen	 peroxide	 1181 




Intra-species	 competition	 within	 pneumococcal	 populations	 has	 been	 seen	 following	 1186 
the	routine	introduction	of	pneumococcal	conjugate	vaccine	(PCV)	(50,59–66).	PCVs	are	 1187 
efficacious	 against	 vaccine-serotype	 (VT)	 disease	 (67–73),	 discussed	 in	 chapter	 5.	 1188 
However,	non-vaccine-serotype	(NVT)	disease	has	increased	(60).	PCV	not	only	reduces	 1189 
VT	disease	but	 is	 also	 thought	 to	 reduce	 the	NP	 carriage	of	VT	 serotypes	 (50,74–77).	 1190 
The	 overall	 carriage	 of	 pneumococci	 within	 the	 nasopharynx	 has	 remained	 largely	 1191 
unchanged	 due	 to	 a	 parallel	 increase	 in	 the	 prevalence	 of	 NVT	 serotypes	 (50).	 This	 1192 
phenomena	occurs	either	through	capsular	switching	or	serotype	replacement	(loss	of	 1193 
 126 
competitive	 strains	 [VT]	 with	 emergence	 of	 previously	 out-competed	 strains	 [NVT])	 1194 
(28).	 Our	 current	 understanding	 of	 serotype-specific	 inter-dependencies	 is	 poorly	 1195 
explored,	 for	 example	 it	 is	 still	 largely	 unknown	 whether	 colonisation	 by	 one	 1196 
pneumococcal	 serotype	 makes	 it	 less	 likely	 for	 that	 specific	 individual	 to	 acquire	 a	 1197 
closely	 related	 or	 different	 pneumococcal	 serotype?	 Taken	 together,	 inter-	 and	 intra	 1198 
species	competitive	strategies	and	perturbations	of	the	NP	microbiome	(either	through	 1199 
antibiotics	or	vaccination)	provide	selection	pressures,	resulting	in	the	rapid	evolution	 1200 
of	 this	 species	 (2,28,37,50,60).	 Pneumococcal	 sero-epidemiology	 may	 therefore	 vary	 1201 
widely	 within	 and	 across	 different	 populations.	 Further,	 in	 order	 to	 develop	 more	 1202 
broadly	protective	vaccines,	we	need	to	improve	our	understanding	of	the	reasons	for	 1203 
persistent	 carriage	with	VT	 serotypes	 as	well	 as	 the	 indirect	 effects	of	 vaccination	on	 1204 
carriage	with	NVT	serotypes.	 1205 




1. Determine	serotype-specific	acquisition	rates	and	the	duration	of	pneumococcal	 1210 
carriage	in	the	nasopharynx	of	children.	 1211 





4.3.1	 Study	setting	 1216 
This	 study	 of	 137	 infants	 enrolled	 between	 May	 29th	 2012	 and	 May	 31
st
	 2014	 was	 1217 
nested	within	 a	 larger	 population-based,	 longitudinal,	 prospective	 birth-cohort	 study,	 1218 
the	Drakenstein	Child	Health	Study.	It	was	conducted	at	two	sites	in	Paarl,	a	peri-urban	 1219 
area	in	the	Drakenstein	sub-district	located	60	km	from	Cape	Town,	South	Africa	(78).	 1220 
The	study	sites	were	based	at	TC	Newman	and	Mbekweni	clinics,	 serving	a	combined	 1221 
population	 of	 200	 000	 people.	 The	 study	 location	 is	 a	 stable,	 semi-urban	 low	 1222 
socioeconomic	 status	 community	 in	 South	 Africa,	 with	 a	 high	 incidence	 of	 childhood	 1223 
pneumonia	 and	 where	 conjugate	 vaccines	 (H.	 Influenzae	 type	 b	 [HiB]	 and	 PCV)	 are	 1224 









18	 months	 amongst	 unimmunised	 children	 (79).	 PCV-13	 is	 administered	 in	 a	 2+1- 1230 
dosing	 schedule	 at	 6	weeks,	 14	weeks	 and	 9	months	 of	 age	 (79).	 The	 residents	 from	 1231 
both	areas	are	ethnically,	 linguistically	and	culturally	heterogeneous	with	TC	Newman	 1232 
serving	 an	 Afrikaans-speaking,	 mixed-race	 (coloured)	 community	 while	 participants	 1233 
from	Mbekweni	were	largely	isiXhosa-speaking	ethnic	black	Africans.	The	details	of	the	 1234 
study	 population	 and	 study	 design	 have	 been	 previously	 described	 (78).	 Briefly,	 1235 
questionnaires	about	maternal	health	were	administered	and	detailed	birth	information	 1236 
was	obtained	at	the	time	of	delivery	and	during	each	study	visit.	Trained	study	nurses	 1237 
performed	 the	 interviews	 in	 the	 mother’s	 home	 language.	 Data	 for	 pneumonia	 risk	 1238 
 128 
factors	and	the	child’s	respiratory	symptoms	were	obtained	at	scheduled	visits,	results	 1239 
presented	 in	 chapter	 5.	 Missed	 visits	 were	 re-booked	 with	 a	 study	 mobile	 phone	 1240 
network	system	or	by	study	community-based	fieldworkers.	 1241 
4.3.2	 Participant	enrollment	 1242 
Pregnant	 women	 (>18	 years)	 between	 20	 and	 28	 weeks’	 gestation	 and	 attending	 1243 





into	 1	 ml	 STGG,	 transported	 on	 ice	 to	 the	 laboratory	 and	 frozen	 at	 -80
o
C	 for	 batch	 1249 






















4.3.7	 Statistical	analysis	 1257 
Initial	exploratory	statistics	were	performed	using	STATA	software	(Stata	Corporation,	 1258 
College	 Station,	 TX)	 and	 the	 rest	 of	 the	 analyses	 were	 performed	 using	 the	 openly	 1259 
available	statistical	environment	R,	version	3.1.1(83).		 1260 
Definition	of	carriage	 1261 
A	 new	 acquisition	 of	 pneumococcal	 carriage	 was	 defined	 when	 a	 pneumococcal	 1262 
serotype	 was	 cultured	 from	 an	 NP	 swab	 for	 the	 first	 time	 or	 when	 a	 pneumococcal	 1263 
serotype	 was	 re-cultured	 after	 two	 consecutive	 negative	 NP	 swabs	 for	 that	 specific,	 1264 
figure	 17	 below	 (19,84).	 	 A	 pneumococcal	 carriage	 episode,	 representing	 ongoing	NP	 1265 
colonisation,	was	therefore	defined	as	the	period	between	acquisition	and	clearance	of	 1266 
the	same	pneumococcal	 serotype.	Pneumococcal	 carriage	duration	was	defined	as	 the	 1267 
difference	between	the	clearance	date	and	the	date	of	carriage	acquisition.	The	average	 1268 
duration	for	each	serotype	is	simply	the	average	of	each	individual’s	carriage	duration	 1269 





Figure	 17:	 Pneumococcal	 carriage	 definition.	 Black	 arrows	 labelled	W,	 X,	 Y	 and	 Z	 (including	 1274 




case	Y,	 at	week	16)	 of	 two	 consecutive	negative	 swabs	 (Y	 and	Z).	 Carriage	duration,	 C,	 is	 the	 1279 
difference	 between	 the	 clearance	 date	 and	 date	 of	 acquisition	 (that	 is	 B	 –	 A),	modified	 from	 1280 
Turner	et	al	(19).	 1281 
	 1282 
Time	 to	pneumococcal	acquisition	and	carriage	duration	were	determined	by	Kaplan- 1283 
Meier	 survival	 estimates	 and	 recurrent	 colonisation	 episodes	 determined	 by	 the	 1284 
conditional	gap-time	model.	Survival	analysis	is	the	analysis	of	time	to	failure.	The	Cox	 1285 
proportional	hazards	model,	a	semi	parametric	model	that	allows	for	no	assumptions	to	 1286 
be	 made	 about	 the	 parametric	 distribution	 of	 the	 survival	 times,	 was	 used.	 The	 1287 
proportional	 hazards	 assumption	 refers	 to	 the	 fact	 that	 the	 hazard	 functions	 are	 1288 
multiplicatively	 related.	 Further	 extensions	 were	 made	 to	 the	 Cox	 model,	 including	 1289 
investigation	 of	 the	 time	 to	 recurring	 events,	 when	 the	 events	 are	 not	 independent.	 1290 
Children	are	colonised	with	pneumococci	repeatedly	through	their	first	few	years	of	life.	 1291 
One	such	model	to	 investigate	the	time	to	recurring	events	 is	 the	model	developed	by	 1292 
Prentice,	Williams	 &	 Peterson	 (1981),	 commonly	 known	 as	 the	 conditional	 gap	 time	 1293 
model.	The	model	investigates	time	to	failure	from	the	subject’s	previous	time	of	failure.	 1294 
Here	 the	 survival	 function	 measures	 the	 probability	 of	 not	 experiencing	 the	 second	 1295 
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event	before	time!! − !!on	condition	that	the	individual	experienced	the	first	failure	at	 1296 
time!!,	where!!	and!!are	the	failure	times	of	the	first	and	second	events	respectively	 1297 
	 1298 
4.3.8	 Ethical	considerations	 1299 




4.4	 RESULTS	 1304 
4.4.1	 Demographic	characteristics	 1305 
One	hundred	and	thirty	seven	infants	(median	age	at	censoring,	365	days;	interquartile	 1306 
range,	 IQR	363	 –	 366)	were	 enrolled	 in	 the	 present	 study.	 A	 total	 of	 3331	NP	 swabs	 1307 













4.4.2		 Pneumococcal	acquisition	dynamics	 1320 
Figure	 19	 shows	 the	 survival	 curve	 estimates,	 by	 age,	 for	 the	 first	 acquisition	 of	 a	 1321 
pneumococcal	strain.	All	but	seven	children	were	colonised	at	least	once	by	260	days	of	 1322 
life.	Three	children	were	never	colonised	during	their	first	year	of	life.	By	120	days,	75%	 1323 
of	 the	 children	 had	 been	 colonised	 by	 a	 pneumococcus	 at	 least	 once.	 Given	 our	 1324 
observation	 above	 that	 a	 child	 can	 have	 recurrent	 pneumococcal	 carriage	 acquisition	 1325 
episodes,	we	applied	the	conditional-gap	time	model	to	account	for	the	multiple	failure	 1326 
events,	 figure	20.	Children	often	took	longer	to	acquire	their	first	carriage	episode	but	 1327 





















Figure	 19:	 Kaplan	 Meier	 survival	 estimate	 showing	 the	 time	 to	 first	 pneumococcal	 carriage	 1334 
episode	in	a	cohort	of	South	African	children	during	their	first	year	of	life,	n=137.	 1335 
	 1336 
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1st	 137	 134	 63	 55	-	90	
2nd	 134	 128	 36	 28	-	47	
3rd	 127	 122	 28	 21	-	35	
4th	 122	 113	 28	 19	-	35	
5th	 111	 102	 31	 28	-	42	
6th	 98	 89	 32	 22	-	42	
7th	 84	 73	 28	 21.5	-	35	
8th	 68	 56	 28	 15	-	42	
9th	 51	 42	 28	 17	-	42	
10th	 40	 34	 35	 28	-	56	
11th	 30	 19	 28	 21	-	NA	
12th	 15	 11	 49	 27	-	NA	
13th	 7	 5	 14	 8	-	NA	
14th	 5	 4	 15	 14	-	NA	
15th	 2	 1	 NA	 27	-	NA	
16th	 1	 1	 28	 28	-	NA	


































4.4.3		 Pneumococcal	carriage	prevalence	 1347 
None	of	 the	 children	 enrolled	 in	 the	present	 study	were	 colonised	 at	 birth,	 figure	21.	 1348 
The	pneumococcal	 point	 prevalence	 at	 2	weeks	 of	 age	was	 2%,	 reaching	 a	maximum	 1349 
prevalence	 of	 60%	 at	 24	 weeks	 of	 age,	 thereafter	 plateauing	 around	 55%	 for	 the	 1350 
remainder	 of	 the	 first	 year	 of	 life.	When	 examined	 for	 trend,	 the	pneumococcal	 point	 1351 
prevalence	increased	linearly	with	time	(X2	test	for	trend	p	=	0.0001).	At	each	sampling	 1352 
point,	 non-PCV-13	 serotypes	 accounted	 for	 more	 than	 80%	 of	 the	 pneumococci	 that	 1353 
were	isolated.	 1354 
 1355 
Figure	21:	 Pneumococcal	 point	 prevalence	 showing	 the	number	of	 children	 colonised	 at	 each	 1356 
sampling	point	and	the	proportion	of	vaccine	type	or	non-vaccine	type	pneumococci	detected.	 1357 
The	 point	 prevalence	 of	 carriage	 increased	 linearly	with	 time	 after	 birth.	 Red	 bars	 =	 PCV-13	 1358 
serotype,	Blue	bars		=	Non-PCV-13	serotypes.	 1359 
  1360 
4.4.4		 Pneumococcal	serotype	distribution	 1361 
Of	the	48	different	pneumococcal	serotypes	detected	in	this	cohort,	the	most	frequently	 1362 
encountered	VT	serotypes	included	19F,	9V,	19A	and	6A	while	NVT	serotypes	included	 1363 
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Figure	 23	 –	 25	 shows	 the	 longitudinal	 carriage	 patterns	 for	 all	 the	 48	 different	 1372 
pneumococcal	serotypes	encountered	 in	 the	present	study.	There	was	a	slight	drop	 in	 1373 
the	prevalence	of	VT	(serotypes	9V,	19F,	19A,	6A,	6B,	14,	3,	4	and	1)	at	weeks,	6	and	14	 1374 
which	 coincides	with	 the	 first	 and	 second	 scheduled	dose	of	 PCV-13	 immunisation	 in	 1375 
our	 cohort,	 figure	 23.	 Thereafter,	 the	 overall	 longitudinal	 distribution	 of	 VT	 seems	 to	 1376 
plateau	 after	week	 14.	 Similar	 trends	where	 seen	 for	 the	 10	most	 predominant	 NVT	 1377 
(Serotypes	15B/15C,	10A,	21,	16F,	9N,	13,	15A,	35B/35C,	17F	and	11A/11D)	with	an	 1378 
initial	 sharp	 increase	 after	 6	 weeks,	 and	 plateau	 after	 14	 weeks,	 figure	 24.	 These	 1379 







































































































Figure	24:	Longitudinal	 carriage	patterns	of	10	most	predominant	non-PCV-13	vaccine	 (NVT)	 1390 











































































Figure	 25:	 Longitudinal	 carriage	 patterns	 of	 all	 the	 remaining	 non-PCV-13	 vaccine	 (NVT)	 1398 




4.4.5		 Pneumococcal	serotype-specific	acquisition	and	 1403 
carriage	duration	 1404 
Serotype-specific	 acquisition	 rates	 ranged	 from	0.0075	 to	 0.8827-episodes/child	 year	 1405 
(e/cy),	whilst	the	carriage	duration	for	the	48	different	serotypes	detected	was	between	 1406 





































































All	VT	 143	 1.07	 0.91	-	1.26	 28.31	 20.35	-		36.28	
9V*	 33	 0.24	 0.17	-	0.34	 7.82	 3.03	-	12.62	
19F*	 29	 0.21	 0.15	-	0.31	 6.53	 3.10	-	9.96	
19A*	 30	 0.22	 0.15	-	0.32	 5.39	 2.29	-	8.48	
6A*	 18	 0.13	 0.08	-	0.21	 3.51	 1.20	-	5.81	
14*	 7	 0.05	 0.02	-	0.11	 1.47	 0.14	-	2.80	
6B*	 4	 0.03	 0.01	-	0.08	 1.60	 0.00	-	4.16	
3*	 5	 0.04	 0.01	-	0.09	 0.92	 0.00	-	1.89	
4*	 4	 0.03	 0.01	-	0.00	 0.41	 0.00	-	0.89	
1*	 1	 0.01	 0.00	-	0.05	 0.10	 0.00	-	0.30	
All	Non-VT	 682	 5.10	 4.74	-	5.49	 129.04	 115.48	-	142.61	
15B/15C	 118	 0.88	 0.73	-	1.05	 29.44	 21.97	-	36.89	
10A	 42	 0.31	 0.23	-	0.42	 10.81	 6.09	-	15.52	
21	 45	 0.33	 0.25	-	0.45	 9.75	 5.55	-	13.96	
16F	 36	 0.26	 0.19	-	0.37	 8.21	 4.32	-	12.10	
9N	 33	 0.24	 0.17	-	0.34	 7.20	 3.61	-	10.79	
13	 27	 0.20	 0.13	-	0.29	 6.58	 2.93	-	10.24	
11A	 34	 0.25	 0.18	-	0.35	 5.99	 3.05	-	8.93	
15A	 31	 0.23	 0.16	-	0.33	 5.94	 2.51	-	9.36	
17F	 24	 0.18	 0.12	-	0.26	 4.05	 1.49	-	6.61	
35B/35C	 25	 0.18	 0.12	-	0.27	 3.51	 1.90	-	5.11	
23A	 14	 0.10	 0.06	-	0.17	 3.15	 0.83	-	5.47	
35B	 25	 0.18	 0.12	-	0.27	 2.94	 1.77	-	4.11	
7C	 19	 0.14	 0.09	-	0.22	 2.88	 1.09	-	4.66	
35F/47F	 9	 0.06	 0.03	-	0.12	 2.78	 0.04	-	5.52	
33C	 14	 0.10	 0.06	-	0.17	 2.36	 0.40	-	4.32	
31	 10	 0.07	 0.04	-	0.13	 2.29	 0.23	-	4.36	
22A	 10	 0.07	 0.04	-	0.13	 1.86	 0.20	-	3.52	
17A	 12	 0.09	 0.05	-	0.15	 1.60	 0.54	-	2.67	
24F	 12	 0.09	 0.05	-	0.15	 1.38	 0.57	-	2.20	
6C/6D	 7	 0.05	 0.02	-	0.11	 1.35	 0.00	-	3.01	
19C	 7	 0.05	 0.02	-	0.11	 1.33	 0.04	-	2.63	
35A	 3	 0.02	 0.01	-	0.07	 1.31	 0.00	-	3.54	
34	 9	 0.06	 0.03	-	0.12	 1.30	 0.27	-	2.32	
23B	 6	 0.04	 0.02	-	0.10	 1.29	 0.00	-	3.14	
33A	 10	 0.07	 0.04	-	0.13	 1.08	 0.24	-	1.92	
47F	 7	 0.05	 0.02	-	0.11	 0.96	 0.21	-	1.72	
20	 6	 0.04	 0.02	-	0.10	 0.67	 0.00	-	1.38	
18B	 5	 0.03	 0.01	-	0.09	 0.66	 0.00	-	1.38	
12B	 6	 0.04	 0.02	-	0.10	 0.55	 0.10	-	0.99	
33B/35C	 4	 0.03	 0.01	-	0.08	 0.45	 0.01	-	0.90	
6D	 4	 0.03	 0.01	-	0.08	 0.44	 0.00	-	0.98	
33B	 4	 0.03	 0.01	-	0.08	 0.40	 0.01	-	0.79	
15B	 3	 0.02	 0.01	-	0.07	 0.31	 0.00	-	0.65	
18A	 2	 0.02	 0.00	-	0.06	 0.30	 0.00	-	0.74	
6C	 2	 0.02	 0.00	-	0.06	 0.25	 0.00	-	0.75	
19B	 2	 0.02	 0.00	-	0.06	 0.24	 0.00	-	0.57	
15A/15F	 1	 0.01	 0.00	-	0.05	 0.10	 0.00	-	0.32	
11F	 1	 0.01	 0.00	-	0.05	 0.10	 0.00	-	0.31	
25A/38	 1	 0.01	 0.00	-	0.05	 0.10	 0.00	-	0.31	
22A/22F	 1	 0.01	 0.00	-	0.05	 0.10	 0.00	-	0.30	
33F/33A	 1	 0.01	 0.00	-	0.05	 0.10	 0.00	-	0.30	
33F/35F	 1	 0.01	 0.00	-	0.05	 0.10	 0.00	-	0.30	
20B/20C	 1	 0.01	 0.00	-	0.05	 0.09	 0.00	-	0.29	
22F	 1	 0.01	 0.00	-	0.05	 0.09	 0.00	-	0.29	
15F	 1	 0.01	 0.00	-	0.05	 0.04	 0.00	-	0.13	







typeable	 pneumococcal	 respectively.	 We	 applied	 a	 one-way	 analysis	 of	 variance	 to	 1417 
investigate	 the	 difference	 between	 carriage	 duration	 for	 VT,	 NVT	 and	 non-typeable	 1418 
pneumococci.	The	analysis	further	showed	a	significant	difference	in	at	least	one	of	the	 1419 
three	pneumococcal	groups	(p	<	0.001).	A	Bonferroni	post	hoc	test	yields	a	significant	 1420 





4.5	 DISCUSSION	 1426 
This	 is	 the	 largest	 African	 study	 that	 longitudinally	 describes	 the	 dynamics	 of	 1427 
pneumococcal	 carriage	 over	 the	 first	 year	 of	 life,	 both	 in	 terms	 of	 the	 number	 of	 1428 
intensively	 sampled	 participants	 and	 the	 collection	 of	 detailed	 clinical	 phenotypes.	 1429 
Despite	the	high	immunisation	coverage	(with	94%,	94%,	92%	and	89%	coverage	at	6,	 1430 
10	and	14	weeks	and	9	months	visits	respectively),	pneumococcal	carriage	prevalence	 1431 
(>55%)	 and	 carriage	 duration	 of	 48	 serotypes	 in	 this	 population	 remained	 high.	 In	 1432 
terms	 of	 carried	 pneumococci,	 children	 were	 less	 likely	 to	 be	 colonised	 by	 VT	 1433 
pneumococci	 compared	 to	 NVT	 (point	 prevalence	 >80%	 throughout	 the	 sampling	 1434 
period).	 This	 is	 consistent	with	 other	 studies	 that	 have	 shown	 similar	 proportions	 of	 1435 
NVT	post	PCV-13	implementation	which	range	from	73%	to	97%	(59,66,87–92).	Once	 1436 
they	 acquired	 their	 first	 pneumococcal	 carriage	 episode,	 children	 experienced	 1437 
subsequent	carriage	episodes	much	earlier.	We	further	show	that,	as	the	children	grew	 1438 
older,	 the	 pneumococcal	 point	 prevalence	 also	 increased	 with	 age	 (X
2




reports	 from	 other	 similar	 LMIC	 settings.	 The	 median	 age	 to	 first	 acquisition	 in	 the	 1442 
Gambia	was	reported	as	24	days	(34)	which	is	lower	than	38.5	days	in	Kenya.	Both	of	 1443 
these	 were	 baseline	 studies	 conducted	 prior	 to	 the	 introduction	 of	 PCV-7	 into	 their	 1444 






years	 of	 life,	 and	 the	 less	 immunogenic	 serotypes	 tend	 to	 be	 carried	 within	 the	 1451 
nasopharynx	 for	 prolonged	 periods	 of	 time	 (e.g.,	 6,	 14,	 19,	 and	 23)	 than	 the	 more	 1452 
immunogenic	strains	(e.g.,	3,	12,	and	33)	(93).	The	longer	duration	of	carriage	observed	 1453 
in	 our	 settings	 for	 serotypes	 9V,	 19F,	 19A,	 6A,	 6B	 and	 14	 are	 consistent	 with	 these	 1454 
findings	 (carriage	 durations	 ranging	 from	 2	 to	 8	 days).	 Serotypes	 3,	 4	 and	 1	 were	 1455 
carried	 for	 shorter	 periods	 of	 times	 (carriage	 duration	 0.99,	 0.42,	 0.10	 days	 1456 





Serotypes	 such	 as	 15B,	 15C,	 10A,	 21,	 16F,	 9N,	 13,	 11A,	 15A,	 17F,	 31	 and	 22A	 are	 1462 
currently	 among	 the	 most	 prevalent	 replacement	 NVTs	 globally	 post	 PCV-13	 1463 
implementation	 (34,64,66,89).	 NP	 colonisation	 increases	 the	 risk	 of	 disease	 (3).	 The	 1464 
observation	 of	 the	 near	 elimination	 of	 PCV-7	 serotypes	 and	 increase	 in	 non-PCV-7	 1465 
 142 
serotypes	 has	 led	 to	 the	 formulation	 of	 higher	 valency	PCV	 vaccines,	 the	most	 recent	 1466 
being	 PCV-13	 and	 PCV-15	 (currently	 under	 development).	 In	 light	 of	 the	 1467 
disproportionate	 increase	 in	 NVT	 observed	 in	 our	 study	 and	 others,	 the	 potential	 of	 1468 
these	 NVT	 in	 causing	 both	 mucosal	 and	 invasive	 pneumococcal	 disease	 constantly	 1469 
overshadows	 the	 success	 of	 current	PCV.	 It	 is	 unknown	whether	 other	 serotypes	will	 1470 
continue	to	cause	replacement	disease	until	all	98	serotypes	have	had	their	moment	of	 1471 
fame.		 1472 
The	 introduction	of	PCV-7	 into	nationwide	 routine	 immunisation	programs	has	had	a	 1473 
significant	impact	in	reducing	the	burden	of	pneumococcal	disease	in	many	settings	but	 1474 
these	 strategies	 have	 also	 been	 accompanied	 by	 significant	 changes	 in	 the	 1475 
pneumococcal	 population	 structure.	 In	many	developing	 countries,	 serotypes	1	 and	5	 1476 
soon	became	 important	cause	of	 IPD	post	PCV-7	 licensure;	 in	South	Africa	serotype	1	 1477 
caused	approximately	13.5%	of	IPD	cases	 in	children	and	were	subsequently	 included	 1478 
in	 PCV9	 formulations	 (44,62,65,93).	 Similar	 observations	were	made	 for	 serotype	 7F	 1479 
and	 serotype	 3	 which	 became	 incorporated	 into	 PCV-10	 and	 PCV-11	 respectively	 1480 
(86,94,95).	The	public	health	benefits	of	PCV	were	further	offset	by	the	demonstration	 1481 




moving	 target	 (96,97).	 Most	 recently,	 preliminary	 data	 from	 developed	 countries	 1486 
suggests	that	IPD	caused	by	serotypes	22F	among	children	<	5	years	of	age	and	adults	≥	 1487 




with	 these	 emerging	 serotypes,	 the	 safety,	 tolerability	 and	 immunogenicity	 of	 a	 15- 1491 
valent	 PCV	 (PCV-15;	 Merck	 &	 Co.	 Inc)	 which	 contains	 all	 PCV-13	 serotypes	 and	 two	 1492 
additional	serotypes,	22F	and	33F,	has	been	evaluated	in	healthy	toddlers	(99).	 1493 
	Given	 the	 demonstrable	 differences	 in	 the	 serotype	 distribution	 between	 developed	 1494 
and	developing	 countries,	 the	public	 health	benefit	 PCV-15	 in	developing	 countries	 is	 1495 
uncertain.	Long-term	surveillance	in	developing	countries	is	critical	in	determining	the	 1496 
impact	 of	 newer	 PCV	 formulations	 on	 IPD,	 carriage,	 and	 invasive	 disease.	 Other	 1497 





and	 the	 burden	 of	 disease	 are	 high	 (36,94–97).	 Our	 study	 was	 however	 not	 able	 to	 1503 
detect	 multiple	 colonising	 pneumococcal	 because	 of	 the	 technique	 employed.	 As	 1504 
described	 in	 detail	 in	 the	 preceding	 chapter,	 finding	 a	 pneumococcal	 capsular	 typing	 1505 
technique	 that	 is	 both	 sensitive	 and	 applicable	 for	 high	 throughput	 typing	 remains	 a	 1506 
challenge.	Given	the	anticipated	perturbations	of	the	NP	microbiome	induced	by	PCV,	it	 1507 
is	very	important	that	alternative	typing	techniques	that	are	both	sensitive	and	specific	 1508 
are	 employed	 in	 accurate	 identification	 of	 co-colonising	 pneumococcal	 serotypes	 1509 
especially	NVT	as	well	as	differentiating	non-typeable	pneumococci	from	other	viridans	 1510 
group	streptococci.	Both	NVT	and	non-typeable	pneumococci	are	 increasing	becoming	 1511 
important	in	disease	as	well	as	serve	as	a	pool	for	virulence	genes	including	antibiotic	 1512 
resistance	genes	(50,60,98–100).	 1513 
Simoès	 et	 al.	 (111)	 has	 recently	 shown	 that	 lytA-based	 identification	 methods	 can	 1514 
misidentify	 S.	 pneumoniae.	 The	 54	 isolates	 that	 were	 phenotypically	 presumed	 to	 be	 1515 
 144 
pneumococcus	 (colony	morphology,	 optochin	 sensitive	 and	 alpha	 hemolysis)	 but	 lytA	 1516 
negative	 need	 to	 be	 investigated	 further	 by	 to	 determine	 whether	 they	 are	 in	 fact	 1517 
pneumococci,	 for	 example	 by	 genome	 sequencing	 and	 phenotypic	 testing.	 Another	 1518 
limitation	of	the	data	presented	here	is	the	lack	of	pneumococcal	carriage	data	from	the	 1519 
mothers	as	well	as	other	siblings	living	in	the	same	household.	This	information	is	key	 1520 
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(herd	 protection)	 largely	 due	 to	 reduced	 transmission	 of	 VT	 pneumococcus	 from	 2020 
vaccinated	 children	 (8,12–15).	 This	 reduction	 has	 however	 been	 offset	 by	 a	 parallel	 2021 
increase	 in	 carriage	 of	 non-vaccine-type	 (NVT)	 pneumococci	 through	 serotype	 2022 
replacement	(16,17).	 2023 
	 2024 
The	13-valent	pneumococcal	 conjugate	vaccine	 (PCV-13)	has	been	 rolled	out	 in	many	 2025 
sub-Saharan	 African	 countries	 as	 well	 as	 other	 low-middle-income	 countries	 (LMIC)	 2026 
where	the	burden	of	pneumococcal	disease	is	disproportionately	high	(18–21).	HIV/TB	 2027 
infections	 in	 these	 settings	 increases	 vulnerability	 to	 pneumococcal	 disease	 (22).		 2028 
Investigating	 the	 shifts	 in	 the	 pattern	 of	 pneumococcal	 colonisation	 provides	 an	 2029 
opportunity	 to	 assess	 the	 impact	 of	 PCV-13	 and	 other	 potential	 risk	 factors	 for	 2030 
acquisition	of	carriage	(23).		 2031 
	 2032 
Our	 current	 understanding	 of	 the	 serotype-specific	 immunity	 afforded	 by	 PCVs	 is	 2033 
incomplete.	In	particular,	the	effect	of	prior	colonisation	(i.e.,	the	pneumococcus	acting	 2034 
as	 a	 natural	 immunising	 agent)	 and	 other	 multifactorial	 risk	 factors	 on	 subsequent	 2035 
colonisation	by	the	same	(or	related)	serotypes	is	understudied.	Similarly,	the	effect	of	 2036 
VT	 colonisation	 prior	 to	 a	 dose	 of	 PCV	 on	 vaccine	 efficacy	 has	 not	 been	 extensively	 2037 
 157 
explored	 in	 an	 intensively	 sampled	birth	 cohort	 (24–26).	 	 Continued	 surveillance	 and	 2038 
identification	 of	 factors	 influencing	 serotype	 distribution	 are	 important	 to	 fully	 2039 
understand	the	effect	of	vaccination	on	carriage	and	allow	rational	vaccine	design	and	 2040 
implementation.	 2041 
5.1.1	 Prevention	of	pneumococcal	infections:	 2042 
Development	of	serotype-specific	pneumococcal	vaccines		 2043 








licensed	 in	 the	 USA	 in	 1940	 (29).	 However,	 the	 discovery	 of	 penicillin	 and	 other	 2052 
effective	 antimicrobial	 drugs	 for	 treating	 pneumonia,	 resulted	 in	 reduced	 interest	 in	 2053 
prophylaxis	(30).	 2054 
	 2055 
It	 was	 not	 until	 the	 mid-1960s	 that	 the	 interest	 in	 pneumococcal	 polysaccharide	 2056 
vaccines	(PPVs)	was	revived	(29).	This	renewed	interest	in	prophylaxis	was	largely	due	 2057 
the	 emergence	 of	 antibiotic	 resistant	 pneumococcal	 serotypes	 and	 observation	 that	 2058 
some	 individuals	 remained	 at	 risk	 of	 pneumococcal	 disease	 (29,31).	 A	 14-valent- 2059 
pneumococcal-polysaccharide	vaccine	(PPV-14),	licensed	in	1977,	was	replaced	by	a	23- 2060 
 158 
valent-pneumococcal-polysaccharide	 vaccine	 (PPV-23;	 Pneumovax
®
	 23,	 Merck	 &	 Co.,	 2061 
Inc.)	in	1983,	details	on	the	serotypes	included	in	each	formulation	are	summarized	in	 2062 
table	16	below.	PPVs	were	primarily	designed	for	use	in	older	children	and	adults	who	 2063 


















4	 4	 4	 4	 4	 4	 4	 4	
6B	 6B	 6B	 6B	 6B	 6B	 6B	 6B	
9V	 9V	 9V	 9V	 9V	 9V	 9V	 9V	
14	 14	 14	 14	 14	 14	 14	 14	
18C	 18C	 18C	 18C	 18C	 18C	 18C	 18C	
19F	 19F	 19F	 19F	 19F	 19F	 19F	 19F	
23F	 23F	 23F	 23F	 23F	 23F	 23F	 23F	
	 1	 1	 1	 1	 1	 1	 1	
	 5	 5	 5	 5	 5	 	 5	
	 	 7F	 7F	 7F	 7F	 7F	 7F	
	 	 	 3	 3	 3	 3	 3	
	 	 	 	 6A	 6A	 6A	 	
	 	 	 	 19A	 19A	 	 19A	
	 	 	 	 	 22F	 8	 8	
	 	 	 	 	 33F	 9N	 9N	
	 	 	 	 	 	 12F	 12F	
	 	 	 	 	 	 20	 20	
	 	 	 	 	 	 2	 2	
	 	 	 	 	 	 	 10A	
	 	 	 	 	 	 	 11A	
	 	 	 	 	 	 	 15B	
	 	 	 	 	 	 	 17F	
	 	 	 	 	 	 	 22F	
	 	 	 	 	 	 	 33F	
#CRM197	 CRM197	 PhiD-CV	
¶TT-DT	 CRM197	 CRM197	 N/A	 N/A	
*15-valent	pneumococcal	conjugate	vaccine	in	development.	#CRM197	=	A	non-toxic	recombinant	 2068 
variant	 of	 diphtheria	 toxin	 (Corynebacterium	 diphtheriae)	 carrier	 protein.	 PhiD-CV	 =	 Protein	 2069 
carrier	 for	 the	 10-valent	 pneumococcal	 conjugate	 vaccine	 that	 is	 conjugated	 to	 non-typeable	 2070 
Haemophilus	 influenzae	 protein	D.	 ¶TT-DT	 =	 PCV11	 includes	 serotypes	 1,	 4,	 5,7F,	 9V,	 19F,	 23	 2071 




5.1.1.2	 Pneumococcal	 polysaccharide	 vaccine	 (PPV-23)	 and	 the	 2075 
unmet	needs	in	childhood	immunisation	 2076 
PPVs	 elicit	 a	 T	 cell-independent	 immune	 response	 which	 is	 characterized	 by	 the	 2077 
production	 of	 serotype-specific	 protective	 antibodies	 (IgG,	 IgA	 and	 IgM	 are	 produced	 2078 
with	 the	 IgG2	 subclass	 dominating	 the	 IgG	 response)	 that	 promote	 bacterial	 2079 
opsonophagocytosis	and	clearance	by	macrophages	and	neutrophils	 (33).	 Such	T	cell- 2080 
independent	antigens	are	poorly	immunogenic	in	children	under	2	years	of	age	(except	 2081 
for	 serotype	 3	 which	may	 induce	 protective	 antibody	 production)	 and	 fail	 to	 induce	 2082 
immune	memory	(34–36).	In	addition,	PPV23	does	not	induce	mucosal	immunity,	hence	 2083 
its	 failure	 to	 reduce	 NP	 carriage,	 an	 important	 reservoir	 for	 person-to-person	 2084 
transmission	of	pneumococci	(35).	Children	younger	than	2	years	of	age	lack	mature	B	 2085 
cells	 which	 are	 necessary	 for	 T	 cell-dependent	 antibody	 mediated	 immunity	 (37).	 A	 2086 
vaccine	 is	 therefore	 effective	 in	 young	 children	only	 if	 it	 can	 elicit	 a	T-cell	 dependent	 2087 
serotype-specific	antibody	response	soon	after	birth	(38).	 	After	receiving	one	dose	of	 2088 
PPV-23,	 infants	 develop	 antibody	 responses	 to	 serotypes	 3,	 4,	 8,	 9N	 and	 18C;	 2089 
intermediate	responses	to	serotypes	1,	2,	7F,	19F	and	25;	and	poor	responses	to	types	 2090 
12,	 14,	 23F,	 and	 6A	 and	 6B,	 most	 of	 which	 are	 multiple	 drug	 resistant	 (15,39).	 The	 2091 




II	molecules	on	 the	 surface	of	 antigen	presenting	 cells	 (APCs;	 includes	dendritic	 cells,	 2096 
macrophages,	 B	 cells).	 Consequently,	 B	 cells	 that	 recognize	 polysaccharide	 antigens	 2097 
using	their	surface	expressed	IgM	cannot	get	help	from	T	cells	(42).	The	failure	of	PPVs	 2098 
 160 
to	induce	T	cell	help	results	 in	the	poor	persistence	of	vaccine	induced	antibody	titers	 2099 
and	the	requirement	for	re-vaccination	(37).		 2100 
5.1.1.3	 Pneumococcal	conjugate	vaccine:	A	tale	of	two	paradigms	 2101 
The	failure	of	PPVs	to	induce	a	T	cell-dependent	immune	response	and	the	added	costs	 2102 
incurred	in	re-vaccination	stimulated	the	development	of	protein	based	PCVs	(4).	The	7- 2103 
valent	 pneumococcal	 conjugate	 vaccine	 (PCV-7;	 Prevenar
®,	 Pfizer)	 contains	 capsular	 2104 
polysaccharides	 from	 pediatric	 serotypes	 4,	 6B,	 9V,	 14,	 18C,	 19F	 and	 23F,	which	 are	 2105 
responsible	for	80%	of	invasive	pneumococcal	diseases	in	developed	countries	(5,	6,	10,	 2106 
27).	The	10	and	13-valent	pneumococcal	 conjugate	vaccines	 (PCV-10,	 -13;	Prevenar
®,	 2107 
Pfizer),	 currently	 incorporated	 in	 routine	 immunisation	 programs	 in	 many	 countries	 2108 
contain	all	serotypes	included	in	PCV-7	with	two	(1,	5)	and	five	(1,	5,	7F,	6A	and	19A)	 2109 
additional	 serotypes	 in	 the	 case	 of	 PCV-9	 and	 PCV-13,	 respectively.	 Altogether,	 these	 2110 
serotypes	account	 for	65-80%	of	 the	serotypes	associated	with	pneumococcal	disease	 2111 
among	children	from	developed	countries	(25).	T-cell	dependent	conjugate	vaccines	not	 2112 
only	 elicit	 protection	 against	 systemic	 bacteremia	 through	 IgG	 but	 also	 induce	 2113 
protection	against	colonisation	of	the	host	mucosal	surfaces	through	production	of	IgA	 2114 
which	 is	 secreted	 on	 the	 mucosal	 surface	 and	 consequently	 reduces	 NP	 carriage	 of	 2115 
pneumococcal	serotypes	included	in	the	PCV	formulation	(42–44).	 2116 
5.1.1.4	 Pneumococcal	conjugate	vaccines	mode	of	action	 2117 
PCVs	 contain	 purified	 capsular	 polysaccharide	 covalently	 linked	 to	 a	 protein	 carrier	 2118 
which	 are	 taken	 up	 by	 surface	 expressed	 antibodies	 on	 B	 cells,	 internalized,	 co- 2119 
processed	 with	 the	 carrier	 protein	 and	 then	 presented	 to	 T	 cells	 (42).	 The	 peptide	 2120 
(protein	 carrier)	 anchors	 the	 polysaccharide	 epitope	 to	 the	 MHC	 and	 allows	 its	 2121 
 161 
presentation	 to	 polysaccharide-specific	 CD4+	 helper-T-cells.	 The	 interaction	 between	 2122 
the	polysaccharide	epitope	and	the	surface	expressed	T	cell	receptor	(TCR)	triggers	the	 2123 
production	 of	 cytokines	 (interleukin	 (IL)-4,	 IL-5	 and	 IL-6)	 responsible	 for	 B	 cell	 2124 
antibody	 class	 switching	 (43).	 These	 cytokines	 stimulate	 B	 cells	 to	 proliferate,	 class- 2125 






carrier	 peptide	 (Blue	 triangles)	 is	 taken	 up	 by	 Antigen	 Presenting	 Cells	 (APC,	 which	 include	 2132 
Macrophages,	Dendritic	and	B	cells),	internalised	and	processed.	The	peptide	then	anchors	the	 2133 
polysaccharide	 epitope	 into	 the	Major	 Histocompatibility	 complex	 Class	 II	 (MHC)	 cavity,	 this	 2134 
allows	the	presentation	of	the	polysaccharide	epitope	to	polysaccharide-specific	type	2	helper	T	 2135 
(Th2)	cells.	The	activated	Th2	cells	secrete	interleukin	(IL)	4,	5	and	6	cytokines	which	causes	B	 2136 
cells	 to	 proliferate,	 switch	 from	 producing	 immunoglobulin	 M	 (IgM)	 to	 produce	 IgG	 and	 2137 
establish	 immunological	memory.	 These	 cells	mature	 in	 the	 lymphoid	 follicles;	 only	 cells	 that	 2138 
express	 very	 high	 affinity	 IgG	 become	 plasma	 B	 cells	 and	 secrete	 IgG	 that	 binds	 to	 specific	 2139 
 162 
pneumococcal	 capsule	 and	 mediates	 opsonic	 activity	 and	 complement-mediated	 bactericidal	 2140 
activities,	modified	from	Pletz	et	al.	(43).	 2141 
5.1.1.4	 Impact	 of	 pneumococcal	 conjugate	 vaccines	 on	 2142 
nasopharyngeal	carriage	 2143 
The	mechanisms	 through	which	PCVs	directly	 protect	 against	 VT	 carriage	 acquisition	 2144 
are	 incompletely	 understood.	 It	 has	 however	 been	 suggested	 that	 this	 protection	 is	 2145 
mediated	by	secretory	IgA	rather	than	IgG.	High	titers	of	naturally	acquired	or	vaccine- 2146 
induced	 circulating	 serotype-specific	 antibody	 correlate	 with	 protection	 against	 2147 




serotypes	 such	 as	 14	 and	 23F,	 and	 this	 rise	 was	 associated	 with	 reduced	 odds	 of	 2152 
reacquiring	the	same	serotype.		 2153 
The	success	of	PCVs	in	preventing	serotype-specific	invasive	disease	has	been	tempered	 2154 
by	 concern	 over	 replacement	 of	 VT	 serotypes	 with	 NVT	 serotypes	 in	 carriage	 and	 2155 
invasive	 clinical	 isolates	 (16,17,23,48,49).	 Previous	 studies	 have	 shown	 a	 decrease	 in	 2156 
NP	 carriage	 of	 VT	 serotypes	 following	 introduction	 of	 PCV	 immunisation	 2157 
(6)(50)(51)(52).	However,	other	studies	evaluated	the	effect	of	PCV-9	on	carriage	and	 2158 
did	not	find	any	significant	differences	in	the	rates	of	VT	carriage	between	the	vaccine	 2159 
group	 and	 the	 control	 arm	 (14,18).	 Some	 initial	 studies	 amongst	 Gambian	 infants	 2160 
evaluated	the	effect	of	administering	two	to	three	doses	of	a	pentavalent	pneumococcal	 2161 
conjugate	vaccine	(PCV-5)	followed	by	PPV-23	booster	dose	(19).	Twenty	months	after	 2162 




received	at	 least	 three	doses	of	PCV	carried	significantly	more	NVT	pneumococci	 than	 2166 
children	in	the	unvaccinated	group	(77%	vs.	43%,	p	=	0.002).		 2167 
5.1.2	 Prevention	of	pneumococcal	infections:	protection	 2168 
induced	by	prior	NP	colonisation		 2169 
5.1.2.1	 Pneumococcal	colonisation	as	a	natural	immunizing	event	 2170 
The	 establishment	 of	 both	 antibody	 mediated	 and	 antigen-specific	 T	 cell	 immune	 2171 
responses	 following	 pneumococcal	 colonisation	 have	 been	 shown	 to	 protect	 against	 2172 
subsequent	 colonisation	 and	 progression	 to	 invasive	 disease	 in	 murine	 models	 (54).	 2173 
Similarly,	prior	pneumococcal	colonisation,	in	both	infant	and	adult	human	subjects,	can	 2174 
in	itself	act	as	an	immunizing	event	(53,54).	This	protection	has	been	associated	with	an	 2175 
increase	 in	 serum	 antibody	 titers	 against	 the	 pneumococcal	 capsule	 and	 surface	 2176 
expressed	proteins.	Ferriera	et	al	recently	showed	the	direct	evidence	of	this	protection	 2177 
using	 a	 controlled	 experimental	 human	 model	 of	 pneumococcal	 colonisation	 to	 2178 
determine	 the	 immunizing	 effects	 of	 prior	 NP	 colonisation	 by	 pneumococcus.	 In	 this	 2179 
study,	healthy	adult	 volunteers	aged	18-60	years	were	 inoculated	with	pneumococcal	 2180 
serotype	6B.	The	 authors	 reported	 successful	 colonisation	 in	41%	 (29/70)	 of	 healthy	 2181 
volunteers.	Similarly,	exposure	to	pneumococcal	antigens	(specifically	protein	and	not	 2182 
capsular)	 without	 carriage	 can	 also	 protect	 against	 subsequent	 carriage	 acquisition	 2183 
(55).	 This	 protection	 has	 been	 associated	 with	 increases	 in	 the	 serum	 and	 mucosal	 2184 




5.1.2.2	 Impact	of	prior	NP	carriage	on	vaccine	efficacy		 2188 
Children	 who	 were	 colonised	 by	 pneumococcus	 in	 early	 life	 were	 more	 likely	 to	 2189 
reacquire	 pneumococcus	 which	 correlates	 with	 increased	 risk	 of	 transmission	 (57).	 2190 
Immunization	with	PPV-23	 results	 in	with	 serotype-specific	 hyporesponsiveness,	 that	 2191 
is,	individuals	initially	primed	with	PPV-23	tend	to	have	lower	functional	anti-capsular	 2192 
antibody	titers	after	challenge	with	a	PPV-23	booster	(58).	This	phenomenon	has	also	 2193 
been	 shown	 during	 invasive	 pneumococcal	 disease	 (IPD)	 in	 which	 it	 was	 speculated	 2194 
that	 the	 observed	 immune	 paralysis	 was	 due	 to	 large	 pneumococcal	 polysaccharide	 2195 
antigen	 loads	during	 IPD	 (59).	Pneumococcal	 conjugate	vaccines	 (PCVs)	were	 initially	 2196 
shown	 to	 overcome	 the	 hyporesponsiveness	 induced	 by	 PPV-23	 (60–62).	 However,	 2197 
recent	 studies	 have	 shown	 that	 NP	 colonisation	 prior	 to	 the	 first	 PCV	 dose	 in	 young	 2198 
infants	could	also	 induce	hyporesponsiveness	to	the	specific	colonizing	serotypes	(63- 2199 
65).	Madhi	et	al	showed	that	South	African	children	colonised	by	VT	(6B,	19F	and	23F)	 2200 
pneumococci	 prior	 to	 completion	 of	 a	 primary	 series	 of	 PCV-7	 immunization	 had	 2201 
inferior	antibody	responses	to	the	colonising	serotype	(65).		 2202 
All	 the	 studies	 described	 above	were	 conducted	 prior	 to	 the	 introduction	 of	 PCV-13.	 2203 
There	are	limited	data	to	demonstrate	whether	prior	colonisation	by	VT	pneumococcus	 2204 
at,	 or	 immediately	 before	 the	 first	 PCV-13	 dose,	 affects	 the	 serotype-specific	 carriage	 2205 
acquisition	 in	response	 to	primary	PCV-13	 immunization	series	and/or	 to	 the	booster	 2206 
PCV-13	dose.		 2207 
 165 
5.1.3	 Risk	factors	associated	with	increased	acquisition	 2208 
of	pneumococcal	carriage		 2209 
Several	 environmental	 and	 host	 factors	 have	 been	 implicated	 in	 increased	 2210 




strains	 which	 disseminate	 among	 contacts.	 A	 large-scale	 longitudinal	 carriage	 study	 2215 
conducted	 in	 Israeli	 day-care	 center	 children	 showed	 that	 56%	 (334/594)	 of	 2216 
pneumococcal	isolates	were	resistant	to	at	least	one	antibiotic	(63).	Antibiotic	use	and	 2217 





leading	 to	 temporary	 crowding	 in	 poorly	 ventilated	 structures	 which	 may	 enhance	 2223 
person-to-person	transmission	(67).	However,	a	study	in	Finland	showed	a	fluctuation	 2224 
in	prevalence	throughout	the	year,	as	opposed	to	a	particular	seasonal	pattern	(68).		 2225 
The	 incidence	 of	 pneumococcal	 disease	 is	 not	 only	 a	 function	 of	 the	 frequency	 of	 2226 
carriage	 but	 may	 also	 be	 related	 to	 differences	 in	 the	 invasive	 disease	 potential	 of	 2227 
particular	 pneumococcal	 strains	 (69-71)	 and	 the	 prevalence	 of	 preceding	 viral	 2228 
infections	 (72-75).	 Other	 host	 risk	 factors	 that	 may	 predispose	 an	 individual	 to	 2229 
pneumococcal	 carriage	 and	 disease	 include	 age,	 active/passive	 smoking,	 inadequate	 2230 
breast	feeding,	asthma,	congestive	heart	failure,	diabetes	mellitus	and	individuals	with	 2231 
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primary	 or	 acquired	 immunodeficiencies	 (76,77).	 Comparisons	 of	 seasonal	 variations	 2232 
and	 other	 environmental	 determinants	 provide	 an	 opportunity	 to	 assess	 drivers	 of	 2233 
pneumococcal	carriage	prevalence	and	acquisition	rates.	 2234 
5.2	 Aims	and	Objectives	 2235 
The	overall	aim	of	the	analysis	described	in	this	chapter	is	to	identify	factors	associated	 2236 
with	pneumococcal	carriage	in	a	South	African	birth	cohort.	These	include:	 2237 
1. What	is	the	impact	of	each	successive	dose	of	PCV-13	on	acquisition	of	carriage	by	 2238 
VT	and	NVT	serotypes	at	the	level	of	the	individual	child?	 2239 
2. Does	prior	(early	 life)	carriage	with	VT	or	NVT	serotypes	 influence	the	 	efficacy	of	 2240 
PCV-13	in	preventing	carriage	with	the	same/related	serotypes?	 2241 
3. Which	risk	factors	(demographic,	socio-economic	and	environmental)	are	associated	 2242 
with	acquisition	of	pneumococcal	carriage?		 2243 
5.3	MATERIALS	AND	METHODS	 2244 
5.3.1	 Study	setting	 2245 
A	detailed	description	of	the	study	setting	is	given	in	chapter	4	(4.4.1).		 2246 
5.3.2	 Participant	enrollment	 2247 
A	 detailed	 account	 of	 participant	 enrolment	 and	 retention	 is	 given	 in	 section	 4.4.2	 of	 2248 
chapter	 4.	 Detailed	 assessment	 of	 risk	 factors	was	 conducted	 by	 trained	 study	 nurses	 2249 
during	 each	 scheduled	 visit	 at	 6,	 10	 and	 14	weeks	 and	 at	 6,	 9	 and	 12	months.	 	 These	 2250 




history	 of	 respiratory	 symptoms	were	 established.	 Information	 on	 daycare	 attendance	 2254 
was	also	collected.	In	addition,	questionnaires	about	maternal	health	were	administered	 2255 




of	 the	year	were	 categorized	as	Summer	 (December–February),	Autumn	 (March–May),	 2260 
Winter	(June–August)	and	Spring	(September–November).	 2261 




5.3.4	 Statistical	analysis	 2266 
Initial	exploratory	statistics	were	performed	using	STATA	software	(Stata	Corporation,	 2267 
College	 Station,	 TX)	 and	 the	 rest	 of	 the	 analysis	 were	 performed	 using	 the	 openly	 2268 
available	 statistical	 environment	 R,	 version	 3.1.1(78).	 Functional	 data	 analysis	 (FDA)	 2269 
including	 curve	 registration	 computations	was	performed	using	 facilities	 provided	by	 2270 




5.3.4.1	 Functional	Data	analysis	methodology	 2274 
One	 of	 the	 limitations	 when	 analyzing	 the	 effect	 of	 sequential	 PCV-13	 vaccination	 is	 2275 
correcting	 for	 the	variations	between	children	 in	 the	actual	ages	at	which	 the	vaccine	 2276 
was	administered.	To	overcome	this,	FDA	was	used	(specifically	curve	registration)	to	 2277 
‘align’	 the	 vaccination	 points	 in	 order	 to	 compare	 the	 serotype-specific	 colonisation	 2278 
patterns	in	response	to	vaccinations.	This	analysis	was	performed	as	follows:	 2279 
In	 FDA	 a	 continuous	 underlying	 function	 is	 assumed.	 For	 our	 data,	 the	 presence	 and	 2280 
absence	of	each	serotype	is	observed	at	two-weekly	intervals.	The	underlying	function	 2281 
has	 values	 zero	 when	 the	 serotype	 is	 absent	 and	 one	 when	 the	 serotype	 is	 present.	 2282 
Hastie	et	al.	 (79)	discuss	nonparametric	 logistic	regression	where	spline	 functions	are	 2283 





!"# !(!"#$%&'" !"#$#%&)!(!"#$%&'" !"#$%&) = ! ! + !	
where	!(!)	is	 a	 cubic	 bspline	 function	 of	 time	 and	!	accounts	 for	 random	noise.	 From	 2289 
the	equation	above	it	follows	that	the	estimated	!(!"#$%&'" !"#$#!")	can	be	written	as	 2290 
!"#$%&#!' ! !"#$%&'" !"#$#%& = exp (! ! )1+ exp (! ! )	
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In	Figure	29,	the	observed	data	is	represented	by	black	dots.	The	serotype	is	absent	at	 2291 




infants	however	 received	 the	 vaccinations	 at	 exactly	 these	 time	points.	 For	 the	 infant	 2296 









































nonparametric	 logistic	 regression	 fits.	 For	 the	 infant	 above,	 the	 first	 vaccination	 took	 2310 
place	 at	 the	 recommended	 time	 point	 of	 6	 weeks.	 Since	 the	 second	 vaccination	 was	 2311 
slightly	late,	at	15	weeks,	the	effect	of	the	vaccination	will	only	be	visible	after	15	weeks.	 2312 
Comparing	 different	 infants	 with	 different	 vaccination	 time	 points	 will	 make	 it	 very	 2313 
difficult	to	judge	the	effect	of	the	vaccination.	By	using	landmark	registration,	the	time	 2314 





























A	 different	 time	warping	 function	 is	 needed	 for	 each	 infant,	 depending	 on	when	 the	 2321 
infant	received	the	three	vaccinations.		 2322 
Once	the	vaccination	time	points	 for	all	 infants	have	been	aligned	with	 the	 landmarks	 2323 
using	the	R	function	landmarkreg	in	the	FDA	package,	the	shapes	of	the	curves	can	be	 2324 
compared.	 A	 mean	 curve	 can	 be	 constructed,	 representing	 the	 mean	 estimated	 2325 
probability	that	the	serotype	is	present	at	each	time	point.		 2326 
 2327 
5.3.4.2	 Anderson	&	Gill	Model		 2328 
The	Anderson	–	Gill	(AG)	model	was	employed	to	assess	the	independent	association	of	 2329 
risk	 factors	 and	 pneumococcal	 carriage.	 This	 model	 extends	 the	 standard	 Cox	 2330 
proportional	Hazard	Model	(CPH	model,	discussed	in	chapter	4)	into	a	counting	process	 2331 
and	 then	 further	 considers	 repeated	events	by	 clustering	 individuals	 (80).	The	model	 2332 
however	assumes	 independence	between	repeated	events	per	 individual	and	 it	uses	a	 2333 
common	 baseline	 hazard	 function	 for	 all	 events	 and	 estimates	 a	 vector	 of	 common	 2334 
parameters	 for	 the	 vector	 of	 covariates	 regardless	 of	 the	 order	 in	 which	 the	 events	 2335 
occurred.	 2336 
5.3.5	 Ethical	considerations	 2337 





5.4	 RESULTS	 2342 
5.4.1	 Incidence	of	pneumococcal	carriage	acquisition	 2343 
Differences	in	baseline	characteristics	of	children	between	the	two	enrolment	sites,	TC	 2344 
Newman	 and	 Mbekweni	 were	 recorded,	 Table	 17.	 All	 the	 children	 enrolled	 from	 TC	 2345 
Newman	 were	 of	 mixed	 race	 origin	 (coloured	 African)	 whereas	 children	 from	 2346 






20%	and	25%	of	 children	 at	TC	Newman	and	Mbekweni.	 Exposure	 to	 tobacco	 smoke	 2353 








Gender	 	 	 	
Female	 34	(57%)	 44	(57%)	 1.00	
Male	 28	(43%)	 33	(43%)	 1.00	
Race	and	ethnic	origin	 	 	 	
Black	African	 0	 76	(99%)	 <0.0001	
Mixed	Race	 60	(100%)	 1	(1%)	 <0.0001	
Preterm	 	 	 	
No	 51	(85%)	 66	(86%)	 0.86	
Yes	 9	(15%)	 11	(14%)	 0.86	
Mode	of	delivery	 	 	 	
Normal	vaginal	 45	(75%)	 63	(82%)	 0.32	
Normal	vacuum	 1	(2%)	 0	 0.21	
Elective	caesarean	 4	(6%)	 6	(8%)	 0.65	
Emergency	caesarean	 10	(17%)	 8	(10%)	 0.22	
HIV	exposure	 	 	 	
 173 
No	 57	(95%)	 47	(61%)	 <0.0001	
Yes	 3	(5%)	 30	(39%)*	 <0.0001	
Feed	choice	 	 	 	
Exclusive	breastfed	 7	(12%)	 15	(20%)	 0.21	
Mixed	fed	 28	(47%)	 44	(57%)	 0.25	
Never	breastfed	 25	(42%)	 18	(23%)	 0.02	
Other	Children	 	 	 	
No	 42	(70%)	 48	(62%)	 0.33	
Yes	 17	(28%)	 29	(38%)	 0.22	
Low	birth	weight	 	 	 	
No	 48	(80%)	 71	(92%)	 0.04	
Yes	 12	(20%)	 6	(8%)	 0.04	
Daycare1	 	 	 	
No	 47	(78%)	 58	(75%)	 0.68	
Yes	 12	(20%)	 19	(25%)	 0.49	
Smoking	status	of	Mother	 	 	 	
No	 24	(40%)	 60	(78%)	 <0.0001	
Yes	 29	(48%)	 7	(9%)	 <0.0001	
Missing	data	 7	(12%)	 10	(13%)	 0.86	
Household	crowding	 	 	 	
Less	than	three	people	 26	(43%)	 46	(60%)	 0.04	
Four	or	five	people	 23	(38%)	 15	(19%)	 0.01	
More	than	five	 7	(11%)	 3	(4%)	 0.11	










Figure	 29:	 Incidence	 of	 pneumococcal	 acquisition	 over	 the	 first	 year	 of	 life.	 Black	 dots	 show	 2366 
carriage	 incidence.	Blue	 line	 shows	 fitted	values.	Upper	and	 low	bound	grey	areas	 represents	 2367 
the	95%	confidence	interval.	 2368 
5.4.2	 PCV-13	vaccine	coverage	 2369 






















The	 booster	 dose	 at	 40	weeks	was	 given	 on	 time	 in	 89%	 (122/137)	with	 only	 11%	 2379 
(15/137)	of	the	children	delayed	in	receiving	their	booster	dose.		 2380 
2381 
Figure	 30:	 Box	 and	 whisker	 plot	 representing	 the	 median	 age	 at	 PCV-13	 immunisation.	 The	 2382 
outer	 bounds	 of	 each	 box	 (green,	 blue	 and	 yellow)	 represent	 the	 interquartile	 ranges	 (IQR;	 2383 
difference	between	25th	and	75th	percentile),	the	median	is	indicated	with	a	vertical	line	inside	 2384 
the	box,	whereas	 the	vertical	 lines	extending	 from	 the	box	 (“whiskers”)	 indicate	variability	 in	 2385 
the	data.	Outliers	are	shown	as	individual	points.	V1	(green	plot)	=	1st	dose	of	PCV-13,	V2	(blue	 2386 
plot)	=	2nd	dose	of	PCV-13	and	V3	(yellow	plot)	=	3rd	dose	of	PCV-13	administration.	 2387 
5.4.3	 Impact	of	sequential	PCV-13	doses	on	mucosal	 2388 
carriage	of	VT	and	NVT	serotypes		 2389 
After	correcting	 for	 the	differences	 in	 the	vaccination	dates	(figure	32	above)	 through	 2390 
FDA	 and	 curve	 registration,	 the	mean	 probability	 of	 VT	 serotypes	 carriage	 remained	 2391 
approximately	 constant	 over	 the	 first	 year	 of	 life	 with	 no	 significant	 increments	 or	 2392 
reductions	 after	 each	 sequential	 dose	 of	 PCV-13	 immunisation,	 figure	33.	 There	were	 2393 
gradual	increments	in	the	mean	probability	of	NVT	serotypes	carriage	through	the	first	 2394 
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line	=	mean	probability	of	pneumococcal	carriage	regardless	of	 the	serotype.	Red	 line	=	mean	 2400 
probability	 of	 PCV-13	 vaccine	 serotype	 carriage.	 Blue	 line	 =	Mean	 probability	 of	 non-PCV-13	 2401 




below	(additional	mean	registered	curves	 for	6B,	14,	3	and	4	are	shown	 in	appendix)	 2406 
Serotype	 1	 was	 not	 included	 in	 the	 plots	 below	 because	 only	 one	 child	 carried	 this	 2407 




































Figure	32:	Mean	registered	curves	showing	the	mucosal	carriage	of	 individual	PCV-13	vaccine	 2413 
serotypes	with	95%	upper	and	lower	confidence	intervals	(dotted	red	lines).	A	=	Serotype	19A,	 2414 
B	=	Serotype	19F,	C	=	Serotype	6A	and	D	=	Serotype	9V.	The	dotted	lines	represent	the	upper	 2415 
































Registered curves: Serotype 9v 





























Registered curves: Serotype 6a 
































Registered curves: Serotype 19a 





























Registered curves: Serotype 19f 














Figure	 33:	Mean	 registered	 curves	 of	 six	 (6)	 commonest	 non-PCV-13	 vaccine	 serotypes	with	 2423 
95%	 upper	 and	 lower	 confidence	 intervals	 (dotted	 red	 lines).	 A=	 Serotype	 15B/15C,	 B=	 2424 
Serotype	 21,	 C=	 Serotype	 10A,	 D=	 Serotype	 16F,	 E=	 Serotype	 9N	 and	 F=	 Serotype	 35B.	 The	 2425 
dotted	 lines	 represent	 the	upper	and	 lower	bound	95%	confidence	 interval	while	 the	vertical	 2426 
dashed	lines	indicate	the	PCV-13	immunisation	dates.	 2427 
5.4.4	 Mucosal	carriage	of	VT	serotypes	stratified	by	HIV	 2428 
exposure.	 2429 
VT	carriage	as	seen	in	figure	34	above	was	further	stratified	according	to	the	children’s	 2430 


















 Registered curves: Serotype 10a 
















Registered curves: Serotype 16f 
























Registered curves: Serotype 15b/15c 



















 Registered curves: Serotype 21 
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5.4.5	 Mucosal	carriage	of	NVT	serotypes	stratified	by	HIV	 2440 
exposure.	 2441 
Although	 the	 prevalence	 of	 NVT	 carriage	 was	 higher	 than	 VT	 serotypes,	 there	 was	 2442 
equally	no	difference	 in	 the	mean	probability	of	NVT	carriage	was	significantly	higher	 2443 
among	HIV	unexposed	children	compared	to	HIV	exposed	children	after	stratifying	for	 2444 
HIV	exposure,	figure	37.		 2445 



































5.4.6	 Impact	of	prior	colonisation	on	vaccine	efficacy	in	 2452 
preventing	carriage	 2453 
To	 determine	 whether	 prior	 (early	 life)	 mucosal	 carriage	 with	 VT	 or	 NVT	 serotypes	 2454 
influences	the	efficacy	of	PCV-13	in	preventing	mucosal	carriage	with	the	same/related	 2455 
serotypes,	the	proportion	of	children	colonised	with	pneumococci	prior	to	any	dose	of	 2456 
PCV-13	 was	 compared	 to	 the	 proportion	 of	 children	 colonised	 after	 sequential	 2457 
administration	of	PCV-13,	Figure	38.	 2458 






























Figure	 36:	 Approach	 to	 assess	 the	 differences	 in	 the	 proportion	 of	 children	 colonised.	 The	 2460 
proportion	of	children	colonised	prior	to	any	PCV-13	dose	was	compared	to	the	proportion	of	 2461 






A	 comparison	 of	 the	 proportion	 of	 VT	 pneumococci	 to	 NVT	 pneumococci	 in	 each	 2468 
interval	(A-D),	Figure	13	below,	showed	that	there	was	no	significant	difference	in	the	 2469 
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5.4.6.2		 Is	 early	 life	 carriage	 (before	 first	 dose	 of	 PCV-13)	 2480 
associated	with	 increased	risk	of	pneumococcal	acquisition	after	 the	 2481 
first	but	before	the	second	dose	of	PCV-13?	 2482 
Based	 on	 the	 descriptive	 summary	 above	 and	 the	 schema	 in	 Figure	 39,	 a	 Cox	 2483 
proportional	hazard	model	was	applied	to	investigate	the	effect	of	prior	pneumococcal	 2484 
colonisation	on	 risk	of	 acquiring	 any	 (either	VT	or	NVT)	pneumococci	 following	 each	 2485 


















































































	dose	 (interval	B)	were	1.78	(95%	CI	 2507 
1.22–	2.57,	p	=	0.003)	more	likely	to	acquire	any	type	of	pneumococci	after	the	2nd	dose	 2508 
of	PCV-13	(interval	C)	compared	to	non-colonised	children.	 2509 









pneumococcus	 after	 the	 2
nd
	 dose	 of	 PCV-13	 compared	 to	 children	 who	 were	 not	 2513 
 184 
colonised,	HR	=	1.99	(95%	CI	0.94	–	4.18,	p	=	0.06)	and	HR	=	1.59	(95%	CI	0.95	–	2.65,	p	 2514 
=	 0.07)	 respectively.	 Similarly,	 children	 colonised	 with	 a	 NVT	 before	 the	 1
st





CI	0.80	–	1.97,	p	=	0.32).	 In	contrast,	children	colonised	with	NVT	between	the	1st	and	 2518 
2
nd


















5.4.7	 Risk	factors	associated	with	pneumococcal	carriage	 2527 
acquisition	 2528 
Due	to	the	differences	in	the	population	profiles	at	TC	Newman	and	Mbekweni,	Table	17	 2529 
above,	 crude	 and	 adjusted	 incidence	 and	 hazard	 ratios	 were	 computed	 using	 Cox	 2530 
proportional	hazard	models	to	compare	the	association	of	each	of	the	risk	factors	with	 2531 
the	incidence	of	pneumococcal	carriage	acquisition.	The	presence	of	other	siblings	in	a	 2532 
household	was	positively	 associated	with	 acquisition	of	 any	 type	of	 pneumococcus	 at	 2533 







Table 17: Risk factors associated with the incidence of acquisition of carriage of ANY pneumococcal 2540 








Site	 	 	 	 	 	
						Mbekweni	 528	 27162	 1.94	(1.78-2.11)	 1	 -	
						TC	Newman	 399	 20987	 1.90	(1.72-2.10)	 0.87	(0.71-1.07)	 0.18	
Gender	 	 	 	 	 	
						Female	 517	 27320	 1.89	(1.73-2.06)	 1	 -	
						Male	 410	 20829	 1.97	(1.78-2.17)	 1.03	(0.88-1.19)	 0.71	
Mode	of	delivery	 	 	 	 	 	
						Normal	vaginal	 743	 37984	 1.95	(1.82-2.10)	 1	 -	
						Vacuum	 2	 381	 0.52	(0.13-2.10)	 0.38	(0.09-1.59)	 0.18	
						Elective	caesarean	 65	 3565	 1.82	(1.42-2.32)	 1.00	(0.75-1.33)	 1.00	
						Emergency	caesarean	 117	 6219	 1.88	(1.57-2.25)	 0.94	(0.75-1.18)	 0.61	
HIV	exposure	 	 	 	 	 	
						No	 704	 36491	 1.93	(1.79-2.08)	 1	 -	
						Yes	 223	 11658	 1.91	(1.68-2.18)	 0.91	(0.75-1.10)	 0.32	
Feed	choice	 	 	 	 	 	
						Exclusive	breastfeeding	 301	 14900	 2.02	(1.80-2.26)	 1	 -	
						Mixed	feeding	 163		 7773	 2.09	(1.79-2.44)	 1.03	(0.81-1.32)	 0.79	
						Never	breastfeeding	 463		 25533	 1.81	(1.66-1.98)	 0.96	(0.80-1.16)	 0.67	
Other	Children1	 	 	 	 	 	
						No	 563		 31918	 1.76	(1.62-1.92)	 1	 -	
						Yes	 364	 16231	 2.24	(2.02-2.49)	 1.21	(1.03-1.41)	 0.02	
Premature		(Mbekweni)																	 	 	 	 	
						No	 470	 23338	 2.01	(1.83-2.20)	 1	 -	
						Yes	 58	 3824	 1.51	(1.17-1.96)	 0.74	(0.54-1.01)	 0.06	
Premature	(TC	Newman)	 	 	 	 	 	
						No	 329		 17858	 1.84	(1.65-2.05)	 1	 -	
						Yes	 70	 3129	 2.23	(1.77-2.82)	 1.12	(0.53-2.39)	 -#	
Season	 	 	 	 	 	
						Summer	 213	 12194	 1.75	(1.53-1.99)	 1	 -	
						Spring	 196	 12024	 1.63	(1.41-1.87)	 0.92		(0.75-1.12)	 0.41	
						Winter	 232	 12213	 1.89	(1.67-2.16)	 1.07	(0.88-1.30)	 0.46	
						Autumn	 286	 11718	 2.44	(2.17-2.74)	 1.38	(1.15-1.65)	 0.00	
Smoking	status	of	Mother	 	 	 	 	 	
						No	 358	 19147	 1.87	(1.69-2.07)	 1	 -	
						Yes	 569	 29002	 1.96	(1.81-2.13)	 1.12	(0.94-1.34)	 0.19	
Sleeps	with	Mother	 	 	 	 	 	
						No	 108	 4907	 2.20	(1.82-2.63)	 1	 -	
						Yes	 819	 43242	 1.89	(1.77-2.03)	 0.81	(0.55-1.19)	 0.29	
Sleeps	with	Father	 	 	 	 	 	
						No	 526	 29208	 1.89	(1.65-1.96)	 1	 -	
						Yes	 401	 18941		 2.11	(1.91-2.33)	 1.19	(1.01-1.40)	 0.03	
Sleeps	with	sibling	 	 	 	 	 	
						No	 493	 29033	 1.69	(1.55-1.85)	 1	 -	
						Yes	 434	 19116	 2.27	(2.06-2.49)	 1.31	(1.12-1.54)	 0.00	
Microwave	 	 	 	 	 	
						No	 180	 8001	 2.24	(1.94-2.63)	 1	 -	
						Yes	 747	 40148	 1.86	(1.73-1.99)	 0.68	(0.45-1.03)	 0.07	
Paraffin	 	 	 	 	 	
						No	 843	 44280	 1.90	(1.78-2.04)	 1	 -	
						Yes	 84		 3869	 2.17	(1.75-2.69)	 0.85	(0.54-1.34)	 0.48	
Wood	 	 	 	 	 	
						No	 903	 47136	 1.91	(1.79-2.04)	 1	 -	
						Yes	 24	 1013	 2.37	(1.59-3.53)	 0.99	(0.56-1.73)	 0.96	
Gas	 	 	 	 	 	
						No	 904	 46382	 1.95	(1.82-2.08)	 1	 -	
						Yes	 23	 1767	 1.30	(0.86-1.96)	 0.74	(0.46-1.22)	 0.24	
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*One	observation	with	excluded	for	missing	data.	1Other	children	staying	with	the	child	 in	the	 2542 
same	 household.	 “-“	 Insufficient	 data	 in	 that	 category	 to	 make	 any	 inferences.	
#
The	 p-value	 2543 




A	 multivariate	 analysis	 of	 risk	 factors	 independently	 associated	 with	 VT	 acquisition	 2548 
showed	that	although	the	presence	of	older	siblings	increased	the	hazard	of	acquiring	a	 2549 
VT	 pneumococci,	 HR	 =	 1.29	 (95%	 CI	 0.73-2.27),	 this	 effect	 was	 not	 statistically	 2550 
significant,	p	 =	0.38,	 table	19.	The	only	 risk	 factors	 independently	 associated	with	VT	 2551 













Site	 	 	 	 	 	
						Mbekweni	 51	 17209	 0.29	(0.22-0.40)	 1	 -	
						TC	Newman	 47	 14803	 0.31	(0.23-0.42)	 1.00	(0.48-2.06)	 1.00	
Gender	 	 	 	 	 	
						Female	 51	 18240	 0.28	(0.21-0.37)	 1	 -	
						Male	 47	 13772	 0.34	(0.26-0.45)	 1.66	(0.97-2.84)	 0.07	
Mode	of	delivery	 	 	 	 	 	
						Normal	vaginal	 80	 25859	 0.31	(0.25-0.39)	 1	 -	
						Vacuum	 1	 382	 0.26	(0.034-1.8)	 2.56	(0.21-31.59)	 0.47	
						Elective	caesarean	 9	 2356	 0.38	(0.19-0.73)	 2.01	(0.80-5.04)	 0.14	
						Emergency	caesarean	 8	 3415	 0.23	(0.12-0.47)	 0.62	(0.23-1.73)	 0.37	
HIV	exposure	 	 	 	 	 	
						No	 73	 23587	 0.31	(0.25-0.39)	 1	 -	
						Yes	 25	 8425	 0.30	(0.20-0.44)	 0.87	(0.44-1.70)	 0.68	
Feed	choice	 	 	 	 	 	
						Exclusive	breastfed	 38	 10672	 0.36	(0.26-0.49)	 1	 -	
						Mixed	fed	 17	 4043	 0.42	(0.26-0.68)	 1.27	(0.54-3.01)	 0.59	
						Never	breastfed	 43	 17297	 0.25	(0.18-0.34)	 0.76	(0.40-1.47)	 0.42	
Other	Children1	 	 	 	 	 	
						No	 58	 21150	 0.27	(0.21-0.35)	 1	 -	
						Yes	 40	 10862	 0.37	(0.27-0.50)	 1.29	(0.73-2.27)	 0.38	
Premature						 	 	 	 	 	
						No	 80	 27406	 0.29	(0.23-0.36)	 1	 -	
						Yes	 18		 4606	 0.39	(0.24-0.62	 1.04	(0.52-2.11)	 0.91	
Season	 	 	 	 	 	
						Summer	 27	 9510	 0.28	(0.19-0.41)	 1	 -	
						Spring	 19	 8681	 0.22	(0.41-0.34)	 0.71	(0.34-1.50)	 0.38	
						Winter	 22	 6050	 0.36	(0.24-0.55)	 1.54	(0.773.11)	 0.23	
						Autumn	 30	 7771	 0.39	(0.27-0.55)	 1.07	(0.56-2.04)	 0.84	
Smoking	status	of	Mother	 	 	 	 	 	
						No	 39	 13033	 0.30	(0.21-0.41)	 	 	
						Yes	 59	 18979	 0.31	(0.24-0.40)	 0.87	(0.45-1.71)	 0.70	
Sleeps	with	Mother	 	 	 	 	 	
						No	 11	 3367	 0.33	(0.18-0.59)	 1	 -	
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						Yes	 87	 28645	 0.30	(0.25-0.37)	 4.60	(0.31-68.96)	 0.27	
Sleeps	with	Father	 	 	 	 	 	
						No	 49	 20269	 0.24	(0.18-0.32)	 1	 -	
						Yes	 49	 11743	 0.42	(0.32-0.55)	 1.95	(1.07-3.53)	 0.03	
Sleeps	with	sibling	 	 	 	 	 	
						No	 49	 20258	 0.24	(0.18-0.32)	 1	 -	
						Yes	 49	 11754	 0.41	(0.31-0.55)	 1.88	(1.07-3.30)	 0.03	
Microwave	 	 	 	 	 	
						No	 23	 4905	 0.47	(0.31-0.71)	 1	 -	
						Yes	 75	 27107	 0.28	(0.22-0.35)	 0.08	(0.01-1.23)	 0.07	
Paraffin	 	 	 	 	 	
						No	 89	 29993	 0.30	(0.24-0.37)	 1	 -	
						Yes	 9	 2019	 0.45	(0.23-0.86)	 0.21	(0.01-3.81)	 0.29	
Wood	 	 	 	 	 	
						No	 95	 31750	 0.30	(0.24-0.37)	 1	 -	
						Yes	 3	 262	 1.14	(0.37-3.55)	 1.79	(0.09-36.74)	 0.71	
Gas	 	 	 	 	 	
						No	 97	 31171	 0.31	(0.26-0.38)	 1	 -	
						Yes	 1	 841	 0.12	(0.02-0.84)	 0.08	(0.00-1.47)	 0.09	
*One	observation	with	excluded	for	missing	data.	1Other	children	staying	with	the	child	in	the	 2558 
same	 household.	 “-“	 Insufficient	 data	 in	 that	 category	 to	 make	 any	 inferences.	
#
The	 p-value	 2559 




A	multivariate	 analysis	 of	 risk	 factors	 independently	 associated	with	NVT	 acquisition	 2564 
showed	 significant	 interaction	 between	 feeding	 choice	 and	 clinic	 site.	 Therefore,	 the	 2565 
relationship	between	feeding	choice	and	NVT	carriage	acquisition	is	presented	by	site.	 2566 
Compared	 to	 children	 from	Mbekweni	who	were	 exclusively	 breastfed	 for	 the	 first	 6	 2567 
months	 of	 life,	 children	 who	 were	 never	 breastfed	 were	 less	 likely	 to	 acquire	 NVT	 2568 
pneumococci	(HR	=	0.60	[95%	CI	0.43-0.83,	p	<	0.001]),	table	20.	In	contrast,	children	 2569 
from	 TC	 Newman	who	were	 both	 breastfed	 and	 formula	 fed	 (mixed	 fed)	were	more	 2570 
likely	to	acquire	NVT	pneumococci	compared	to	children	who	were	exclusively	breast	 2571 
(HR	 =	 1.68	 [95%	 CI	 1.08-2.62,	 p	 =	 0.02]).	 Additional	 risk	 factors	 independently	 2572 
associated	with	 acquisition	 of	NVT	 pneumococci	were	weather	 (autumn)	 (HR	 =	 1.44,	 2573 
95%	CI	1.16-1.80,	p	<	0.001);	children	staying	with	mothers	with	self-reported	tobacco	 2574 














Site	 	 	 	 	 	
						Mbekweni	 382	 27222	 1.40	(1.27-1.55)	 1	 -	
						TC	Newman	 280	 20870	 1.34	(1.19-1.51)	 0.87	(0.68-1.12)	 0.28	
Gender	 	 	 	 	 	
						Female	 373	 27336	 1.36	(1.23-1.51)	 1	 -	
						Male	 289	 20756	 1.39	(1.24-1.56)	 1.00	(0.83-1.21)	 0.98	
Mode	of	delivery	 	 	 	 	 	
						Normal	vaginal	 531	 37825	 1.40	(1.29-1.53)	 1	 -	
						Vacuum	 1	 382	 0.26	(0.03-1.85)	 0.27	(0.03-2.14)	 0.22	
						Elective	caesarean	 43	 3575	 1.20	(0.89-1.62)	 0.83	(0.57-1.21)	 0.34	
						Emergency	caesarean	 87	 6310	 1.38	(1.11-1.70)	 1.01	(0.76-1.33)	 0.96	
HIV	exposure	 	 	 	 	 	
						No	 507	 36492		 1.39	(1.27-1.51)	 1	 -	
						Yes	 155	 11600	 1.34	(1.14-1.56)	 0.84	(0.65-1.08)	 0.18	
Feed	choice	(Mbekweni)	 	 	 	 	 	
						Exclusive	breastfed	 107	 6276	 1.70	(1.41-2.06)	 1	 -	
						Mixed	fed	 76	 5323	 1.43	(1.14-1.79)	 0.72	(0.49-1.05)	 0.09	
						Never	breastfed	 199	 15623	 1.27	(1.10-1.46)	 0.60	(0.43-0.83)	 0.00	
Feed	choice	(TC	Newman)	 	 	 	 	 	
						Exclusive	breastfed	 106	 8321	 1.27	(1.05-1.54)	 1	 -	
						Mixed	fed	 47	 2461	 1.91	(1.43-2.54)	 1.68	(1.08-2.62)	 0.02	
						Never	breastfed	 127		 10088	 1.26	(1.06-1.50)	 1.01	(0.72-1.40)	 0.97	
Other	Children1	 	 	 	 	 	
						No	 398	 32063	 1.24	(1.13-1.37)	 1	 -	
						Yes	 264	 16029	 1.65	(1.46-1.86)	 1.19	(0.98-1.44)	 0.09	
Premature					 	 	 	 	 	
						No	 570	 41193	 1.38	(1.27-1.50)	 1	 -	
						Yes	 92	 6899	 1.33	(1.09-1.63)	 0.96	(0.72-1.26)	 0.75	
Season	 	 	 	 	 	
						Summer	 155	 13251	 1.17	(1.00-1.37)	 1	 -	
						Spring	 145	 11728	 1.24	(1.05-1.45)	 1.03	(0.81-1.31)	 0.80	
						Winter	 172		 12106	 1.42	(1.22-1.65)	 1.16	(0.93-1.46)	 0.20	
						Autumn	 190	 11007	 1.73	(1.50-1.99)	 1.44	(1.16-1.80)	 0.00	
Smoking	status	of	Mother	 	 	 	 	 	
						No	 250	 19107	 1.31	(1.16-1.48)	 1	 -	
						Yes	 412	 28985	 1.42	(1.29-1.57)	 1.26	(1.01-1.57)	 0.04	
Sleeps	with	Mother	 	 	 	 	 	
						No	 81	 5003	 1.62	(1.30-2.01)	 1	 -	
						Yes	 581	 43089	 1.35	91.24-1.46)	 0.73	(0.45-1.18)	 0.19	
Sleeps	with	Father	 	 	 	 	 	
						No	 388	 28998	 1.33	(1.21-1.48)	 1	 -	
						Yes	 274		 19094		 1.44	(1.27-1.61)	 1.05	(0.85-1.29)	 0.65	
Sleeps	with	sibling	 	 	 	 	 	
						No	 358	 29085	 1.23	(1.11-1.37)	 1	 -	
						Yes	 304	 19007	 1.60	(1.43-1.79)	 1.31	(1.07-1.60)	 0.01	
Microwave	 	 	 	 	 	
						No	 128	 8105	 1.58	(1.32-1.88)	 1	 -	
						Yes	 534	 39987	 1.34	(1.22-1.45)	 0.77	(0.46-1.29)	 0.32	
Paraffin	 	 	 	 	 	
						No	 603	 44216	 1.36	(1.26-1.48)	 1	 -	
						Yes	 59	 3876	 1.52	(1.18-1.96)	 1.01	(0.57-1.80)	 0.97	
Wood	 	 	 	 	 	
						No	 644	 47077	 1.37	(1.27-1.48)	 1	 -	
						Yes	 18	 1015	 1.77	(1.12-2.81)	 1.19	(0.59-2.40)	 0.63	
Gas	 	 	 	 	 	
						No	 649	 46322	 1.40	(1.29-1.51)	 1	 -	
						Yes	 13	 1770	 0.73	(0.42-1.26)	 0.54	(0.27-1.04)	 0.07	
 2581 
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5.5	 DISCUSSION	 2582 
In	 this	 intensively	 sampled	 birth	 cohort	 study,	 we	 show	 a	 gradual	 increase	 in	 the	 2583 
incidence	of	pneumococcal	carriage	acquisition	from	1.2	episodes	per	100	child-days	to	 2584 
1.8	episodes	per	100	child-days	and	finally	2.0	episodes	per	100	child-days	at	the	time	 2585 
of	 the	 first,	 second	 and	 third	 PCV-13	 dose	 respectively.	 Pneumococcal	 colonisation	 2586 
either	prior	to	the	first	dose	or	after	the	first	but	before	the	second	dose	of	PCV-13	was	 2587 
associated	with	 an	 increased	hazard	 for	 subsequent	pneumococcal	 colonisation,	HR	=	 2588 
2.4	 (95%	 CI	 1.50-3.90,	 p	 <	 0.001)	 and	 HR	 =	 1.78	 (95%	 CI	 1.22-2.57,	 p	 =	 0.003)	 2589 
respectively.	This	 finding	 is	 consistent	with	data	 from	other	 studies	 that	 showed	 that	 2590 
prior	 VT	 colonisation	 was	 associated	 with	 reduced	 PCV	 efficacy	 against	 serotypes	 2591 
included	 in	 the	 vaccine	 formulations	 (60,61,81).	 This	 was	 characterized	 by	 serotype	 2592 
hypo-responsiveness	to	PCV-7	in	infants	carrying	pneumococcus	prior	to	or	at	the	time	 2593 
of	 immunisation.	Dagan	et	al.	 showed	 that	VT	pneumococcal	 carriage	 amongst	 Israeli	 2594 
children	 at	 the	 time	 of,	 or	 shortly	 before,	 PCV-7	 immunisation	 was	 associated	 with	 2595 
serotype	hypo-responsiveness	to	the	carried	VT	pneumococcal	capsular	polysaccharide	 2596 
(61).	 Similarly,	 Madhi	 et	 al.	 demonstrated	 that	 VT	 carriage	 amongst	 South	 African	 2597 
children	 at	 any	 stage	 prior	 to	 completion	 of	 sequential	 PCV-7	 immunisation	 schedule	 2598 
was	 associated	 with	 inferior	 qualitative	 and	 quantitative	 serotype-specific	 antibody	 2599 




The	 exact	 mechanism	 behind	 serotype	 hyporesponsiveness	 remains	 incompletely	 2604 
understood.	 It	 has	 however	 been	 suggested	 that	 early	 life	 carriage	 in	 healthy	 infants	 2605 
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results	 in	 high	 capsular	 polysaccharide	 loads	 that	 may	 induce	 B-cell	 exhaustion	 or	 2606 
unresponsiveness	(61,66,82).	Serotype-specific	immune	response	to	the	pneumococcal	 2607 
polysaccharide	 is	 T-cell	 independent	 and	 incapable	 of	 generating	 functional	 B-cell	 2608 
immunologic	 memory	 (37).	 Therefore,	 early	 life	 pneumococcal	 carriage	 may	 lead	 to	 2609 
immature	 B-cells	 that	 do	 not	 effectively	 differentiate	 into	 antibody	 producing	 plasma	 2610 
cells	 in	 response	 to	 PCV	 immunisation	 (83,84).	 The	 turn-over	 of	 insufficiently	 2611 
differentiated	 plasma	B-cells	 can	 also	 deplete	 the	 serotype-specific	 B-cell	 pool	within	 2612 
the	marginal	zone	of	the	spleen	and	nodes	(83,84).		 2613 
	 2614 
PCV	 immunisation	 reduces	 NP	 colonisation	 by	 VT	 serotypes,	 and	 increase	 NVT	 2615 
colonisation	within	months	 following	receipt	of	primary	vaccine	series	 (11,39,85–88).	 2616 
Further,	 the	 degree	 to	 which	 PCV	 confers	 protection	 against	 VT	 carriage	 acquisition	 2617 
depends	on	pneumococcal	 carriage	prevalence	and	 the	 immunisation	coverage	within	 2618 
communities.	 In	our	study,	 ‘residual’	carriage	of	VT	pneumococci	did	not	appear	to	be	 2619 
affected	 by	 sequential	 doses	 of	 PCV-13.	 This	 contrasts	 earlier	 randomized	 controlled	 2620 
trials	 and	 observational	 studies	 (most	 of	which	were	 conducted	 prior	 to	 community- 2621 
wide	 introduction	 of	 PCVs)	 from	 different	 setting	 and	 using	 different	 vaccine	 2622 
formulations	 that	 showed	 reduced	 VT	 colonisation	 (11,39,85–88).	 A	 randomized,	 2623 
double-blinded	 placebo	 controlled	 trial	 conducted	 by	 Mbelle	 et	 al	 using	 PCV-9	 2624 
administered	 at	 6,	 10	 and	 14	 weeks	 in	 500	 infants	 from	 Soweto	 showed	 significant	 2625 
reductions	 in	 overall	 VT	 NP	 carriage	 (18	 vs	 36%,	 p	 <	 0.001)	 in	 vaccinees	 at	 age	 9	 2626 
months	and	was	accompanied	by	an	increase	in	NVT	NP	carriage	(36	vs	25%,		p	<	0.001)	 2627 
(11).	There	are	limited	data	on	the	long-term	effect	of	each	sequential	PCV	dose	on	the	 2628 
likelihood	 of	 VT	 acquisition	 post	 community-wide	 implementation	 of	 PCVs	 in	 routine	 2629 
immunisation	programs.	Lakshman	et	al	found	no	reduction	in	VT	NP	colonisation	a	few	 2630 
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VT	 carriage	 in	 our	 setting	 and	 the	 lack	 of	 evidence	 to	 suggest	 reductions	 in	 VT	 2636 
colonisation	may	be	 a	 function	 of	 (1)	 high	 community-wide	PCV-13	 vaccine	 coverage	 2637 
resulting	in	significant	changes	in	the	dynamics	of	VT	community-wide	exposure	(herd	 2638 
protection)	and	risk	of	colonisation	(2)	incompletely	immunised	older	siblings	or	adults	 2639 
with	 waning	 immunity	 (particularly	 amongst	 HIV-infected	 adults)	 may	 serve	 as	 2640 
reservoirs	 for	 increased	 risk	 of	 person-to-person	 transmission.	 The	 lack	 of	 catch-up	 2641 
immunisation	 in	 older	 children	 and	 low	 immunogenicity	 of	 pneumococcal	 serotypes	 2642 
presents	 constant	 challenges	 in	maintaining	 highly	 protective	 antibody	 titres	 in	 early	 2643 




We	did	not	observe	any	differences	 in	susceptibility	to	VT	pneumococci	between	HIV- 2648 
exposed	 uninfected	 (HEU)	 and	 HIV-unexposed	 uninfected	 (HUU)	 children.	 This	 2649 
corroborates	 earlier	 findings	 from	 a	 longitudinal	 (CIPRA	 04)	 study	 amongst	 children	 2650 
from	Soweto	 (Gauteng)	 and	Tygerberg	 (Western	 cape)	which	 showed	 that	PCV-7	had	 2651 
similar	 effect	 against	 VT	 colonisation	 in	 HEU,	 HUU	 and	 HIV	 infected	 children	 during	 2652 
their	first	18	months	of	life	(91).	Some	studies	In	contrast,	Gill	et	al	suggested	that	HEU	 2653 
children	 are	 at	 increased	 risk	 pneumococcal	 colonisation,	 especially	 serogroups	 6,	 19	 2654 
and	 23,	 than	 HUU	 (92,93).	 The	 differences	 in	 susceptibility	 to	 pneumococcal	 2655 
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in	 general.	 However,	 children	 who	 were	 never	 breastfed	 from	 Mbekweni	 were	 less	 2660 
likely	 to	 acquire	 NVT	 pneumococci	 than	 children	 who	 were	 exclusively	 breastfed	 2661 
(HR=0.60	 [95%	CI	0.43-0.83],	p	<	0.001).	The	association	between	breast-feeding	and	 2662 
pneumococcal	 carriage	 in	 human	 and	 in	 vitro	 studies	 is	 largely	 inconclusive	 (94,95).	 2663 
Some	 studies	 have	 shown	 that	 breastfeeding	 protects	 against	 respiratory	 tract	 2664 
infections	 as	well	 as	 IPD.	 	 Lower	 rates	of	pneumococcal	 carriage	have	been	 shown	 in	 2665 
exclusively	 breastfed	 children	 while	 another	 study	 suggests	 no	 association	 between	 2666 
breastfeeding	 and	 pneumococcal	 carriage.	 There	 are	 several	 factors	 that	may	 explain	 2667 
these	differences	(1)	behavior	–	HIV	 infected	mothers	may	 less	 likely	breastfeed	 their	 2668 
children	in	order	to	minimize	the	risk	of	postpartum	HIV	transmission	to	infants.	This	 2669 
corroborated	 our	 findings	 as	 well	 as	 others	 that	 suggests	 that	 HEU	 infants	 from	 2670 
Mbekweni,	a	setting	with	a	high	HIV	prevalence,	are	less	likely	to	be	colonised	by	NVT	 2671 
compared	 to	 HUU	 (HR	 =	 0.60	 [95%	 CI	 0.43-0.83,	 p	<	 0.001])	 (2)	 other,	 unmeasured	 2672 
demographic	factors	 2673 
	 2674 
Several	 risk	 factors	 including	 daycare	 center	 attendance,	 viral	 respiratory	 tract	 2675 
infections,	 living	 in	a	crowded	family	(especially	the	presence	of	older	siblings),	 lower	 2676 
socioeconomic	status,	use	of	antibiotics	and	exposure	 to	 tobacco	smoke	predispose	 to	 2677 
nasopharyngeal	 carriage	 of	 pneumococci	 (67–70,72,77).	 In	 our	 settings	 however,	 the	 2678 
presence	 of	 other	 children	 that	was	 associated	with	VT	 and	NVT	 carriage	 acquisition	 2679 
irrespective	of	site.	In	addition,	environmental	tobacco	smoke	exposure	was	associated	 2680 
 193 
with	 NVT	 carriage	 acquisition	 and	 this	 effect	 was	 more	 pronounced	 at	 TC	 Newman	 2681 
where	50%	of	mothers	reported	tobacco	smoking	compared	to	9%	observed	amongst	 2682 
mothers	 at	 Mbekweni.	 Evidence	 suggests	 that	 tobacco	 smoke	 exposure	 decreases	 2683 
mucocilliary	clearance	and	induces	the	inflammation	of	the	respiratory	epithelial	lining	 2684 
thereby	 predisposing	 individuals	 to	 bacterial	 adherence	 and	 subsequent	 colonisation	 2685 
(96,97).	 Similar	 finding	 have	 been	 reported	 amongst	 children	 staying	 in	 a	 crowded	 2686 
refugee	camp	in	Thailand	(26).	Our	finding	that	tobacco	smoking	is	associated	with	NVT	 2687 
acquisition	 is	 different	 from	what	was	 reported	by	Greenberg	et	al.	who	 showed	 that	 2688 
tobacco	 smoking	 as	 rather	 associated	with	 VT	 carriage	 and	 not	NVT	 (98).	 This	 study	 2689 





Study	 limitations	 include	 the	 inability	 to	 identify	 co-colonisation	 with	 multiple	 2695 
serotypes	 and	 the	 lack	 of	MLST	data.	 Therefore,	we	 cannot	 speculate	whether	 all	 the	 2696 
NVT	 detected	 in	 the	 present	 study	 result	 from	 expansion	 of	 pre-existing	 clones	 2697 
(unmasking),	 introduction	of	new	clones	not	previously	encountered	 in	our	setting	or	 2698 
acquisition	of	novel	capsular	types	through	partial	or	complete	exchange	of	the	capsular	 2699 
biosynthetic	gene	cluster	(capsular	switching).	Such	a	process	would	generally	result	in	 2700 
persistence	of	VT	pneumococci	 in	the	form	of	mutants	expressing	NVT	capsular	types.	 2701 
Another	limitation	of	the	present	study	is	the	fact	that	tobacco	exposure	was	based	on	 2702 
self-reported	smoking	which	might	be	inaccurate.	Inclusion	of	biochemical	measures	of	 2703 
passive	 smoking	 such	 as	 urinary	 cotinine	 levels	 might	 provide	 a	 more	 objective	 2704 
measure	of	 the	amount	of	 tobacco	exposure	 in	children	 (99).	However,	another	study	 2705 
 194 
has	 shown	 that	 urinary	 cotinine	 level	 did	 not	 improve	 the	 validity	 of	 tobacco	 smoke	 2706 
exposure	and	its	relation	to	lower	respiratory	illness	in	infants	questionnaires	(100).	 2707 
	 2708 
In	 summary,	 early	 life	 NP	 colonisation	 was	 associated	 with	 an	 increased	 hazard	 for	 2709 
subsequent	 pneumococcal	 colonisation	 post	 PCV-13	 immunisation.	 The	 season	 2710 
(autumn),	presence	of	older	siblings	in	the	household	and	fathers	who	slept	in	the	same	 2711 
room	 as	 the	 child	 were	 associated	 with	 VT	 pneumococcal	 carriage	 acquisition	 2712 
irrespective	of	site.	On	the	other	hand,	infant	mode	of	feeding	within	the	first	six	years	 2713 
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6.1	 INTRODUCTION	 3136 
Lower	 respiratory	 tract	 infection	 is	 a	 leading	 cause	 of	 mortality	 and	 morbidity	 in	 3137 




comorbidity	 amongst	 children	 with	 pneumonia,	 particularly	 in	 settings	 endemic	 for	 3142 
human	immunodeficiency	virus	(HIV)	and	tuberculosis	(3).		 3143 
TB	 diagnosis	 in	 children	 is	 largely	 made	 on	 the	 basis	 of	 clinical	 and	 radiological	 3144 
presentations,	which	may	be	non-specific.	Therefore	TB	cannot	be	easily	differentiated	 3145 
from	other	causes	of	acute	or	chronic	respiratory	tract	infection	(4).	Recent	studies	have	 3146 
reported	 an	 increase	 in	 the	 detection	 of	 polymicrobial	 infections	 in	 children	 with	 3147 
respiratory	 tract	 infections,	 including	 children	 with	 pulmonary	 TB	 (5-7).	 Culture	 3148 
confirmed	 TB	 was	 reported	 in	 8%	 of	 children	 hospitalised	 with	 acute	 pneumonia	 in	 3149 
South	Africa,	with	no	difference	by	HIV	status;	 similar	 findings	have	been	reported	 in	 3150 
other	African	studies(8).		A	recent	meta-analysis	confirmed	Mycobacterium	tuberculosis	 3151 
in	8%	of	childhood	pneumonia	cases	in	high	TB	endemic	areas	(3).			 3152 
The	 availability	 of	 a	 real-time,	 fluorescent	 probe-based	 reverse	 transcription	 3153 
polymerase	 chain	 reaction	 (RT-PCR),	 has	 led	 to	 an	 exponential	 increase	 in	 our	 3154 
understanding	of	the	diversity	of	polymicrobial	respiratory	infections	which	often	have	 3155 
indistinguishable	clinical	presentations	(6,9-20).	It	is	the	method	of	choice	for	sensitive	 3156 
detection	and	precise	quantification	of	minute	amounts	of	nucleic	 acid	 from	potential	 3157 
respiratory	 tract	 pathogens.	 In	 addition,	 RT-PCR	 offers	 the	 ability	 to	 amplify	 and	 3158 
differentiate	 multiple	 targets	 within	 a	 single	 reaction	 tube.	 A	 number	 of	 both	 3159 
 209 
laboratory-developed	 and	 commercial	 multiplex	 RT-PCR	 assays	 employing	 different	 3160 




PCR	 assays	 are	 nonetheless	 costly,	 require	 specialised	 laboratory	 equipment	 and	 use	 3165 
highly	multiplexed	reactions	that	may	be	deficient	in	individual	assay	performance	and	 3166 
can	 be	 difficult	 to	 modify	 without	 extensive	 assay	 re-optimisation.	 The	 Fast-track	 3167 
Diagnostics	(FTD)	respiratory	pathogens	multiplex	assay	kit	(FTD	Resp33	kit,	Fast-track	 3168 
Diagnostics,	 Luxembourg)	 utilises	 a	 standard	 commercial	 one-step	 RT-PCR	 3169 
amplification	reaction	with	differentially	labelled	target-specific	hydrolysis	probes.	The	 3170 
assay	 can	 easily	 be	 performed	 on	most	 common	 real-time	 PCR	 instruments.	 A	 single	 3171 
assay	is	comprised	of	eight	multiplex	RT-PCR	reactions	for	the	detection	of	33	potential	 3172 
respiratory	 pathogens.	 Similar	 FTD	 assays	 have	 been	 adopted	 for	 the	 study	 of	 3173 
polymicrobial	 infections	 elsewhere	 although	mostly	 targeting	 fewer	 than	21	potential	 3174 
respiratory	pathogens	(23,29,34,35).	 3175 
Little	is	known	about	the	range	and	role	of	respiratory	pathogens	that	may	be	detected	 3176 
in	 children	 presenting	with	 suspected	 TB,	 either	 as	 the	 primary	 cause	 of	 respiratory	 3177 
symptoms	in	children	who	do	not	have	TB,	or	as	co-pathogens	in	children	who	do	have	 3178 
TB.	 To	 date,	 only	 one	 study	 in	 adults	 has	 addressed	 this	 issue	 (36).	 Lockman	 et	 al.,	 3179 
utilising	microscopy	and	culture,	showed	that	among	TB	suspects	in	Botswana,	TB	was	 3180 
confirmed	 in	 52%;	 17%	 had	 acute	 Mycoplasma	 pneumoniae	 infection,	 and	 3%	 had	 3181 
Pneumocystis	 jirovecii	 infection.	 Co-infection	 with	 two	 or	 more	 pathogens	 was	 3182 




TB	 (PTB),	 15%	 had	 microbiologically-confirmed	 PTB,	 48%	 were	 classified	 as	 having	 3186 
possible	 PTB	 and	 in	 37%	 PTB	 was	 excluded,	 with	 respiratory	 disease	 due	 to	 other	 3187 
pathogens	 (37).	 Approximately	 half	 of	 children	 were	 treated	 for	 PTB,	 including	 all	 3188 
children	with	definite	PTB	and	most	with	possible	PTB	(37).	There	is	therefore	a	large	 3189 
amount	of	unaccounted	respiratory	illness	amongst	this	cohort,	as	well	as	possible	co- 3190 
infection	with	M.	 tuberculosis	 (MTB)	 and	 other	 pathogens.	We	 therefore	 conducted	 a	 3191 
study	 to	 describe	 the	 diversity	 of	 potential	 respiratory	 pathogens	 in	 children	 3192 
hospitalised	with	suspected	PTB	and	to	explore	co-infection	patterns	between	MTB	and	 3193 
other	respiratory	pathogens.	 3194 
6.2	 Aims	and	Objectives	 3195 
We	 aim	 to	 describe	 the	 diversity	 of	 potential	 respiratory	 pathogens	 in	 children	 3196 
hospitalised	with	suspected	PTB	and	to	explore	co-infection	patterns	between	MTB	and	 3197 
other	respiratory	pathogens.	Specific	objectives	are:	 3198 
1. To	 identify	 the	 diversity	 of	 potential	 respiratory	 pathogens	 in	 children	 3199 
hospitalised	with	suspected	pulmonary	TB	in	whom:	 3200 
a. TB	was	microbiologically	confirmed	 3201 
b. TB	was	excluded		 3202 
2. To	assess	the	age-dependent	microbial	pathogen	distribution	among	children.	 3203 





6.3.1	 Study	population	 3208 
Children	under	15	years	of	age	suspected	of	PTB	presenting	at	Red	Cross	War	Memorial	 3209 
Children’s	 Hospital	 (RCH)	 in	 Cape	 Town,	 between	 July	 2011	 and	 May	 2012	 were	 3210 
considered	for	enrolled	in	the	TB	diagnostic	study,	as	previously	described	(10).	RCH	is	 3211 
a	 specialist	 referral	 paediatric	 hospital	 that	 manages	 approximately	 250	 000	 patient	 3212 





the	 following:	 i)	 a	 household	 contact	 infected	 with	 tuberculosis	 within	 the	 previous	 3218 
three	months,	ii)	loss	of	weight	or	failure	to	gain	weight	in	the	previous	three	months,	 3219 
iii)	a	positive	 tuberculin	skin	 test	 (TST)	 to	purified	protein	derivative	(PPD;	2TU,	PPD	 3220 
RT23,	 Staten	 Serum	 Institute,	 Denmark,	 Copenhagen),	 or	 iv)	 a	 chest	 radiograph	 3221 
suggestive	of	pulmonary	tuberculosis.	A	positive	skin	test	was	defined	as	5	mm	or	more	 3222 




adequate	 induced	 sputum).	 All	 patients	 with	 laboratory	 confirmed	 TB	 and	 those	 3227 
strongly	suspected	of	having	TB	based	on	clinical	and	radiological	criteria	were	referred	 3228 
for	TB	therapy	at	a	local	TB	clinic	in	accordance	with	South	African	National	Guidelines	 3229 
(40).	 	 Children	were	 followed	up	at	1	 and	3	months	 to	assess	 response	 to	 therapy	or	 3230 
 212 
improvement	 without	 TB	 treatment.	 	 All	 children	 received	 care	 in	 the	 public	 health	 3231 
system	 that	 includes	 free	 EPI	 immunisation	 for	 DPT,	 HiB,	 PCV13	 etc	 –	 you	 need	 to	 3232 
provide	basic	EPI	schedule	for	SA	as	pathogens	may	depend	on	immunisation	provided.	 3233 
(PCV7	from	2009,	replaced	with	PCV13	in	2011	at	6,	14	weeks	and	9	months.	 3234 
6.3.2	 Collection	of	respiratory	specimens	 3235 
Children	with	signs	and	symptoms	suggestive	of	TB	were	categorised	as	definite	TB	(i.e.	 3236 
culture	confirmed),	not	TB	(i.e.	not	clinically	diagnosed	with	improvement	on	follow-up	 3237 




6.3.3	 Processing	of	induced	sputum	for	mycobacterial	 3242 
culture	and	confirmation	 3243 
Induced	 sputum	 (IS)	 was	 collected	 by	 a	 trained	 research	 nurse	 at	 least	 30	 m	 after	 3244 
obtaining	an	NP	swab.	This	was	timed	after	subjecting	the	study	participants	to	a	2	−	3	h	 3245 
fast	in	a	well-ventilated	room,	as	previously	described	(42).	The	respiratory	specimens	 3246 
were	 then	submitted	 to	 the	National	Health	Laboratory	Services	 (NHLS)	Microbiology	 3247 
Laboratory	 at	 Groote	 Schuur	 Hospital	 (Cape	 Town,	 South	 Africa)	 for	 mycobacterial	 3248 




6.3.4	 Processing	of	NP	swabs	for	detection	of	respiratory	 3252 
pathogens		 3253 
Each	 NP	 swab	 was	 immediately	 placed	 into	 1.5	 ml	 PrimeStore
®
	 transport	 and	 3254 
stabilization	 medium	 (PrimeStore
®
	 	 MTM,	 Longhorn	 Vaccines	 and	 Diagnostics,	 San	 3255 
Antonio,	TX)	and	stored	at	−80oC	until	further	batch	processing	as	shown	below	(figure	 3256 





6.3.5	 Total	nucleic	acid	extraction			 3262 
NP	 swabs	 stored	 in	PrimeStore
®
	MTM	were	 thawed	at	 room	 temperature	 (22
o
C)	 and	 3263 
vortexed	 for	 15	 s.	 Thereafter,	 400	 µl	 of	 each	 sample	 was	 transferred	 to	 a	 ZR	 3264 
BashingBeads
TM
	 Lysis	 tube	 (Zymo	 Research	 Corp.,	 Irvine,	 CA)	 and	 subjected	 to	 a	 3265 
standardised	 “off	 board”	 mechanical	 lysis	 step	 on	 a	 Tissuelyzer	 LT	 (Qiagen,	 Hilden,	 3266 
Germany)	(43).	The	lysed	samples	were	then	centrifuged	at	10	000	g	for	1	m	to	pellet	all	 3267 
cellular	 debris.	 The	 supernatant	 was	 transferred	 to	 a	 sterile	 2	 ml	 reaction	 tube	 3268 
(Sarstedt,	 Nümbrecht,	 Germany)	 and	 4	 µl	 of	 an	 exogenous	 internal	 control	 (Equine	 3269 

















Total	 nucleic	 acid	 was	 eluted	 with	 60	 µl	 elution	 buffer	 and	 stored	 at	 −20oC	 until	 3273 
processing	(figure	40).	 3274 
6.3.6	 Real-time	multiplex	PCR	assay	 3275 
The	 FTD	 Resp33	 includes	 eight	 multiplex	 RT-PCR	 reactions	 per	 specimen	 for	 the	 3276 
detection	 of	 the	 following	 respiratory	 pathogens;	 Reaction	 1:	 influenza	 virus	 A,	 3277 
influenza	 virus	 B	 and	 rhinovirus;	 Reaction	 2:	 parainfluenza	 virus	 2-4	 and	 the	 equine	 3278 
arteritis	 virus	 (EAV)	 derived	 internal	 control;	 Reaction	 3:	 coronaviruses	 229E,	 NL63,	 3279 
O43	 and	 HKU1;	 Reaction	 4:	 parainfluenza	 virus	 1,	 human	 metapneumovirus	 A/B,	 3280 
bocavirus,	 and	Mycoplasma	 pneumoniae;	 Reaction	 5:	 respiratory	 syncytial	 virus	 A/B,	 3281 
cytomegalovirus,	 enterovirus/parechovirus,	 and	 adenovirus	 (AV);	 Reaction	 6:	 3282 
Staphylococcus	aureus,	Chlamydophila	pneumoniae,	Haemophilus	 influenzae	 type	 b	 and	 3283 
Streptococcus	pneumoniae;	Reaction	7:	Pneumocystis	jirovecii,	Legionella	species	(Legio),	 3284 
Klebsiella	 pneumoniae	 and	 Salmonella	 species;	 Reaction	 8:	 	 Moraxella	 catarrhalis,	 3285 































































Briefly,	 the	 eight	multiplex	RT-PCR	 reactions	were	 set-up	 on	 two	96-well	 PCR	plates,	 3293 
with	 the	 first	 five	 multiplex	 reactions	 on	 plate	 1	 and	 the	 three	 remaining	 multiplex	 3294 
reactions	on	plate	2.	Each	multiplex	reaction	comprised	194	µl	of	2×	RT-PCR	buffer	with	 3295 
23.3	µl	of	each	primer/probe	mix	and	15.5	µl	of	25×	enzyme	mix	 (AgPath-IDTM	One- 3296 
Step	 RT-PCR	 Kit,	 Applied	 Biosystems,	 Carlsbad,	 CA).	 Subsequently,	 15	 µl	 of	 each	 3297 
reaction	mix	was	added	 to	14	wells	of	 a	PCR	plate	 that	 included	12	 sample	 reactions	 3298 




thermal	 cycling	 conditions	 consisted	 of	 an	 initial	 denaturation	 at	 95°C	 for	 10	 m,	 3303 
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followed	 by	 40	 amplification	 cycles	 of	 95°C	 for	 8	 s	 (denaturation)	 and	 60°C	 for	 34	 s	 3304 
(amplification	 and	detection).	 Specimens	were	 considered	positive	 if	 they	had	 a	well- 3305 
defined	 amplification	 curve	 that	 crossed	 the	 cycle	 threshold	 (Cq-)	 within	 40	 cycles.	 3306 
Assay	performance	was	monitored	by	the	positive,	negative	and	internal	amplification	 3307 
controls	that	were	provided	with	the	kit.		 3308 
6.3.7	 Development	of	FTD	Resp33	qPCR	Analyser	 3309 
To	 minimize	 transcription	 errors	 when	 analysing	 the	 multiplex	 real-time	 RT-PCR	 3310 
results,	a	JAVA	based	program,	FTD	Resp	33	qPCR	Analyser	(figure	41),	was	developed	 3311 
and	 is	 freely	 available	on	 the	web	 (http://www.gematics.com/analyser.html).	 Further	 3312 
details	on	how	to	run	the	program	are	provided	(Appendix	6.3	and	snapshot	of	the	excel	 3313 
output	[figure	S6.3]).	The	FTD	Resp33	qPCR	Analyser	program	automatically	analyses	 3314 
FTD	 resp33	 results	 from	 the	 Bio-Rad	 CFX96	 Touch™	RT-PCR	 amplification	 system	 to	 3315 






6.3.8	 Statistical	Considerations	 3321 
Initial	exploratory	statistics	were	performed	using	STATA	software	(Stata	Corporation,	 3322 
College	 Station,	 TX)	 and	 the	 rest	 of	 the	 analyses	 were	 performed	 using	 the	 openly	 3323 
available	statistical	environment	R,	version	3.1.1	(44).	A	logistic	regression	model,	with	 3324 
age	group	as	a	predictor	of	 the	occurrence	of	 each	 respiratory	pathogen,	was	used	 to	 3325 
determine	 the	 age-dependent	 respiratory	 pathogen	 distribution.	We	 used	 analysis	 of	 3326 
variance	 (ANOVA)	 to	 compare	 the	 occurrence	 of	 each	 pathogen	 across	 the	 three	 TB	 3327 
categories	 and	 the	 resulting	 significance	 (p-values)	were	 adjusted	 for	 false	 discovery	 3328 
due	 to	 multiple	 comparisons	 by	 using	 the	 Benjamini	 &	 Hochberg	 method	 (45).	 3329 
 218 
Permutation	 tests	 were	 used	 to	 determine	 which	 pathogen	 pairs	 were	 statistically	 3330 







of	 co-occurrence	 counts	 under	 purely	 random	 conditions,	was	 estimated	 from	 the	 10	 3338 





Linear	 Discriminant	 Analysis	 (LDA)	 and	 Quadratic	 Discriminant	 Analysis	 (QDA)	 (47)	 3344 
were	used	 to	optimally	discriminate	 respiratory	pathogens	occurring	 in	children	with	 3345 
and	without	microbiologically	 confirmed	 TB,	 and	 those	 in	whom	TB	was	 excluded.	 A	 3346 
Canonical	Variate	Analysis	(CVA)	biplot	was	used	to	provide	a	graphical	representation	 3347 
of	 the	 LDA	 and	 a	 QDA	 biplot	 analysis	 (47).	 The	 QDA	 plot	 was	 constructed	 of	 C.	 3348 
pneumoniae,	M.		pneumoniae,	RSV,	Influenza	C	virus,	coronavirus	043,	S.	pneumoniae,	P.	 3349 
jirovecii,	H.	influenzae	type	b,	M.	cartarrhalis,	S.	aureus,	Influenza	B	virus,	enterovirus,	H.	 3350 
influenzae	 spp,	 rhinovirus,	 cytomegalovirus	 and	 hMPV	 in	 order	 to	 obtain	 a	 visual	 3351 
representation	of	the	observed	differences	in	the	definite	TB,	non-TB,	and	possible	TB	 3352 
groups.	 For	 all	 the	 tests,	 a	 p-value	 less	 than	 0.05	 was	 used	 as	 the	 limit	 of	 statistical	 3353 
significance.		 3354 
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6.3.9	 Ethical	considerations		 3355 
Written	informed	consent	was	obtained	from	a	parent	and/or	legal	guardian.	This	study	 3356 
was	 approved	 by	 the	 Human	 Research	 Ethics	 Committee,	 Faculty	 of	 Health	 Science,	 3357 
University	of	Cape	Town	(HREC	ref:	045/2008)	and	the	Provincial	Government	of	the	 3358 
Western	Cape,	South	Africa.	 3359 
6.4	 RESULTS	 3360 
6.4.1	 Patient	characteristics	and	TB	culture	results.		 3361 





























15	(6	–	25)	 20	(6	–	22)	 17	(9	–	26)	 14	(6	–	22)	 0.36	
Sex:	female,	n	(%)	 109	(51)	 14	(41)	 45	(52)	 50	(53)	 0.22	
HIV	infection,	n	(%)	 27	(13)	 7	(21)	 13	(15)	 7	(7)	 0.14	
HIV	WHO	clinical	
staging,	n	(%)*	
	 	 	 	 	
Stage	1		 0	 0	 0	 0	 -	
Stage	2	 0	 0	 0	 0	 -	
Stage	3	 21	(10)	 5	(15)	 10	(12)	 6	(6)	 0.36	
Stage	4	 6	(3)	 2	(6)	 3	(35)	 1	(1)	 0.48	
*Refers	to	the	WHO	HIV	classification	which	is	based	on	the	clinical	manifestation	of	disease	in	the	 3377 
absence	 of	 CD4	 cell	 count	measurements	 or	 other	 diagnostic	 and	 laboratory	 testing	methods	 in	 3378 
resource	constrained	settings	to	inform	patient	care.	 3379 
	 3380 
6.4.2	 Diversity	of	potential	respiratory	pathogens		 3381 
Among	 the	 214	 nasopharyngeal	 samples,	 97%	 (207/214)	 positive	 for	 at	 least	 one	 3382 
potential	 respiratory	 pathogen.	 M.	 catarrhalis	 (64%),	 S.	 pneumoniae	 (42%),	 H.	 3383 
influenzae	spp	(29%)	and	S.	aureus	(22%)	were	the	most	common	bacterial	pathogens	 3384 
detected	 (Table	 23	 and	 figure	 42).	 M.	 pneumoniae	 (9%),	 B.	 pertussis	 (7%)	 or	 C.	 3385 
pneumoniae	 (4%)	were	 detected	 less	 commonly.	 The	most	 common	 viruses	 detected	 3386 












p-value			 Definite	TB	 Possible	TB	 Not-TB	
Number	of	Participants	 214	(100)	 34	(16)	 86	(40)	 94	(44)	 	
Bacteria	 	 	 	 	 	
M.	catarrhalis	 137	(64)	 24	(71)	 56	(65)	 57	(60)	 	
S.	pneumoniae	 90	(42)	 18	(53)	 38	(44)	 34	(36)	 	
H.	influenzae	spp	 62	(29)	 8	(24)	 25	(29)	 29	(31)	 	
S.	aureus	 47	(22)	 7	(21)	 18	(21)	 22	(23)	 	
H.	influenzae	B	 31	(15)	 5	(15)	 15	(17)	 11	(12)	 	
M.	pneumoniae	 19	(9)	 2	(6)	 9	(10)	 8	(9)	 	
B.	pertussis	 12	(6)	 3	(9)	 6	(7)	 3	(3)	 	
C.	pneumoniae	 9	(4)	 4	(12)	 4	(5)	 1	(1)	 0.42	
	 	 	 	 	 	
Viruses	 	 	 	 	 	
Metapneumovirus	A/B	 41	(19)	 7	(21)	 21	(24)	 13	(14)	 	
Rhinovirus	 31	(15)	 6	(18)	 13	(15)	 12	(13)	 	
Enterovirus	 22	(10)	 1	(3)	 10	(12)	 11	(12)	 0.65	
Adenovirus	 14	(7)	 3	(9)	 5	(6)	 6	(6)	 	
Cytomegalovirus	 14	(7)	 3	(9)	 3	(3)	 8	(9)	 	
Bocavirus	 14	(7)	 8	(24)	 1	(1)	 5	(5)	 	
Coronavirus	 17	(8)	 5	(15)	 8	(9)	 4	(4)	 0.42	
									Coronavirus	O43	 12	(6)	 5	(15)	 5	(6)	 2	(2)	 0.42	
	Coronavirus	HKU	 2	(1)	 0	(0)	 1	(1)	 1	(1)	 	
		Coronavirus	NL63	 2	(1)	 0	(0)	 1	(1)	 1	(1)	 	
	Coronavirus	229E	 1	(0.5)	 0	(0)	 1	(1)	 0	(0)	 	
RSV	A/B*	 7	(3)	 1	(3)	 3	(3)	 3	(3)	 	
Influenza	virus		 33	(15)	 8	(24)	 15	(17)	 10	(11)	 	
							Influenza	A	 7	(3)	 1	(3)	 4	(5)	 2	(2)	 	
							Influenza	B	 7	(3)	 1	(3)	 2	(2)	 4	(4)	 	
							Influenza	C	 19	(9)	 6	(18)	 9	(10)	 4	(4)	 	
Parainfluenza	virus	 10	(5)	 1	(3)	 4	(5)	 5	(5)	 	
							Parainfluenza	1	 5	(2)	 1	(3)	 2	(2)	 2	(2)	 	
							Parainfluenza	2	 1	(0.5)	 0	(0)	 0	(0)	 1	(1)	 	
							Parainfluenza	3	 2	(1)	 0	(0)	 1	(1)	 1	(1)	 	
							Parainfluenza	4	 2	(1)	 0	(0)	 1	(1)	 1	(1)	 	
	 	 	 	 	 	
Fungi	 	 	 	 	 	
P.	jirovecii	 23	(11)	 3	(9)	 10	(12)	 10	(11)	 	
£Arranged	 in	 order	 of	 decreasing	 colonisation	 or	 detection	 rates.	 *RSV	 A/B	 =	 Respiratory	 3395 
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6.4.3	 Age-dependent	respiratory	pathogen	distribution	 3406 
B.	pertussis	infection	was	mostly	detected	in	children	between	12	and	23	months	old	(p	 3407 
<	0.01)	while	bocavirus	was	mostly	detected	in	children	younger	than	three	months	(p	=	 3408 
0.04).	 (Figures	 44	 and	 45,	 respectively).	M.	catarrhalis,	rhinovirus,	 hMPV,	 influenza	 C	 3409 
virus,	 cytomegalovirus	 enterovirus	 and	 bocavirus	 were	 most	 commonly	 detected	 in	 3410 
children	younger	than	three	months	(figures	44	and	45).	 3411 
	 3412 
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	 3418 
Figure	43:	Age-dependent	 viral	 pathogen	distribution	 among	 children's	 age	 groups	with	95%	 3419 
confidence	 intervals.	 The	 y-axes	 represents	 the	 proportion	 of	 children	 in	 whom	 a	 virus	 was	 3420 
detected	and	the	x-axes	show	age	categories,	as	used	by	Tenenbaum	et	al.	(19).		 3421 
6.4.4	 Seasonality	patterns	 3422 
Seasonal	 patterns	 were	 observed	 for	 the	 most	 prevalent	 viruses	 namely,	 hMPV,	 3423 
rhinovirus,	 enterovirus	and	 influenza	viruses	 in	both	2011	and	2012.	 In	all	 instances,	 3424 
seasonal	 peaks	 were	 observed	 over	 late	 winter	 and	 spring	 (figure	 46).	 No	 distinct	 3425 
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6.4.5	 Co-infection	patterns	 3431 
Among	 the	 214	 nasopharyngeal	 samples	 that	 were	 collected,	 97%	 (207/214)	 tested	 3432 
positive	for	at	least	one	potential	respiratory	pathogen.	A	single	bacterium	was	detected	 3433 
in	18%	(39/214)	of	samples	tested,	25%	(53/214)	had	two	bacterial	species	detected	 3434 
and	 52%	 (111/214)	 had	 three	 or	 more	 bacterial	 species	 detected.	 A	 single	 viral	 3435 
pathogen	was	detected	in	33%	(71/214)	of	the	samples	tested,	22%	(47/214)	had	two	 3436 

















































































































































































	 0	 1	 2	 3	 >3	 Number	of	samples	
No	viral	infections	 7	 25	 20	 21	 13	 86	
1	viral	infection	 2	 9	 18	 24	 18	 71	
2	viral	infections	 2	 2	 13	 16	 14	 47	
≥3	viral	infections	 0	 3	 2	 3	 2	 10	











associations	 co-occurring	 significantly	 more	 than	 would	 be	 expected	 by	 chance,	 3453 
included:	 bocavirus	 and	 influenza	 A	 virus	 (p	 =	 0.02),	 parainfluenza	 1	 virus	 and	 3454 
coronavirus	NL63	(p	=	0.01)	as	well	as	hMPV	and	enterovirus	(p	=	0.01)	(Table	6).	Viral- 3455 
bacterial	 associations	 co-occurring	 significantly	 more	 than	 would	 be	 expected	 by	 3456 
chance,	included:	hMPV	and	S.	pneumoniae	(p	=	0.03),	enterovirus	and	H.	influenzae	type	 3457 
b	 (p	 =	 0.03),	 coronavirus	 O43	 and	M.	catarrhalis	 (p	 =	 0.03),	 influenza	 C	 virus	 and	M.	 3458 
pneumoniae		(p	=	0.02),	parainfluenza	virus	3	and	M.	pneumoniae		(p	=	0.01),	influenza	C	 3459 
virus	 and	H.	 influenzae	type	b	 (p	 <	0.01),	 influenza	C	virus	 and	B.	pertussis	 (p	 <	0.01),	 3460 
influenza	A	virus	and	H.	influenzae	spp	(p	=	0.02),	hMPV	and	H.	influenzae	spp	(p	=	0.02),	 3461 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pathogens	 including	 cytomegalovirus,	 influenza	 B,	 S.	aureus,	 parainfluenza	 virus	 2,	H.	 3481 




Figure	 45:	 Canonical	 Variate	 Analysis	 (CVA)	 biplot	 for	 graphical	 visualisation	 of	 Linear	 3486 


























































































pathogens	 in	 the	 definite	 TB	 (red	 squares),	 not	 TB	 (blue	 squares)	 and	 possible	 TB	 (green	 3488 
squares)	groups.	 3489 
	 3490 
In	 further	analyses,	 the	possible	TB	cases	were	excluded	and	only	definite	TB	and	not	 3491 
TB	groups	were	considered.	By	doing	this,	the	CVA	biplot	was	reduced	to	one	dimension	 3492 











the	 TB	 groups,	 figure	 49	 below.	 HMPV,	 C.	 pneumoniae,	 coronavirus	 043,	 influenza	 C	 3504 
virus,	 rhinovirus	 and	 cytomegalovirus	 grouped	 more	 towards	 the	 definite	 TB.	 In	 3505 
contrast,	M.	pneumoniae,	H.	influenzae	spp.,	P.	jirovecii,	enterovirus,	influenza	B	virus	and	 3506 





classification.	Clustering	of	respiratory	pathogens	 in	the	definite	TB	(red	squares)	and	non	TB	 3511 
(blue	 squares)	 groups	 is	 shown.	 Since	 the	 pathogens	 were	 recorded	 on	 a	 presence/absence	 3512 
scale	 rather	 than	quantitative	 results,	 the	biplot	 axes	 are	 replaced	with	 arrows	 indicating	 the	 3513 
direction	of	presence	of	the	pathogens.	*RSVAB	=	Respiratory	Syncyntial	virus	A	and	B.	 3514 
	 3515 
6.5	 DISCUSSION	 3516 
This	study	describes	for	the	first	time,	the	diversity	of	respiratory	pathogens,	other	than	 3517 
MTB,	detected	in	children	presenting	to	hospital	with	suspected	TB	in	a	high	TB	and	HIV	 3518 
endemic	 setting.	 Of	 the	 children	 admitted	 to	 hospital	 with	 suspected	 pulmonary	 TB,	 3519 
16%	(34/214)	had	microbiologically	culture	confirmed	TB,	while	40%	(86/214)	had	a	 3520 
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clinical	 and	 radiological	 findings.	 The	 observed	 culture-confirmed	 rate	 of	 TB	 is	 3522 
consistent	with	that	of	McNally	et	al.	(5)	but	was	high	when	compared	to	the	reported	5	 3523 
-	8%	 from	studies	 in	 similarly	TB	endemic	 settings	amongst	 children	presenting	with	 3524 
acute	 respiratory	 infections	 (8,48–51).	 These	 differences	 may	 be	 attributed	 to	 3525 
differences	 in	 the	 study	 populations,	 enrollment	 criteria	 and	 diagnostic	 tests	 utilised	 3526 
across	 the	 studies.	 The	non-specific	 clinical	 presentation	 of	 PTB	 in	 infants	 and	 young	 3527 
children	 and	 the	 potential	 contribution	 of	 co-infections	 (bacterial,	 viral	 and	 fungal)	 3528 
highlights	a	need	for	 improved	diagnosis	of	PTB	and	identification	of	respiratory	tract	 3529 
pathogens	other	than	MTB	in	children	with	suspected	PTB.	 3530 
There	was	no	clear	evidence	of	age-dependent	 infection	patterns	 in	this	cohort	except	 3531 
for	bocavirus	and	B.	pertussis	which	were	more	commonly	detected	in	children	younger	 3532 
than	 three	 months	 (p	 =	 0.03)	 and	 those	 between	 12	 months	 and	 23	 months	 old	 3533 
respectively	(p	<	0.01).	This	is	in	contrast	with	a	study	by	Fry	et	al.	who	found	that	Thai	 3534 
children	 below	 the	 age	 of	 one	 year	 were	 less	 likely	 to	 be	 infected	 with	 bocavirus	 3535 
compared	 with	 children	 between	 one	 and	 four	 years	 of	 age	 (13%	 vs.	 70%)	 (52).	 3536 
However,	 the	 authors	 also	 found	 a	 low	 prevalence	 of	 bocavirus	 infections	 4.5%	 3537 
(53/1168),	which	was	similar	to	the	prevalence	found	in	our	study.	Although	a	number	 3538 
of	other	viruses	were	mostly	detected	in	children	younger	than	three	months,	the	small	 3539 
sample	 size	 limits	 our	 ability	 to	 draw	 conclusions	 from	 these	 results.	 According	 to	 a	 3540 
population-based	 study	 in	 Kilifi,	 Kenya,	 RSV	 was	 more	 prevalent	 among	 infants,	 3541 
compared	 to	 children	 12	 -	 59	months	 old	 (33%	 [45/137]	 vs	 17%	 [24/117],	 p<0.01)	 3542 
(53).	We	did	not	observe	any	differences	in	the	prevalence	of	RSV	infection	across	any	 3543 
age	groups,	however	numbers	were	very	small.		 3544 
Overall,	 at	 least	 one	 potential	 respiratory	 pathogen	 was	 detected	 in	 97%	 of	 the	 3545 
respiratory	specimens	collected	from	the	children	in	our	cohort.	Similar	detection	rates	 3546 
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have	 been	 shown	 elsewhere	 amongst	 children	 hospitalised	 with	 lower	 respiratory	 3547 




22%,	 respectively).	 These	 findings	 are	 in	 line	 with	 the	 nasopharyngeal	 colonisation	 3552 
rates	 described	 elsewhere	 in	 children	 with	 lower	 respiratory	 tract	 infections	 3553 
(17,19,20,55).		 3554 
The	prevalence	of	viral	infection	in	this	cohort	is	lower	than	that	previously	reported	in	 3555 
children	with	 acute	 lower	 respiratory	 infections	 (ALRI)	 (6,7,9,10,13,56).	 This	may	 be	 3556 
explained	 by	 the	 enrolment	 criteria	 that	 encompassed	 children	 with	 symptoms	 3557 
suggestive	of	PTB	and	with	a	long	duration	of	cough,	whereas	most	of	the	other	studies	 3558 
focused	on	children	with	acute	 symptoms,	which	are	more	 likely	 to	be	of	viral	origin.	 3559 
The	most	 commonly	detected	viruses	were	hMPV	 (19%),	 rhinovirus	 (15%),	 influenza	 3560 
virus	(9%),	adenovirus	(7%),	cytomegalovirus	(7%)	and	coronavirus	O43	(6%).	Similar	 3561 
viral	 detection	 rates	 have	been	 reported	 elsewhere	 amongst	 children	hospitalised	 for	 3562 
either	 community	acquired	pneumonia	 (CAP)	or	ALRI	 (6,7,15,16,18,57).	The	 reported	 3563 
range	of	detection	rates	for	each	of	the	above	viruses	were:	hMPV	(1	-	13%),	rhinovirus	 3564 
(20	-	45%),	 influenza	virus	(4	-	14%),	adenovirus	(6	-	13%)	and	coronavirus	O43	(1	-	 3565 
7%)	(6,7,16,18,34).		 3566 
Care	 needs	 to	 be	 taken	 in	 the	 interpretation	 of	 molecular	 detection	 of	 rhinovirus,	 3567 
cytomegalovirus,	 coronavirus,	 enterovirus	 and	 bocavirus	 in	 respiratory	 specimens,	 3568 
since	 these	 viruses	 may	 be	 detected	 in	 children	 without	 lower	 respiratory	 tract	 3569 




Our	 understanding	 of	microbial	 interactions	 is,	 in	 part,	 constrained	 by	 the	 tools	 that	 3573 
allow	 us	 to	 adequately	 visualise	 such	 interactions	 without	 reducing	 vital	 data	 3574 
dimensions.	 Using	 a	 novel	methodology,	 QDA,	we	 have	 shown	 that	 the	 only	 bacterial	 3575 
species	that	clustered	more	towards	children	with	microbiologically	confirmed	TB	was	 3576 
C.	 pneumoniae.	 The	 significance	 of	 detecting	 other	 potential	 bacterial	 pathogens	 in	 3577 
children	 presenting	 with	 prolonged	 symptoms	 suggestive	 of	 TB	 is	 unclear.	 One	 3578 
possibility	is	that	the	relative	immune	suppression	associated	with	TB	may	render	the	 3579 
host	susceptible	 to	a	bacterial	 infection,	or	alternatively,	 that	reactivation	of	 latent	TB	 3580 
may	occur	following	intracellular	bacterial	infection	(66-69).		 3581 
Viruses	 that	 clustered	with	 the	TB	group	 include	hMPV,	 coronavirus	O43,	 influenza	C	 3582 
virus,	rhinovirus	and	cytomegalovirus.	MTB	has	a	slow	replication	rate.	Therefore,	acute	 3583 




shown	an	increased	risk	of	death	 in	 individuals	with	TB-influenza	A	virus	co-infection	 3588 
(adjusted	 relative	 risk	 ratio	 [aRRR]	 6.1,	 95%	 confidence	 interval	 [CI]	 1.6	 –	 23.4)	 3589 
compared	to	TB	infection	alone	(74).	In	contrast,	de	Paus	et	al.	did	not	find	a	correlation	 3590 
between	 the	 seroprevalence	of	 influenza	 antibodies	 and	 the	development	of	 clinically	 3591 
active	 TB	 in	 an	 Indonesian	 cohort.	 They	 did	 however	 show	 an	 association	 between	 3592 
elevated	 antibody	 titers	 against	 influenza	 A	 and	 the	 clinical	 stage	 of	 TB	 lung	 disease	 3593 
suggesting	recent	re-infection	with	influenza	precedes	clinical	manifestation	of	TB	(75).		 3594 
	 235	
Although	 rhinoviruses,	 which	 also	 clustered	 in	 the	 TB	 group,	 are	 most	 commonly	 3595 
associated	with	mild	upper	 respiratory	 tract	 infections	 (59,60,76),	 infections	of	 lower	 3596 
airways	do	occur	(58,77,78).	These	include	bronchiolitis,	pneumonia,	chronic	bronchitis	 3597 
and	the	development	of	asthma	(57,58,77,78).	Some	rhinovirus	genotypes,	specifically	 3598 
subtype	 C,	 correlate	 with	 ALRI	 disease	 severity	 (14,58,59,61,79).	 A	 more	 3599 
comprehensive	 study	 of	 rhinovirus	 genotypes	 in	 this	 cohort	 would	 be	 of	 interest	 3600 
(14,58,59,61,79).		 3601 
On	 the	 other	 hand,	 respiratory	 pathogens	 that	 clustered	 with	 the	 non-TB	 group	 3602 
included	 P.	 jirovecii,	 H.	 influenzae	 spp.,	 RSV,	 M.	 pneumoniae,	 influenza	 B	 virus	 and	 3603 
enteroviruses.	 While	 disease	 causation	 cannot	 be	 inferred	 by	 the	 mere	 presence	 of	 3604 
bacteria	in	the	nasopharynx,	the	presence	of	either	M.	pneumoniae,	C.	pneumoniae	and	B.	 3605 
pertussis	 has	 been	 shown	 to	be	 associated	with	ALRI	 (56,80–82).	 The	 incidence	of	M.	 3606 
pneumoniae	 and	 C.	 pneumoniae	 was	 generally	 low	 (10%	 and	 4%	 respectively)	 and	 3607 
appeared	 to	 be	 more	 common	 in	 children	 younger	 than	 two	 years	 of	 age.	 Similar	 3608 
detection	 rates	 have	 been	 reported	 in	 children	 hospitalised	 with	 ALRI	 (9,83,84).	 3609 
Bezerra	et	al.	 (9)	examined	 the	aetiological	 causes	of	ALRI	of	varying	 clinical	 severity	 3610 
among	407	hospitalised	children	in	Brazil.	They	showed	that	M.	pneumoniae	was	more	 3611 
likely	 to	 be	 detected	 in	 children	 hospitalised	 with	 pneumonia	 than	 ambulatory	 3612 
bronchiolitis	cases	(13.8%	vs.	7.1%	respectively,	p	=	0.04).	In	contrast,	Tsolia	et	al.	(7)	 3613 
and	 Principi	 et	 al.	 (85)	 have	 reported	 higher	 rates	 of	 M.	 pneumoniae	 infection	 in	 3614 






in	other	 settings	 in	 children	with	ALRI,	 10	–	20	years	post	 transition	 from	whole-cell	 3620 
vaccines	 (WCV)	 to	 acellular	 vaccines	 (ACV)	 (86–89).	 Persistence	 and	 resurgence	 of	 3621 
pertussis	 has	 been	 attributed	 to	 waning	 immunity	 and/or	 pathogen	 adaptation	 in	 3622 
response	to	vaccination	(Reviewed	by	(90)).		 3623 
RSV	 infections	 were	 less	 frequently	 encountered	 in	 our	 cohort	 in	 contrast	 to	 other	 3624 
reported	prevalences	(3%	vs	10	-	40%)	amongst	children	with	ALRI	(9,10,13,16,18,91– 3625 
93).	 The	 lower	 detection	 rates	 of	 RSV	 in	 our	 cohort	may	 be	 attributed	 to	 enrollment	 3626 
criteria	 and	 long	 symptom	duration.	The	 recent	 finding	of	 novel	 respiratory	 syncytial	 3627 
virus	 A	 genotype	 ON1	 (originally	 characterised	 in	 Ontario,	 Canada)	 in	 a	 Cape	 Town	 3628 




assessed	 the	 effect	 of	 a	 9-valent	 pneumococcal	 conjugate	 vaccine	 (PCV9)	 in	 South	 3633 
African	children	showed	decreased	rates	of	culture-confirmed	and	clinically	diagnosed	 3634 
TB	 in	PCV9	recipients	 compared	with	placebo	 recipients	 (relative	 risk	 reduction	43%	 3635 
[95%	CI,	11.5%	-	63.8%],	p	=	0.0114)	(8).	This	suggests	an	intriguing	possibility	that	S.	 3636 
pneumoniae	 coinfection	 might	 increase	 children's	 vulnerability	 to	 develop	 active	 TB.	 3637 




would	 be	 a	 representative	 sample	 from	 the	 disease	 affected	 tissue,	 in	 this	 case	 lung	 3642 
aspirates	or	good	quality	sputum.	 Induced	sputum	was	not	available	 for	analysis	as	 it	 3643 





M.	 pneumoniae,	 C.	 pneumoniae	 (56,80–83),	 hMPV,	 influenza	 A/B	 viruses	 and	 RSV	 3648 
(76,96).	These	pathogens	have	been	strongly	associated	with	disease	 in	other	studies.	 3649 
Studies	 that	 clearly	 differentiate	 between	 infection	 and	 colonisation	 are	 essential	 for	 3650 
advancing	therapeutic	strategies	and	prioritising	diagnostic	efforts.		 3651 
In	 conclusion,	 this	 study	described	 the	detection	of	multiple	 respiratory	pathogens	 in	 3652 
the	nasopharynx	of	children	hospitalised	with	suspected	TB.	Whilst	there	was	no	clear	 3653 
separation	between	the	pathogens	present	in	the	airways	of	children	with	and	without	 3654 
PTB,	 C.	 pneumoniae,	 hMPV,	 coronavirus	 O43,	 influenza	 C	 virus,	 rhinovirus	 and	 3655 
cytomegalovirus	were	associated	with	PTB.	On	the	other	hand,	P.	jirovecii,	H.	influenzae	 3656 
spp,	 RSV,	 M.	 pneumoniae,	 influenza	 B	 virus	 and	 enteroviruses	 were	 more	 common	 3657 
amongst	 children	 without	 TB.	 This	 pilot	 work	 may	 signal	 broader	 differences	 in	 the	 3658 
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CHAPTER 7 4008 
General	Conclusions	and	future	prospects	 4009 
Chapter	 1	 of	 this	 thesis	 provides	 an	 overview	 of	 the	 work	 presented	 in	 this	 thesis	 4010 
including	the	rationale.	 4011 
The	work	in	Chapter	2	evaluated	the	recovery	of	pneumococcus	from	different	types	of	 4012 




healthy	 children.	 It	 has	 been	 shown	 that	 the	 DNA	 extraction	methods	may	 influence	 the	 4017 
DNA	 recovery	 from	 both	 cotton	 and	 flocked	 swabs	 used	 for	 the	 collection	 of	 DNA	 from	 4018 
saliva	 stains.	 In	 this	 study,	 we	 only	 employed	 one	 platform	 for	 nucleic	 acid	 extraction.	 4019 
Looking	ahead,	 there	 is	a	need	 to	assess	whether	 the	observed	higher	bacterial	 load	 from	 4020 
flocked	 swabs	 was	 inherent	 to	 the	 specific	 DNA	 extraction	 method	 used,	 by	 performing	 4021 
studies	using	different	nucleic	acid	extraction	methods.	 4022 
Public	 health	 programs	 use	 serotype	 data	 from	 invasive	 pneumococcal	 disease	 and	 4023 
carriage	 to	 advise	 vaccine	 formulation	 strategies.	 One	 of	 the	 challenges	 for	 4024 
pneumococcal	 surveillance	 programs	 is	 the	 lack	 of	 an	 inexpensive	 and	 robust	 4025 
pneumococcal	serotyping	method.	Assessment	of	serotyping	methods	needs	to	take	into	 4026 
account	the	number	of	pneumococci	to	be	serotyped,	serotype	coverage,	sample	type	to	 4027 
be	 used,	 how	 long	 it	 takes	 to	 perform	 the	 test	 and	 resource	 availability.	 Chapter	 3	 4028 
therefore	 described	 a	 comparison	 of	 a	 real-time	 multiplex	 PCR	 (rmPCR)	 to	 a	 4029 
sequetyping	 method	 in	 order	 to	 assess	 their	 suitability	 for	 high	 throughput	 4030 
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pneumococcal	 capsular	 typing.	 Whole	 genome	 re-sequencing	 was	 used	 to	 resolve	 4031 
discordant	molecular	serotyping	and	reference-standard	Quellung	results.	Although	the	 4032 
rmPCR	assay	performed	well	for	the	21	serotypes/-groups	included	in	the	assay,	a	large	 4033 
proportions	 of	 the	 serotypes	 encountered	 in	 our	 settings	 could	 not	 be	 detected.	 In	 4034 
contrast,	 the	 sequetyping	 assay	performed	well,	with	 specific	 exceptions,	 and	may	be	 4035 
more	 useful	 in	 settings	 where	 vaccine	 serotypes	 are	 less	 common.	 We	 detected	 4036 
structural	 variation	 in	 the	wzh	 gene	 of	 some	 strains	 that	 were	 serotyped	 as	 16F	 by	 4037 
Quellung,	but	incorrectly	sequetyped	as	9V	by	employing	whole	genome	re-sequencing.	 4038 
This	highlights	a	limitation	of	this	approach.		 4039 
Future	 work	 planned	 is	 the	 application	 of	 genomic	 analysis	 to	 understand	 4040 
nasopharyngeal	 colonization,	 serotype	 distribution	 and	 impact	 of	 vaccination	 during	 4041 
the	first	year	of	life.	This	would	specifically	address	the	following	objectives:	 4042 
1) To	apply	a	whole	genome	sequencing	(WGS)	approach	in	understanding	the	 4043 
evolution	 of	 pneumococcal	 isolates	 carried	 in	 the	 nasopharynx	 over	 4044 
prolonged	periods	of	time	at	the	individual	and	community	level.	 4045 
2) To	 use	WGS	 to	 determine	multilocus	 sequence	 type	 in	 order	 to	 define	 the	 4046 
population	structure	of	pneumococci	in	this	intensively	sampled	population.	 4047 
3) To	understand	the	relationship	between	the	presence	of	bacteriocin	cassettes	 4048 
and	colonization	with	other	commensal	bacteria	within	 the	nasopharyngeal	 4049 
microbiome.	 4050 
Chapter	 4	 and	5	describe	 the	application	of	 the	optimised	protocols	 from	chapters	2	 4051 
and	 3	 to	 describe	 the	 longitudinal	 pneumococcal	 colonisation	 patterns	 and	 serotype	 4052 
distribution	during	the	 first	year	of	 life	among	South	African	 infants	participating	 in	a	 4053 
birth	cohort	(Drakenstein	Child	Health	Study).	 In	addition,	Chapter	4	details	serotype- 4054 
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specific	acquisition	rates	and	duration	of	pneumococcal	carriage.	Chapter	5	specifically	 4055 
investigates	 risk	 factors	 for	 acquisition	of	 pneumococcal	 carriage	 including	 the	 short- 4056 
term	 impact	 of	 sequential	 PCV-13	 immunisation	 on	 carriage.	 Given	 that	 the	 4057 
“unmeasured”	contribution	of	pneumococcus	 to	non-bacteraemic	pneumonia	can	only	 4058 
be	 inferred	 through	 pneumococcal	 vaccine	 studies,	 the	 residual	 burden	 of	 4059 
pneumococcus	 to	 non-bacteraemic	 pneumonia	 post	 PCV	 implementation	 remains	 4060 
unclear.	 We	 have	 recently	 shown	 no	 difference	 in	 the	 proportion	 of	 children	 with	 4061 
detectable	 S.	 pneumoniae	 in	 the	 nasopharynx	when	 comparing	 children	 enrolled	 in	 a	 4062 
birth	 cohort	 who	 developed	 pneumonia	 and	 controls	 who	 did	 not.	 However,	 4063 
colonization	 is	 likely	 to	 mask	 the	 true	 contribution	 of	 S.	 pneumoniae	 to	 childhood	 4064 
pneumonia.	We	therefor	hypothesize	that,	since	pneumococcal	serotypes	differ	in	their	 4065 
invasive	 potential,	 if	 S.	pneumoniae	 contributes	 to	 the	 aetiology	 of	 pneumonia	 in	 this	 4066 
cohort	this	would	manifest	as	a	difference	in	the	distribution	of	S.	pneumoniae	serotypes	 4067 
between	cases	and	controls.	 Future	work	will	 therefore	be	 to	 investigate	 in	detail	 the	 4068 
serotype-specific	association	with	the	development	of	pneumonia	in	this	cohort.		 4069 
Chapter	6	describes	the	detection	of	multiple	respiratory	microbes	in	the	nasopharynx	 4070 
of	 children	 hospitalised	 with	 suspected	 PTB.	 Whilst	 there	 was	 no	 clear	 separation	 4071 
between	 the	 pathogens	 present	 in	 the	 airways	 of	 children	 with	 and	 without	 PTB,	 C.	 4072 
pneumoniae,	hMPV,	coronavirus	O43,	influenza	C	virus,	rhinovirus	and	cytomegalovirus	 4073 
























































Table	 S1.1:	 Colony	 forming	 units	 of	 Streptococcus	 pneumoniae	 calibrated	 bacterial	 cell	 4127 
suspension	at	mid-log	phase	 4128 







Day1	 Day2	 Day3	 Day1	 Day2	 Day3	
19F	
flocked	
71	 75	 85	 2.5	*	106	 1.78	*	108	 1.88	*	108	 2.13	*	108	
62	 67	 73	 2.5	*	10
6	 1.55	*	108	 1.68	*	108	 1.83	*	108	
68	 71	 79	 2.5	*	10
6	 1.70	*	108	 1.78	*	108	 1.98	*	108	
Average	 67	 71	 79	   1.68 *	108 1.78 *	108 1.98 *	108 
PET	
30	 32	 30	 2.5	*	10
6	 7.50	*	107	 8.00	*	107	 7.50	*	107	
25	 36	 34	 2.5	*	10
6	 6.25	*	107	 9.00	*	107	 8.50	*	107	
22	 29	 26	 2.5	*	10
6	 5.50	*	107	 7.25	*	107	 6.50	*	107	
Average	 26	 32	 30	   6.42	*	107 8.08	*	107 7.50	*	107 
rayon	
9	 3	 4	 2.5	*	10
6	 2.25	*	107	 7.50	*	106	 1.00	*	107	
11	 4	 2	 2.5	*	10
6	 2.75	*	107	 1.00	*	107	 5.00	*	107	
7	 2	 4	 2.5	*	10
6	 1.75	*	107	 5.00	*	106	 1.00	*	107	
Average	 9	 3	 3	   2.25	*	107 7.50	*	107 8.33	*	107 
"Control"	
68	 67	 77	 2.5	*	10
6	 1.70	*	108	 1.68	*	108	 1.93	*	108	
66	 71	 70	 2.5	*	10
6	 1.65	*	108	 1.78	*	108	 1.75	*	108	
72	 75	 82	 2.5	*	10
6	 1.80	*	108	 1.88	*	108	 2.05	*	108	
Average	 69	 71	 76	   1.72	*	108 1.78	*	108 1.91	*	108 
1	
flocked	
82	 79	 75	 2.5	*	10
6	 2.05	*	108	 1.98	*	108	 1.88	*	108	
76	 73	 67	 2.5	*	10
6	 1.90	*	108	 1.83	*	108	 1.68	*	108	
86	 85	 71	 2.5	*	10
6	 2.15	*	108	 2.13	*	108	 1.78	*	108	











10-4 tmtc 45 49 47 2.5 * 105 1.1*108  
1.2*108 
 
10-5 8 4 3 5 2.5 * 106 1.3*108 
10-6 NG NG NG NA 2.5 * 107 NA 
	
1	
10-4 56 67 40 54 2.5 * 105 1.3*108  
1.2*108 10-5 16 2 6 8 2.5 * 106 2.0*108 
10-6 NG 1 NG 1 2.5 * 107 2.5*107 
	
5	
10-4 29 31 22 27 2.5 * 105 6.6*107  
7.1*107 
 
10-5 2 3 3 3 2.5 * 106 7.5*107 
10-6 NG NG NG NA 2.5 * 107 NA 
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PET	
29	 29	 38	 2.5	*	10
6	 7.25	*	107	 7.25	*	107	 9.50	*	107	
31	 34	 42	 2.5	*	10
6	 7.75	*	107	 8.50	*	107	 1.05	*	108	
30	 36	 36	 2.5	*	10
6	 7.50	*	107	 9.00	*	107	 9.00E	*	107	
Average	 30	 33	 39	   7.50	*	107 8.25	*	107 9.67	*	107 
rayon	
6	 4	 1	 2.5	*	10
6	 1.50	*	107	 1.00	*	107		 2.50	*	106	
7	 7	 1	 2.5	*	10
6	 1.75	*	107	 1.75	*	107	 2.50	*	106	
4	 4	 1	 2.5	*	10
6	 1.00	*	107	 1.00	*	107	 2.50	*	106	
Average	 6	 5	 1	   1.42	*	107 1.25	*	107 2.50	*	107 
"Control"	
77	 67	 85	 2.5	*	10
6	 1.93	*	108	 1.68	*	108	 2.13	*	108	
72	 71	 78	 2.5	*	10
6	 1.80	*	108	 1.78	*	108	 1.95	*	108	
82	 75	 81	 2.5	*	10
6	 2.05	*	108	 1.88	*	108	 2.03	*	108	
Average	 77	 71	 81	   1.93	*	108 1.78	*	108 2.03	*	108 
5	
flocked	
20	 24	 30	 2.5	*	10
6	 5.00	*	107	 6.00	*	107	 7.50	*	107	
26	 18	 27	 2.5	*	10
6	 6.50	*	107	 4.50	*	107	 6.75	*	107	
23	 20	 22	 2.5	*	10
6	 5.75	*	107	 5.00	*	107	 5.50	*	107	
Average	 23	 21	 26	   5.75	*	107 5.17	*	107 6.58	*	107 
PET	
13	 3	 6	 2.5	*	10
6	 3.25	*	107	 7.50	*	106	 1.50	*	107	
19	 1	 7	 2.5	*	10
6	 4.75	*	107	 2,50	*	106	 1.75	
17	 2	 5	 2.5	*	10
6	 4.25	*	107	 5.00	*	106	 1.25	*	107	
Average	 16	 2	 6	   4.08	*	107 5.00	*	106 1.50	*	107 
rayon	
3	 4	 3	 2.5	*	10
6	 7.50	*	106	 1.00	*	107	 7.50	*	106	
1	 2	 5	 2.5	*	10
6	 2.50	*	106	 5.00	*	106	 1.25	*	107	
2	 3	 1	 2.5	*	10
6	 5.00	*	106	 7.50	*	106	 2.50	*	106	
Average	 2	 3	 3	   5.00	*	106 7.50	*	106 7.50	*	106 
"Control"	
19	 26	 29	 2.5	*	10
6	 4.75	*	107	 6.50	*	107	 7.25	*	107	
11	 25	 33	 2.5	*	10
6	 2.75	*	107	 6.25	*	107	 8.25	
16	 22	 30	 2.5	*	10
6	 4,00	*	107	 5,50	*	107	 7,50	*	107	






Dil	 Colony	forming	Units	 AVG	CFU	 Tot	DIL	Factor	 CFU/ml	
	
Flocked	
10-2	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	105	 NA	
10-3	 67	 71	 79	 71	 2.5	*	106	 1.8*108	
10-4	 4	 11	 6	 7	 2.5	*	107	 1.8*108	
	
Dacron	
10-2	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	105	 NA	
10-3	 26	 32	 30	 29	 2.5	*	106	 7.3*107	
10-4	 1	 1	 1	 1	 2.5	*	107	 2.5*107	
	
Rayon	
10-2	 78	 44	 86	 69	 2.5	*	105	 1.7*107	
10-3	 9	 3	 3	 5	 2.5	*	106	 1.3*107	
10-4	 NG	 NG	 NG	 NA	 2.5	*	107	 NA	
	
“Control”	
10-2	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	105	 NA	
10-3	 69	 71	 76	 72	 2.5	*	106	 1.8*108	









Dil	 Colony	forming	Units	 AVG	CFU	 Tot	DIL	Factor	 CFU/ml	
	
Flocked	
10-2	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	105	 NA	
10-3	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	106	 NA	
10-4	 81	 79	 70	 77	 2.5	*	107	 1.9*109	
	
Dacron	
10-2	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	105	 NA	
10-3	 116	 121	 128	 122	 2.5	*	106	 3.1*108	
10-4	 30	 33	 39	 34	 2.5	*	107	 8.5*108	
	
Rayon	
10-2	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	105	 NA	
10-3	 59	 26	 34	 40	 2.5	*	106	 1.0*108	
10-4	 6	 5	 1	 4	 2.5	*	107	 1.0*108	
	
“Control”	
10-2	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	105	 NA	
10-3	 tmtc	 tmtc	 tmtc	 NA	 2.5	*	106	 NA	








Dil	 Colony	forming	Units	 AVG	CFU	 Tot	DIL	Factor	 CFU/ml	
	
Flocked	
10-2	 tmtc	 116	 105	 111	 2.5	*	105	 2.8*107	
10-3	 23	 21	 26	 23	 2.5	*	106	 5.8*107	
10-4	 3	 2	 4	 3	 2.5	*	107	 7.5*107	
	
Dacron	
10-2	 56	 67	 40	 54	 2.5	*	105	 1.3*107	
10-3	 16	 2	 6	 8	 2.5	*	106	 2.0*107	
10-4	 NG	 1	 NG	 1	 2.5	*	107	 2.5*107	
	
Rayon	
10-2	 29	 31	 22	 27	 2.5	*	105	 6.6*106	
10-3	 2	 3	 3	 3	 2.5	*	106	 7.5*106	
10-4	 NG	 NG	 NG	 NA	 2.5	*	107	 NA	
	
“Control”	
10-2	 83	 89	 80	 84	 2.5	*	105	 2.1*107	
10-3	 22	 23	 25	 23	 2.5	*	106	 5.8*107	
















S.	pneumoniae	strain	(“Control”	)a	 Swab	type	 nb	 Mdian	CFU	recovery/ml	(IQR)c	 Percentage	recovery	d	
Serotype	19Fe	(18	x	107)	
Flocked	 9	 17.8	x	107		(17	x	107	–	18.8	x	107	)	 99	(94-105)	
PET	 9	 7.8	x	107		(6.5	x	107	-	8	x	107)	 43	(36-44)	
rayon	 9	 1.0	x	107		(0.8	x	107	–	1.8	x	107)	 6	(4-10)	
Serotype	1	(19	x	107)	
Flocked	 9	 19	x	107		(18.3	x	107	–	20.5	x	107)	 100	(96-107)	
PET	 9	 8.5	x	107		(7.5	x	107	-	9	x	107)	 45	(39-47)	
Rayon	 9	 1.0	x	107		(0.25	x	107	–	1.5	x	107)	 5	(1-8)	
Serotype	5	(5.8	x	107)	
Flocked	 9	 5.8	x	107		(5	x	107	–	6.5	x	107)	 100	(86-112)	
PET	 9	 1.5	x	107		(0.8	x	107	–	3.3	x	107)	 26	(14-57)	















































(OD600nm	 measurement)	 against	 time.	 Growth	 curve	 was	 used	 to	 determine	 the	 mid-log	 4172 





Figure	 S1.2:	 Box	 and	whisker	 plots	 for	 the	 recovery	 of	 Streptococcus	pneumoniae	 from	mock	 4178 
specimens	 using	 nylon	 flocked,	 PET	 (Dacron™)	 and	 rayon	 swabs.	 Red=Flocked	 swabs,	 4179 
Green=PET,	Blue=rayon	swabs.	The	data	is	presented	as	the	pooled	median	CFU	recovered	from	 4180 





APPENDIX 2: Chapter	3	supplementary	 4185 
tables	and	figures 4186 
2.1	rmPCR	Assay	 4187 














FAM LNAb BHQ1 
300 
1-R GCTTTAGAAGGTAGAGTTAACAAC 300 




FAM “T”d=BHQ1 BHQ1 
300 
2-R AAAATTACCCCAAAAGCTATCCAA 300 




HEX “T”d=BHQ1 BHQ1 
300 
3-R CCCGAACGTAAAGCTTCTTCA 300 








4-R CACCACCATAGTAACCAAAGTTCC  300 




HEX “T”d=BHQ1 BHQ1 
300 
5-R GACAGTATAAGAAAAAGCAAGGGCTAA 300 





FAM “T”d=BHQ1 BHQ1 
200 
6A/6B/6









FAM LNAb BHQ1 
200 
6C/6D-R CTCTTCAATTAGTTCTTCAGTTCG 200 
6C/6D-








7F/7A-R ATTCTCGCCATCAATTGCATATTC  200 7F/7A-
Probe 
ACACCACTATAGGCTGTTGAGACTAACGCA




HEX LNAb BHQ1 
300 
9V/9A-R CGAATCTGCCAATATCTGAAAG 300 
9V/9A-










-R AGTGCTAACTGTAAAACTTGATTATGAG  300 
11A/11D


















TGCCCACCAACACCAGGTCCAGGT  200 
CR931662 
(wzy) 
14-F AGAGTGTATGAGGAATCC FAM “T”d=BHQ1 BHQ1 300 14-R ATATATCTACTGTAGAGGGAAT 300 
	 257	
Table	S2.2:	Reaction	1	(Pneumococcal	serotypes	1*,	5	and	23F)	for	the	African	region	rmPCR	mix	for	40	reactions	 4189 
Reagent	(initial	concentration)	 1	Reaction	(µl)	 X40	Reactions	(µl)	 Final	Concentration	
2x	Mastermix	 12,5	 500	 1X	
1-F	(10uM)	 0,75	 30	 300nM	
1-R	(10uM)	 0,75	 30	 300nM	
1-pb	FAM	(10uM)	 0,25	 10	 100nM	
5-F	(10uM)	 0,75	 30	 300nM	
5-R	(10uM)	 0,75	 30	 300nM	
5-pb	HEX	(10uM)	 0,50	 20	 200nM	
23F-F	(10uM)	 0,75	 30	 200nM	





FAM LNAb BHQ1 
200 
15A/15F-
R CCATAGGAAGGAAATAGTATTTGTTC 200 
15A/15F-
Probe CCCGCAAACTCTGTCCT 100 
CR931668 
(wzy)  
16F-F  TAATGTTATGACCTTGGTAATCTTCCC 
HEX “T”d=BHQ1 BHQ1 
300 




























19A-F  CGCCTAGTCTAAATACCA 











19F-F  TGAGGTTAAGATTGCTGATCG 
CY5 LNAb BHQ1 
300 
19F-R CACGAATGAGAACTCGAATAAAAG  300 
19F-




F  TCTATTAAATAACCCATTGGAATTGAAACG 
HEX “T”d=BHQ1 BHQ1 
200 
22F/22A-







23A-F CTCCCCTCCATTACCCATTTGG CY5 “T”d=BHQ2 BHQ2 200 23A-R TGAAGAAAGTGCTGTTTGTGAACC 200 
 23A-Probe AGCTAGAAC“T”CCCACACTCCCTACTCCCA   100  CR931685 
(wzy) 
23F-F GACAGCAACGACAATAGTCATCTC 
CY5 “T”d=BHQ2 BHQ2 
300 








37-F  GGAACTGGTTCAGCAACTATACG  
HEX “T”d=BHQ1 BHQ1 
200 
33F/33A/





aAbbreviations: FAM, 6-carboxyfluorescein; HEX, hexachloro-6-
carboxyfluorescein; ROX, 6-carboxy-X-rhodamine; CY5, indodicarbocyanine;  BHQ, black hole 
quencher; ID, identification; LNA, locked nucleic acid. bLocked nucleic acid nucleotides are 
underlined. d “T” black hole quencher placed internally on the thymidine, highlighted with a green 




23F-R	(10uM)	 0,75	 30	 200nM	
23F-pb	Cy5	(10uM)	 0,5	 20	 100nM	
H2O	 1,75	 70	 	
DNA	 5	 	 	




Reagent	(initial	concentration)	 1	Reaction	(µl)	 X40	Reactions	(µl)	 Final	Concentration	
4-F	(10	uM)	 0,75	 30	 300nM	
4-R	(10	uM)	 0,75	 30	 300nM	
4-pb	(10	uM)	 0,25	 10	 100nM	
6A/6B/6C/6D-F	(10	uM)	 0,5	 20	 200nM	
6A/6B/6C/6D-R	(10	uM)	 0,5	 20	 200nM	
6A/6B/6C/6D-pb	(10	uM)	 0,5	 20	 200nM	
9V/9A-F	(10	uM)	 0,75	 30	 300nM	
9V/9A-R	(10	uM)	 0,75	 30	 300nM	
9V/9A-pb	(10	uM)	 0,25	 10	 100nM	
Mastermix	 12,5	 500	 1X	
H2O	 2,5	 100	 	
DNA	 5	 	 	




Reagent	(initial	concentration)	 1	Reaction	(µl)	 X40	Reactions	(µl)	 Final	Concentration	
14-F	(10	uM)	 0,75	 30	 300nM	
14-R	(10	uM)	 0,75	 30	 300nM	
14-pb	(10	uM)	 0,25	 10	 100nM	
18C/18F/18B/18A-F	(10	uM)	 0,5	 20	 200nM	
18C/18F/18B/18A-R	(10	uM)	 0,5	 20	 200nM	
18C/18F/18B/18A-pb	(10	uM)	 0,25	 10	 100nM	
19F-F	(10	uM)	 0,75	 30	 300nM	
19F-R	(10	uM)	 0,75	 30	 300nM	
19F-pb	(10	uM)	 0,25	 10	 100nM	
Mastermix	 12,5	 500	 1X	
H2O	 2,75	 110	 	
DNA	 5	 	 	
Total	 25	 800	 	
	 4196 
Table	S2.5:	Reaction	4	(Pneumococcal	serotypes	3*,	7F/7A,19A)	for	the	African	region	rmPCR	mix	for	40	reactions	 4197 
Reagent	(initial	concentration)	 1	Reaction	(µl)	 X40	Reactions	(µl)	 Final	Concentration	
3-F	(10uM)	 0,75	 30	 300nM	
3-R	(10uM)	 0,75	 30	 300nM	
3-pb	HEX	(10uM)	 0,5	 20	 200nM	
7F/7A-F	(10uM)	 0,5	 20	 200nM	
7F/7A-R	(10uM)	 0,5	 20	 200nM	
7F/7A-pb	ROX	(10uM)	 0,25	 10	 100nM	
19A-F	(10uM)	 0,5	 20	 200nM	
19A-R	(10uM)	 0,5	 20	 200nM	
19A-pb	FAM	(10uM)	 0,25	 10	 100nM	
	 259	
Mastermix	 12,5	 500	 1X	
H2O	 3	 120	 	
DNA	 5	 	 	




Reagent	(initial	concentration)	 1	Reaction	(µl)	 X40	Reactions	(µl)	 Final	Concentration	
6C/6D-F	(10uM)	 0,5	 20	 200nM	
6C/6D-R	(10uM)	 0,5	 20	 200nM	
6C/6D-pb	FAM	(10uM)	 0,25	 10	 100nM	
12F/12A/12B/44/46-F	(10uM)	 0,75	 30	 300nM	
12F/12A/12B/44/46-R	(10uM)	 0,75	 30	 300nM	
12F/12A/12B/44/46-pb	ROX	(10uM)	 0,5	 20	 200nM	
22F/22A-F	(10uM)	 0,5	 20	 200nM	
22F/22A-R	(10uM)	 0,5	 20	 200nM	
22F/22A-pb	HEX	(10uM)	 0,5	 20	 200nM	
Mastermix	 12,5	 500	 1X	
H2O	 2,75	 110	 	
DNA	 5	 	 	




Reagent	(initial	concentration)	 1	Reaction	(µl)	 X40	Reactions	(µl)	 Final	Concentration	
15A/15F-F		(10	uM)	 0,5	 20	 300nM	
15A/15F-R	(10	uM)	 0,5	 20	 300nM	
15A/15F-pb	(10	uM)	 0,25	 10	 200nM	
23A-F	(10	uM)	 0,5	 20	 200nM	
23A-R	(10	uM)	 0,5	 20	 200nM	
23A-pb	(10	uM)	 0,25	 10	 100nM	
33F/33A/37-F	(10	uM)	 0,5	 20	 200nM	
33F/33A/37-R		(10	uM)	 0,5	 20	 200nM	
33F/33A/37-pb		(10	uM)	 0,5	 20	 100nM	
Mastermix	 12,5	 500	 1X	
H2O	 3,5	 140	 	
DNA	 5	 	 	
Total	 25	 800	 	
	 4204 
Table	S2.8:	Reaction	7	(Pneumococcal	serotypes	2,	11A/11D,16F)	for	the	African	region	rmPCR	mix	for	40	reactions	 4205 
Reagent	(initial	concentration)	 1	Reaction	(µl)	 X40	Reactions	(µl)	 Final	Concentration	
2-F		(10uM)	 0,75	 30	 300nM	
2-R	(10uM)	 0,75	 30	 300nM	
2-pb	FAM	(10uM)	 0,5	 20	 200nM	
11A/11D-F	(10uM)	 0,75	 30	 200nM	
11A/11D-R	(10uM)	 0,75	 30	 200nM	
11A/11D-pb	ROX	(10uM)	 0,25	 10	 100nM	
16F-F	(10uM)	 0,75	 30	 200nM	
16F-R		(10uM)	 0,75	 30	 200nM	
	 260	
16F-pb	HEX		(10uM)	 0,25	 10	 100nM	
Mastermix	 12,5	 500	 1X	
H2O	 2	 80	 	
DNA	 5	 	 	




Reagent	(initial	concentration)	 1	Reaction	(µl)	 X80	Reactions	(µl)	 Final	Concentration	
2x	Mastermix	 12.5	 1000	 1X	
Cps	Primer_F	10	uM	 1	 80	 400nM	
Cps	Primer_R	10	uM	 1	 80	 400nM	
dH2O	 8.5	 680	 	
DNA		 2	 	 	
	 	 	 	



































2.3	 How	to	run	the	Sequetyper	program	 4213 
In	 order	 to	 assign	 serotypes,	 download	 the	 sequetyper	 program	 from	 4214 
http://www.gematics.com/sequetyper.html,	 which	 is	 stored	 as	 a	 zip	 folder.	 After	 4215 
extracting	the	program	to	a	specified	location:	 4216 
1) Navigate	to	the	sequetyper	folder	and	double	click	the	run	in	order	to	launch	the	 4217 
program	for	Windows	users	or	use	the	run.	Command	for	MAC	operating	system	 4218 
users.		 4219 
2) Click	on	“File”	and	then	“Open	directory”	 4220 
3) Now	navigate	to	a	specified	directory	that	contains	the	AB1	files	which	have	been	 4221 
labelled	 using	 a	 set	 convention	 (See	 under	 rebuilding	 the	 database	 for	 the	 4222 
naming	format).	 4223 
4) Once	you	have	selected	a	directory,	click	on	the	“Open”	button	 4224 
5) A	window	will	open	to	notify	the	user	if	 there	are	any	errors	in	file	processing,	 4225 
which	can	include	sequences	that	for	below	the	0.05	PHRED	cut-off	or	sequences	 4226 
that	are	duplicated	or	have	a	missing	compliment	sequence.	 4227 
6) If	this	QC	step	is	resolved,	click	on	“Proceed	anyway”	 4228 
7) The	program	will	then	find	all	the	alignments	for	the	input	files.	 4229 
8) Once	the	alignment	is	complete,	a	report	window	will	open	showing	the	results.	 4230 
Rebuilding	the	Sequetyper	database	 4231 
In	 order	 to	 rebuild	 the	 database	 of	 reference	 sequences	 the	 following	 steps	must	 be	 4232 
carried	out:	 4233 
1) First	locate	the	file	called	"categoryCatAll.fasta"	located	in	the	"db"	folder,	 4234 
	 262	
2) Open	this	file	for	editing	in	a	text	editor	and	 4235 
3) Paste	in	new	sequence	in	fasta	format.	 4236 
Note:	The	new	sequence	must	have	a	specific	format.	The	specific	format	applies	to	the	 4237 





§ >w|x|y|z|can	be	anything	but	 4243 
§ _A_	is	the	Pneumococcal	serogroup,	 4244 
§ _B	_Pneumococcal	serotype,	which	could	be	designated	as	F,	A,	B,	C,	D,	N,	L,	V		 4245 
§ or	 left	 blank	 for	 serotypes	 that	 do	not	 have	 any	 serotypes	 included	within	 the	 4246 
serogroup,	 4247 
§ _C_is	the	allele	number	if	applicable	and	 4248 
§ _D_	is	the	Pneumococcal	sequence	description.	 4249 
An	example	of	what	it	should	look	like	is:		 4250 


















We	 applied	 functional	 data	 analysis	 to	 explore	 the	 inter-strain-	 and	 serotype	 specific	 4268 
relationship	using	our	longitudinal	serotype	distribution	data.	In	multiple	regression,	a	 4269 
single	response,	!,	is	predicted	by	!	predictor	variables,	!!, !!,… , !!.		 4270 
	 ! = !! + !!!! +⋯+ !!!! + !	 (214)	 4271 
In	functional	data	analysis,	observations	are	in	the	form	of	continuous	functions.	In	the	 4272 
case	here,	!(!)	is	the	presence	/	absence	of	serotype	!	over	the	continuous	time	period	 4273 
from	 birth	 to	 one	 year.	 Discreet	 observations	 are	 made	 of	!(!)	at	 time	 points	! = 4274 
!"#$ℎ, 2 !""#$, 4 !""#$,… , 52 !""#$.	 4275 
	 264	
Functional	 regression	 analysis	 with	 functional	 response	 and	 functional	 predictors,	 4276 
replace	 the	 observations	 in	 (1)	 with	 continuous	 functions	!(!)	for	 the	 response	 and	 4277 
!! ! ,… , !!(!)	for	the	predictors.	Here,	each	serotype	is	in	turn	modeled	as	a	response,	 4278 
with	 all	 the	 other	 serotypes	 are	 predictors.	 A	 naïve	 form	of	 the	 functional	 regression	 4279 
model	will	be	 4280 
	 ! ! = !!(!)+ !!(!)!!(!)+⋯+ !!(!)!!(!)+ !(!)	 (213)	 4281 
In	 (2),	 the	 presence/absence	 of	 serotype	 ! 	at	 time	 point	 ! ,	 depends	 on	 the	 4282 
presence/absence	 of	 serotypes	!!, !!,… , !! 	at	 time	 point	! .	 A	 more	 realistic	 model,	 4283 
models	 the	 presence/absence	 of	 serotype	! 	at	 time	 point	! ,	 as	 a	 function	 of	 the	 4284 
presence/absence	of	the	predictor	serotypes	at	all	time	points	from	birth	to	time	point	 4285 
!.	 We	 shall	 denote	 the	 presence/absence	 of	 predictor	 serotype	!	over	 this	 period	 as	 4286 
!! ! , 0 ≤ ! ≤ !.		 4287 
The	regression	model	as	given	by	Ramsay,	Hooker	and	Graves	(2009)	is	now	of	the	form	 4288 
	 ! ! = !! ! + !!(!, !)!!(!)!"!! +⋯+ !! !, ! !! ! !"
!
! + !(!)	 (379)	 4289 
The	 integral	 in	 each	 predictor	 term	 in	 (3),	 essentially	 combines	 the	 effect	 of	!! 	from	 4290 
birth	up	to	time	point	!.	Mathematically	an	integral	can	be	interpreted	as	the	area	under	 4291 
the	integrant,	i.e.	the	area	under	the	function	!!(!, !)!!(!)	between	the	points	! = 0	and	 4292 
! = !.	 The	 fitting	 of	 the	 regression	 function	 is	 implemented	 in	 the	 fda	 package	 in	 R	 4293 
(213,379).	 4294 
As	!	varies	 from	birth	to	52	weeks,	!(!)	changes	over	time.	The	changes	 in	!(!)	is	now	 4295 
modelled	by	an	 intercept	 term	!! ! ,	which	 is	 also	a	 function	over	0 < ! < 52	and	 the	 4296 
predictors.	!(0)	can	only	be	predicted	 from	the	values	of	 the	predictors	at	 time	! = 0.	 4297 
As	!	increases	towards	! = 52,	a	larger	spread	of	the	predictor	functions,	!! ! , 0 ≤ ! ≤ 4298 
!,	 could	 possibly	 predict	!(!).	 The	 regression	 coefficients	 are	 therefore	 depending	 on	 4299 
	 265	
the	 value	 of	!,	 and	 all	 the	 values	 of	!,	0 ≤ ! ≤ !,	 spreading	 a	 triangular	 region.	 As	 in	 4300 
ordinary	 multiple	 regression,	 the	 size	 of	 the	 regression	 coefficients	 indicates	 the	 4301 
magnitude	 of	 the	 effect	 of	 the	 predictor	 on	 the	 response.	 A	 coefficient	 value	 of	 zero,	 4302 




Also,	 there	 is	no	 indication	of	 the	meaning	of	 the	numerical	values	of	 the	coefficients,	 4307 
since	it	should	be	interpreted	in	terms	of	the	area	under	a	function	between	! = 0	and	 4308 





Figure	 S4.1:	 Colour	 grids	 utilised	 in	 exploring	 the	 strength	 of	 pneumococcal	 serotype	 inter- 4314 


















APPENDIX 4: Chapter	5	supplementary	 4320 
tables	and	figures 4321 
4.2	Cox	proportion	hazard	models	 4322 




HR	 95%	CI	 p	 HR	 95%	CI	 p	 HR	 95%	CI	 p	
Gender	
Female	 1	 -		 -		 1	 -		 -		 1	 -		 -		







1	 -		 -		 1	 -		 -		 1	 -		 -		
Normal	
vacuum	
0.30	 0.25-0.36	 0.00	 -	 -	 -	 0.30	 0.27-0.34	 0.00	
Elective	
caesarean	
0.63	 0.27-1.48	 0.29	 1.24	 0.89-1.71	 0.20	 1.01	 0.70-1.45	 0.97	
Emergency	
caesarean	
0.98	 0.77-1.26	 0.89	 0.92	 0.79-1.06	 0.25	 0.96	 0.83-1.12	 0.61	
HIV	
exposure	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		




1	 -		 -		 1	 -		 -		 1	 -		 -		
Mixed	fed	 1.19	 0.92-1.55	 0.19	 0.97	 0.70-1.33	 0.84	 1.05	 0.85-1.31	 0.64	
Never	
breastfed	
0.89	 0.69-1.16	 0.40	 0.90	 0.70-1.15	 0.40	 0.91	 0.76-1.08	 0.29	
Other	
Children1	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.49	 1.21-1.85	 0.00	 1.07	 0.88-1.31	 0.51	 1.23	 1.06-1.43	 0.00	
Premature	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		




No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.22	 0.88-1.68	 0.23	 1.01	 0.82-1.24	 0.94	 1.05	 0.90-1.22	 0.56	
Sleeps	with	
Mother	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.24	 0.67-2.29	 0.50	 0.72	 0.56-0.94	 0.01	 0.84	 0.65-1.09	 0.20	
Sleeps	with	
Father	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.17	 0.93-1.48	 0.19	 1.20	 0.98-1.47	 0.08	 1.17	 1.01-1.36	 0.03	
Sleeps	with	
sibling	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.50	 1.18-1.89	 0.00	 1.15	 0.95-1.39	 0.16	 1.28	 1.11-1.48	 0.00	
Microwave	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 0.98	 0.59-1.63	 0.94	 0.79	 0.64-0.98	 0.03	 0.83	 0.69-1.00	 0.05	
Paraffin	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1	 -	 -	 1.12	 0.90-1.38	 0.30	 1.12	 0.92-1.35	 0.27	
Wood	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.27	 0.91-1.77	 0.17	 1	 -	 -	 1.24	 0.92-1.69	 0.16	
Gas	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 0.74	 0.47-1.17	 0.20	 0.62	 0.22-1.71	 0.35	 0.69	 0.43-1.10	 0.12	
*One observation with excluded for missing data. 1Other children staying with the child in the same 4325 
household. “-“ Insufficient data in that category to make any inferences 4326 
 4327 
	 267	
In order to clearly determine which pneumococcal serotypes was actually acquired by these 4328 
children, the CPH models were extended to categorically determine which risk factors were 4329 
significant drivers of VT or NVT carriage acquisition, table 4. HIV exposure and presence of 4330 
older siblings were associated with increased risk of time to first episode of VT 4331 
pneumococcal acquisition amongst children at TC Newman (HR = 4.12, 95% CI = 1.21 - 4332 
14.03, p = 0.02 and HR = 2.57, 95% CI  = 1.24 - 5.30, p = 0.01 respectively). In contrast, 4333 
HIV exposure and presence of older siblings were not significant drivers of VT acquisition at 4334 
Mbekweni, (HR = 0.97, 95% CI  = 0.54 - 1.74, p = 0.92 and HR = 1.36, 95% CI  = 0.81 - 4335 
2.26, p = 0.24 respectively). In Mbekweni, older had to be sleeping in the same room as the 4336 
child in order for them to be potential sources of VT transmission, HR = 1.66, 95% CI = 1.00 4337 
- 2.73, p = 0.04.  4338 




HR	 95%	CI	 p	 HR	 95%	CI	 p	 HR	 95%	CI	 p	
Gender	
Female	 1	 -		 -		 1	 -		 -		 1	 -		 -		








1	 -		 -		 1	 -		 -		 1	 -		 -		
Normal	
vacuum	
1.17	 0.72-1.90	 0.53	 1	 -		 -		 1.26	 0.89-1.79	 0.19	
Elective	
caesarean	
0.95	 0.28-3.21	 0.94	 1.55	 0.66-3.62	 0.32	 1.26	 0.63-2.51	 0.51	
Emergency	
caesarean	
0.72	 0.30-1.74	 0.47	 0.36	 0.06-2.29	 0.28	 0.60	 0.26-1.37	 0.23	
HIV	
exposure	









1	 -		 -		 1	 -		 -		 1	 -		 -		






0.01	 0.99	 0.44-2.21	 0.98	 0.67	 0.42-1.07	 0.09	
Other	
Children1	




0.00	 0.72	 0.37-1.40	 0.34	 1.35	 0.86-2.11	 0.19	
Prematur
e	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		




No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 2.46	 1.07-5.69	 0.03	 0.58	 0.31-1.08	 0.08	 0.99	 0.63-1.55	 0.97	






































No	 1	 -		 -		 1	 -		 -		 1	 -		 -		





No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 -	 -	 -	 1.27	 0.60-2.71	 0.53	 1.17	 0.58-2.37	 0.67	
Wood	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1	 -		 -		 -	 -	 -	 1.42	 0.55-3.68	 0.47	
Gas	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 0.41	 0.09-2.01	 0.27	 -	 -	 -	 0.26	 0.04-1.53	 0.14	
1Other children staying with the child in the same household. 4341 
 4342 
On the contrary, HIV exposure did not increase the risk of acquiring NVT at either TC 4343 
Newman or Mbekweni (crude HR = 1.13, 95% CI = 0.76-1.71, p = 0.53). On the other hand, 4344 
the presence of older siblings were significant drivers for acquisition of first episodes of NVT 4345 





HR	 95%	CI	 p	 HR	 95%	CI	 p	 HR	 95%	CI	 p	
Gender	
Female	 1	 -		 -		 1	 -		 -		 1	 -		 -		





1	 -		 -		 1	 -		 -		 1	 -		 -		
Normal	
vacuum	
0.22	 0.18-0.27	 0.00	 1	 -		 -		 0.22	 0.19-0.25	 0.00	
Elective	
caesarean	
0.95	 0.73-1.24	 0.71	 1.15	 0.86-1.53	 0.34	 0.58	 0.26-1.28	 0.18	
Emergency	
caesarean	
0.94	 0.67-1.31	 0.71	 1.04	 0.79-1.38	 0.78	 1.00	 0.83-1.22	 0.99	
HIV	
exposure	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		




1	 -		 -		 1	 -		 -		 1	 -		 -		
Mixed	fed	 1.13	 0.87-1.46	 0.37	 0.90	 0.61-1.32	 0.58	 1.48	 1.12-1.96	 0.00	
Never	
breastfed	
1.02	 0.75-1.39	 0.88	 0.78	 0.57-1.06	 0.12	 0.91	 0.73-1.12	 0.37	
Other	
Children1	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.41	 1.07-1.85	 0.01	 1.14	 0.89-1.46	 0.32	 1.25	 1.04-1.50	 0.02	
Premature	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.13	 0.83-1.54	 0.43	 0.81	 0.51-1.26	 0.35	 0.95	 0.72-1.24	 0.69	
Smoke	
exposure	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.21	 0.82-1.79	 0.35	 1.09	 0.86-1.39	 0.46	 1.09	 0.90-1.31	 0.40	
Sleeps	with	
Mother	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.10	 0.55-2.19	 0.78	 0.70	 0.52-0.94	 0.01	 0.80	 0.60-1.06	 0.12	
Sleeps	with	
Father	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		




No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.37	 1.03-1.82	 0.03	 1.13	 0.88-1.44	 0.33	 1.22	 1.02-1.46	 0.03	
Microwave	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.01	 0.59-1.72	 0.98	 0.80	 0.62-1.04	 0.09	 0.83	 0.67-1.04	 0.11	
Paraffin	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 		 	 		 1.07	 0.83-1.39	 0.61	 1.09	 0.85-1.39	 0.50	
Wood	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 1.36	 1.00-1.85	 0.05	 1	 -		 -		 1.32	 0.99-1.74	 0.05	
Gas	
No	 1	 -		 -		 1	 -		 -		 1	 -		 -		
Yes	 0.57	 0.29-1.11	 0.09	 0.56	 0.15-2.06	 0.38	 0.55	 0.29-1.06	 0.07	




















































































































































































































 Registered curves: Serotype 13 


















 Registered curves: Serotype 11a 

















 Registered curves: Serotype 15a 



















 Registered curves: Serotype 17f 
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Figure	 S4.4:	Mean	 registered	 curves	 for	 the	 less	 commonly	 encountered	 non-PCV-13	 vaccine	 4395 
serotypes.	 A=	 Serotype	 35F/47,	 B=	 Serotype	 47F,	 C=	 Serotype	 19C,	 D=	 Serotype	 23A,	 E=	 4396 
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 Registered curves: Serotype 18b 



















 Registered curves: Serotype 19c 

























0 10 20 30 40 50 












 Registered curves: Serotype 23a 
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 Registered curves: Serotype 24f 
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 Registered curves: Serotype 33c 
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 Registered curves: Serotype 23b 

























 Registered curves: Serotype 33a 
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 Registered curves: Serotype 33b/35c 
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 Registered curves: Serotype 35a 
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Figure	 S4.6:	Mean	 registered	 curves	 for	 the	 less	 commonly	 encountered	 non-PCV-13	 vaccine	 4407 
serotypes.		 4408 












 Registered curves: Serotype 18a 



















 Registered curves: Serotype 19b 







Registered curves: Serotype 20 
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 Registered curves: Serotype 31 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure	 S5.1:	 Cononical	 variate	 analysis	 (CVA)	 biplot	 showing	 the	 presence	 or	
















































































































































































Parainfluenza 3, n = 2 














Parainfluenza 2, n = 1 














Parainfluenza 4, n= 2 














Coronavirus 229, n = 1 














Coronavirus NL63, n = 2 









Coronavirus HKU, n = 2 



















Parainfluenza 1, n = 1 
p = 0.97 
0 - 3 months 
4 - 11 months 
12 - 23 months 
24 - 59 months 






Figure	 S5.3:	 Screen	 shot	 of	 the	 FTDResp33	 Analyser	 results	 output.	 The	 first	 column	
contains	the	names	of	each	pathogens	included	in	the	FTD	Ressp33	assay,	and	the	adjucent	
rows	 iincludes	 the	 cycle	 threhold	 value	 for	 each	 pathogen	 detected	 for	 all	 the	 12	 clinical	
samples,	column	4	–	15.	Empty	cells	represents	negative	samples.	
5.4	 How	to	run	the	FTD	Resp33	qPCR	Analyser	program	
In	 order	 to	 FTD	 results,	 downloaded	 the	 FTD	 Resp33	 qPCR	 Analyser	 program	 at	
http://www.gematics.com/analyser.html,	 which	 is	 stored	 as	 a	 zip	 folder.	 After	
extracting	the	program	to	a	specified	location:	
1) Users	 of	 either	 MAC	 or	 windows	 operating	 system	 must	 launch	 the	 program	 by	
double	clicking	on	the	analyser.jar	file	located	in	the	deployAnalyser	directory.	
2) To	 import	 the	 data	 files	 click	 on	 "File"	 and	 then	 select	 one	 of	 two	 options.	 For	
relative	 quantification	 select	 the	 first	 option	 and	 for	 absolute	 quantification	 select	
the	 second	 option.	 The	 relative	 quantification	 approach	 rearranges	 the	 Cq	 values	
obtained	from	the	CFX	realtime	machine	into	a	table	that		
3) If	 you	 are	 performing	 relative	 quantification,	 you	 will	 need	 to	 specify	 a	 set	 of	
gradients	 and	 intercepts	 for	 the	 calculation.	 Click	 on	 the	 "Open	 constants	 file"	
  POS NEG 111142 111162 111299 111315 111374 111452 111468 111557 112678 308861 310159 512197 
Internal Control  32.12 34.95 33.70 33.99 34.10 34.52 33.51 35.10 32.88 33.29 34.52 32.42 33.03 
Influenza A 31.40              
Rhinovirus 28.11       39.24 38.42      
Influenza B 29.05              
Parainfluenza 3 29.28              
Parainfluenza 2 32.26              
Parainfluenza 4 29.56              
Coronavirus 229 32.19              
Coronavirus 63 29.11              
Coronavirus hku 27.81              
Coronavirus 43 30.63  21.46            
Parainfluenza 1 29.40              
Metapneumovirus A and B 27.72  32.27     28.31 32.59 34.35 36.70    
Bocavirus 29.42              
M_ pneumoniae 26.88  23.78      35.31      
Respiratory syncyncial virus A and B 29.27              
Cytomegalovirus 27.40  32.11     28.09 32.01 33.61     
Enterovirus/Parechovirus 29.22              
Adenovirus 26.67  23.28      36.64      
S_ aureus 28.17    27.88    32.16  23.70  27.02  
C_  pneumoniae 28.42              
H. influenzae B 29.16              
S_ pneumoniae 28.90  26.35   21.00 23.25 29.25    27.41   
Pneumocystis jirovecii 28.01   30.54       31.29    
Legionella spp 27.27  36.92   35.15 35.21 35.94 38.05 36.73  36.88   
k_ pneumoniae 27.16    34.38 34.54 34.06   35.29 34.47 36.48 34.80 36.34 
Salmonella spp 28.97              
M_catarrhalis 29.41  25.30 25.27  19.11 25.04 23.46 25.87 25.35  28.09   
Influenza C 28.51              
Bordetella pertussis 26.75              















8) Now	 navigate	 to	 a	 secified	 directory	 that	 contains	 the	 AB1	 files	which	 have	 been	




can	 include	sequences	 that	 for	below	the	0.05	PHRED	cutoff	or	sequences	 that	are	
duplicated	or	have	a	missing	compliment	sequence.	
11) If	this	QC	step	is	resolved,	click	on	“Proceed	anyway”	
12) The	program	will	then	find	all	the	alignments	for	the	input	files.	
13) Once	the	alignment	is	complete,	a	report	window	will	open	showing	the	results.	
	
 
 
 
